A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral BCX9930 Monotherapy for the Treatment of Paroxysmal Nocturnal Hemoglobinuria
Phase: PHASE2
Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Sponsor: BioCryst Pharmaceuticals

 
 
 
BIOCRYST 
PHARMACEUTICALS, INC. 
BCX9930 
PROTOCOL No. BCX9930-203 
IND No. 142,217 
EudraCT No. 2020-004403-14 
 
A Randomized, Double-Blind, Multicenter, 
Placebo-Controlled, Parallel-Group Study to Evaluate the 
Efficacy, Safety, and Tolerability of Oral BCX9930 
Monotherapy for the Treatment of Paroxysmal Nocturnal 
Hemoglobinuria 
 
 
Version 4.0: 01 August 2022 
 
 
BioCryst Pharmaceuticals, Inc. 
4505 Emperor Boulevard, Suite 200 
Durham, North Carolina 27703, USA 
Phone: +1 919-859-1302 
Fax: +1 919-851-1416 
 
 
CONFIDENTIAL 
The information in this document contains proprietary and confidential information belonging to 
BioCryst Pharmaceuticals, Inc. As a result, no part of this document should be copied, referred 
to, released, published, or otherwise disclosed in any manner or media without prior written 
approval from BioCryst Pharmaceuticals, Inc. 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
3 
 
CONFIDENTIAL 
INVESTIGATOR AGREEMENT 
 
Protocol No. BCX9930-203 
A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-
Group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral 
BCX9930 Monotherapy for the Treatment of Paroxysmal Nocturnal 
Hemoglobinuria 
Version (Date): Version 4.0: 01 August 2022 
 
I have received and read the Investigator’s Brochure (IB) for BCX9930. 
I have carefully read this protocol and agree that it contains all of the necessary information 
required to conduct this study. I agree to conduct this study as described and according to the 
Declaration of Helsinki, International Council for Harmonisation guidelines for Good Clinical 
Practice, and all locally applicable regulations. 
I agree to maintain the confidentiality of all information received or developed in connection 
with this protocol. 
 
 
 
 
 
Printed Name of Investigator 
 
 
 
 
Signature of Investigator 
 
 
 
 
Date 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
4 
 
CONFIDENTIAL 
STUDY INFORMATION 
Protocol No.: 
BCX9930-203 
Study Title: 
A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-
Group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral 
BCX9930 Monotherapy for the Treatment of Paroxysmal Nocturnal 
Hemoglobinuria 
IND No.: 
142,217 
EudraCT No.: 
2020-004403-14 
Investigational Product: 
BCX9930 
Indication Studied: 
Paroxysmal nocturnal hemoglobinuria (PNH) 
Sponsor: 
BioCryst Pharmaceuticals, Inc. 
4505 Emperor Boulevard 
Nottingham Hall, Suite 200 
Durham, North Carolina 27703, USA 
Sponsor Medical 
Monitor: 
 
 
Office: 
 
Mobile: 
 
Email: 
 
(Note: See Section 12.4.1 for contact information for SAE reporting.) 
Sponsor Clinical Study 
Manager: 
 
 
Office: 
 
Mobile: 
 
Email: 
 
Lead or Coordinating 
Investigator: 
 
 
Compliance Statement: 
This study will be conducted in accordance with the ethical principles that 
have their origin in the Declaration of Helsinki and clinical research 
guidelines established by the Code of Federal Regulations (Title 21, CFR 
Parts 50, 56, and 312), International Council for Harmonisation Guidelines, 
and all locally applicable regulations. Essential study documents are 
currently archived in accordance with applicable regulations. 
Final Protocol Date: 
Version 4.0: 01 August 2022 (Amendment 3) 
Previous Version(s): 
Version 3.0: 29 June 2022 (Amendment 2) 
Version 2.0: 27 May 2021 (Amendment 1) 
Version 1.0: 18 March 2021 (Original) 
 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
5 
 
CONFIDENTIAL 
2. 
SYNOPSIS 
Name of Sponsor/Company: 
BioCryst Pharmaceuticals, Inc. 
Name of Investigational Product: 
BCX9930 
Name of Active Ingredient: 
 
Title of Study: 
A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Study to Evaluate the 
Efficacy, Safety, and Tolerability of Oral BCX9930 Monotherapy for the Treatment of Paroxysmal 
Nocturnal Hemoglobinuria 
BioCryst Protocol No.: BCX9930-203 
Lead or Coordinating Investigator: 
 
 
Study Centers: 
This study will be conducted at study centers in multiple countries/regions 
Phase of development: 2 
Objectives: 
Part 1 Primary Objective: 
• 
To determine the efficacy of oral BCX9930 monotherapy administered for 12 weeks, as 
compared to placebo, in subjects with paroxysmal nocturnal hemoglobinuria (PNH) 
Part 1 Secondary Objectives: 
• 
To evaluate the safety and tolerability of BCX9930 monotherapy administered for 12 weeks, 
as compared to placebo, in subjects with PNH 
• 
To characterize the effects of BCX9930 monotherapy administered for 12 weeks, as 
compared to placebo, using clinical and laboratory measurements, including complement 
and thrombosis biomarkers, and PNH clone size, in subjects with PNH 
• 
To evaluate the effects of BCX9930 monotherapy administered for 12 weeks, as compared 
to placebo, on the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scale 
and other patient-reported outcomes (PROs) in subjects with PNH 
• 
To characterize BCX9930 plasma concentrations and pharmacokinetic (PK) parameters in 
subjects with PNH 
In Part 1 of this study, unless indicated otherwise, all endpoints will be assessed at or to Week 12. 
Part 1 Primary Endpoint: 
• 
Change from baseline (CFB) in hemoglobin (Hb) [at Week 12] 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
6 
 
CONFIDENTIAL 
Part 1 Key Secondary Endpoints: 
1. Proportion of subjects who are transfusion-free [from Week 4 to Week 12] 
2. Number of units of packed red blood cells (pRBCs) transfused [from Week 4 to Week 12] 
3. Percent CFB in lactate dehydrogenase (LDH) [at Week 12] 
4. CFB in FACIT-Fatigue scale score [at Week 12] 
Part 1 Other Secondary Endpoints: 
• 
Percent reduction in the rate of pRBC units transfused [from Week 4 to Week 12 vs. 
prestudy transfusion rate] 
• 
Proportion of subjects with Hb ≥ 12 g/dL [at Week 12] 
• 
Proportion of subjects achieving Hb stabilization, defined as avoidance of a > 2 g/dL 
decrease in the absence of transfusion [from Week 4 to Week 12] 
• 
CFB in total PNH red blood cell (RBC) clone size [at Week 12] 
• 
CFB in ratio of total PNH RBC clone size to PNH white blood cell (WBC) clone size 
(ie, ratio of percent PNH RBCs / percent PNH WBCs) [at Week 12] 
• 
CFB in absolute reticulocyte count (ARC) [at Week 12] 
• 
Proportion of subjects with ARC in the normal range [at Week 12] 
• 
CFB in haptoglobin [at Week 12] 
• 
Proportion of subjects with haptoglobin ≥ lower limit of normal reference range (LLN) [at 
Week 12] 
• 
CFB in total bilirubin [at Week 12] 
• 
CFB in aspartate aminotransferase (AST; also serum glutamic-oxaloacetic transaminase 
[SGOT]) [at Week 12] 
Part 1 Exploratory Endpoints: 
 
 
Part 1 Other Health-related Quality of Life (HRQoL) Endpoints: 
• 
Proportion of subjects achieving a within-subject meaningful change for the FACIT-Fatigue 
scale [at Week 12] 
• 
CFB in Quality of Life Questionnaire for patients with Aplastic Anemia/Paroxysmal 
Nocturnal Hemoglobinuria (QLQ-AA/PNH) Physical Functioning and other domain scores 
[at Week 12] 
• 
Proportion of subjects with improvement on individual PNH symptom items (ie, frequency, 
severity, and/or interference) from baseline as assessed using the modified Patient-Reported 
Outcome Questionnaire for Aplastic Anemia/Paroxysmal Nocturnal Hemoglobinuria 
(PRO-AA/PNH) symptom collection tool [at Week 12] 
• 
CFB in individual PNH symptom items on the modified PRO-AA/PNH [at Week 12] 
• 
CFB in EuroQoL 5-dimension, 5-level (EQ-5D-5L) utility and visual analog scale (VAS) 
scores [at Week 12] 
• 
Treatment Satisfaction Questionnaire for Medication (TSQM) scale score [at Week 12] 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
7 
 
CONFIDENTIAL 
• 
Patient global impression of change in fatigue, impact of fatigue, and physical functioning as 
assessed using the Patient Global Impression of Change (PGIC)-Fatigue, PGIC-Impact of 
Fatigue, and PGIC-Physical Functioning scores, respectively [at Week 12] 
• 
CFB in patient global impression of severity of fatigue, impact of fatigue, and physical 
functioning as assessed using the Patient Global Impression of Severity (PGIS)-Fatigue, 
PGIS-Impact of Fatigue, and PGIS-Physical Functioning scores, respectively [at Week 12] 
Part 1 Safety Endpoints: 
• 
Number and proportion of subjects with a treatment-emergent adverse event (TEAE) 
• 
Number and proportion of subjects who discontinue treatment due to a TEAE 
• 
Number and proportion of subjects who experience a treatment-emergent serious adverse 
event (TESAE) 
• 
Number and proportion of subjects who experience a Grade 3 or Grade 4 TEAE assessed 
using the Common Terminology Criteria for Adverse Event (CTCAE) grading scales 
• 
Number and proportion of subjects who experience a treatment-emergent CTCAE Grade 3 
or Grade 4 laboratory abnormality 
Part 2 Primary Objective: 
• 
To evaluate the long-term safety and tolerability of oral BCX9930 monotherapy 
administered for up to 52 weeks in subjects with PNH 
Part 2 Secondary Objectives: 
• 
To assess the effectiveness of BCX9930 monotherapy administered for up to 52 weeks in 
subjects with PNH 
• 
To characterize the effects of BCX9930 monotherapy administered for up to 52 weeks using 
clinical and laboratory measurements, including complement and thrombosis biomarkers, 
and PNH clone size, in subjects with PNH 
• 
To evaluate the effects of BCX9930 monotherapy administered for up to 52 weeks on 
FACIT-Fatigue scale and other PROs 
• 
To characterize BCX9930 plasma concentrations and PK parameters over time in subjects 
with PNH 
In Part 2, unless indicated otherwise, all endpoints will be assessed at Week 52. For subjects who are 
switched from placebo to BCX9930 monotherapy at the end of Part 1, the baseline for treatment with 
BCX9930 will be defined as the last value prior to first dose of active treatment. 
Part 2 Primary Endpoints: 
• 
Number and proportion of subjects with a TEAE 
• 
Number and proportion of subjects who discontinue due to a TEAE 
• 
Number and proportion of subjects who experience a TESAE 
• 
Number and proportion of subjects who experience a CTCAE Grade 3 or Grade 4 TEAE 
• 
Number and proportion of subjects who experience a treatment-emergent CTCAE Grade 3 
or Grade 4 laboratory abnormality 
Part 2 Secondary Endpoints: 
• 
CFB in Hb [mean of values from Weeks 12 to 52 for subjects randomized to BCX9930 in 
Part 1 and from Weeks 24 to 52 for subjects randomized to placebo] 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
8 
 
CONFIDENTIAL 
• 
Proportion of subjects with Hb ≥ 12 g/dL [at Week 52] 
• 
Proportion of subjects achieving Hb stabilization (avoidance of a > 2 g/dL decrease in the 
absence of transfusion) [from Weeks 12 to 52 for subjects randomized to BCX9930 in Part 1 
and from Weeks 16 to 52 for subjects randomized to placebo in Part 1] 
• 
Proportion of subjects who are transfusion-free [from Weeks 12 to 52 for subjects 
randomized to BCX9930 in Part 1 and from Weeks 16 to 52 for subjects randomized to 
placebo in Part 1] 
• 
Number of units of pRBCs transfused [from Weeks 12 to 52 for subjects randomized to 
BCX9930 in Part 1 and from Weeks 16 to 52 for subjects randomized to placebo] 
• 
Percent reduction in rate of pRBCs transfused [from Weeks 12 to 52 for subjects randomized 
to BCX9930 in Part 1 and from Weeks 16 to 52 for subjects randomized to placebo in Part 1 
vs. prestudy transfusion rate] 
• 
Percent CFB in LDH [mean of values from Weeks 12 to 52 for subjects randomized to 
BCX9930 in Part 1 and from Weeks 24 to 52 for subjects randomized to placebo] 
• 
CFB in ARC [mean of values from Weeks 12 to 52 for subjects randomized to BCX9930 in 
Part 1 and from Weeks 24 to 52 for subjects randomized to placebo] 
• 
Proportion of subjects with ARC in the normal range [at Week 52] 
• 
CFB in haptoglobin [mean of values from Weeks 12 to 52 for subjects randomized to 
BCX9930 in Part 1 and from Weeks 24 to 52 for subjects randomized to placebo] 
• 
Proportion of subjects with haptoglobin ≥ LLN [at Week 52] 
• 
CFB in total PNH RBC clone size [mean of values from Weeks 12 to 52 for subjects 
randomized to BCX9930 in Part 1 and from Weeks 24 to 52 for subjects randomized to 
placebo] 
• 
CFB in total PNH RBC clone size relative to PNH WBC clone size [mean of values from 
Weeks 12 to 52 for subjects randomized to BCX9930 in Part 1 and from Weeks 24 to 52 for 
subjects randomized to placebo] 
Part 2 Exploratory Endpoints: 
• 
 
 
 
 
Part 2 Health-related Quality of Life Endpoints: 
• 
Durability of FACIT-Fatigue scale, QLQ-AA/PNH domain, modified PRO-AA/PNH, 
EQ-5D-5L utility and VAS, and TSQM scale scores 
• 
Proportion of subjects achieving a within-subject meaningful change for FACIT-Fatigue 
scale 
• 
Proportion of subjects with improvement in individual PNH symptom items (ie, frequency, 
severity, and/or interference) on the modified PRO-AA/PNH as compared to baseline 
• 
Patient global impression of change in fatigue, impact of fatigue, and physical functioning 
since the start of open-label treatment as assessed using the PGIC-Fatigue, PGIC-Impact of 
Fatigue, and PGIC-Physical Functioning scores, respectively 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
9 
 
CONFIDENTIAL 
• 
CFB in patient global impression of severity of fatigue, impact of fatigue, and physical 
functioning as assessed using the PGIS-Fatigue, PGIS-Impact of Fatigue, and PGIS-Physical 
Functioning scores, respectively 
PK and Pharmacodynamic (PD) Endpoints – Parts 1 and 2: 
• 
PK data will be used to estimate PK parameters using appropriate PK analyses based on the 
sampling collection approaches 
• 
PD data will be used to estimate PD parameters as well as in combination with PK data to 
perform PKPD analyses 
• 
CFB in PD and complement biomarker measurements, including constitutive complement 
levels and ex vivo stimulation assays 
PK and PD data may be analyzed in combination with data from other clinical studies as appropriate. 
Study Design: 
This is a randomized, placebo-controlled, double-blind, multicenter, parallel-group, 2-part study. 
Parts 1 and 2 will be conducted in the same subjects. Part 1 of the study is designed to evaluate the 
efficacy, safety, and tolerability of treatment with oral BCX9930 monotherapy for 12 weeks versus 
placebo in subjects with PNH who are not currently receiving treatment with complement inhibitor 
therapy. Subjects will be randomized to receive BCX9930 monotherapy or to placebo under 
double-blind conditions for the 12-week randomized treatment period. The primary efficacy and 
safety analyses will be based on Part 1. Part 2 of the study is designed to evaluate the long-term 
safety, tolerability, and effectiveness of open-label BCX9930 monotherapy when administered 
through Week 52. All subjects in Part 2 will receive BCX9930. Subjects who are randomized to 
BCX9930 monotherapy in Part 1 will continue to receive BCX9930 in Part 2. Subjects who are 
randomized to placebo in Part 1 will discontinue that therapy at the Week 12 visit and receive 
BCX9930 in Part 2. 
Methodology: 
Part 1: Eligible subjects will be randomized in a 2:1 ratio to receive BCX9930 monotherapy or 
matched placebo twice-daily (BID) under double-blind conditions. Randomization will be stratified 
based on whether a pRBC transfusion was received within the 6 months prior to baseline (yes vs. no). 
All subjects will be required to return to the clinic for scheduled study visits at Weeks 1, 2, 4, 8, and 
12. Additional safety assessments will be performed at Weeks 3, 5, 6, 7, and 10. At the Week 12 visit, 
the treatment assignment for Part 1 will be unblinded. 
During the blinded treatment phase of the study, any subject who experiences a qualifying event 
reflecting a significant worsening of their PNH may be allowed to switch to open-label BCX9930. 
Data collected through Week 12 will constitute the primary data set for the study. 
Part 2: Subjects randomized to placebo during Part 1 will discontinue placebo at the Week 12 visit 
and be switched to open-label BCX9930 in Part 2, so that all subjects receive BCX9930 monotherapy 
in Part 2. All subjects will be required to return to the clinic at Weeks 13, 14, and 16, and then every 
4 weeks thereafter through Week 52. Additional safety assessments will be performed at Weeks 15, 
17, 18, 19, and 22 for subjects randomized to placebo who are newly switched to BCX9930 for 
Part 2. Data collected through Week 52 will be used to assess the long-term safety of BCX9930. 
After completion of Part 2, all subjects continuing to derive clinical benefit will be allowed to 
continue treatment with BCX9930 through enrollment in a separate long-term extension study, or via 
another access mechanism, where available. Subjects who do not continue BCX9930 therapy after 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
10 
 
CONFIDENTIAL 
Week 52, or who are prematurely discontinued from BCX9930 treatment prior to Week 52, will be 
monitored for potential hemolysis and may be required to return to the clinic for an additional visit(s) 
to assess for acute symptomatic hemolysis, if and when symptoms occur. Subsequently, they will 
return to the clinic approximately 3 weeks after the date of last dose of BCX9930 for end of study 
assessments. 
An independent BCX9930 program-wide data monitoring committee (DMC) will provide oversight 
of the ongoing exposure of subjects to BCX9930. 
Number of Subjects (Planned): 
Approximately 57 subjects with PNH who are not currently receiving treatment with a complement 
inhibitor. 
Diagnosis and Main Criteria for Inclusion: 
Subjects must meet all of the following criteria, as applicable, to be eligible for participation in this 
study: 
1. Male or female, aged ≥ 18 years old. 
2. Body weight ≥ 40 kg. 
3. Documented diagnosis of PNH confirmed by flow cytometry with a PNH granulocyte or 
monocyte clone size of ≥ 10% during screening. 
4. Are either: (a) naïve to treatment with a complement inhibitor, or (b) have received no 
treatment with a complement inhibitor for at least 12 months prior to the screening visit. 
5. Do not have access to or have a contraindication (ie, have had a serious adverse reaction) to 
approved complement, C5 or C3, inhibitor therapies. 
6. Recorded the following results during screening: 
a. Hb ≤ 105 g/L (≤ 10.5 g/dL). 
b. LDH ≥ 2 × upper limit of normal reference range (ULN) 
c. ARC of ≥ 100 × 109 cells/L (≥ 100,000 cells/µL; ≥ 100 G/L). 
d. Absolute neutrophil count (ANC) of ≥ 0.75 × 109 cells/L (≥ 750 cells/µL; ≥ 0.75 G/L). 
e. Platelet count of ≥ 30 × 109/L (≥ 30,000/µL; ≥ 30 G/L). 
f. Estimated glomerular filtration rate of ≥ 60 mL/min/1.73 m2 using the Chronic Kidney 
Disease Epidemiology Collaboration (CKD-EPI) equation (Levey and Stevens 2010) and no 
evidence of clinically relevant abnormal renal function unrelated to underlying PNH 
disease. 
7. Contraception requirements: 
Female participants must meet at least one of the following requirements: 
a. Be a woman of nonchildbearing potential. 
b. Be a woman of childbearing potential who agrees to use a highly effective contraceptive 
method throughout the study and for a duration of 30 days after the last dose of study drug. 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
11 
 
CONFIDENTIAL 
c. Alternatively, true abstinence is acceptable for women of childbearing potential when it is 
in line with the subject’s preferred and usual lifestyle. 
Male participants must meet at least one of the following requirements: 
a. Males with a female partner of childbearing potential must use condoms throughout the 
study and for a duration of 90 days after the last dose of study drug unless their partner is 
using a highly effective contraceptive method independent of the study. 
b. Alternatively, true abstinence is acceptable when it is in line with the subject’s preferred 
and usual lifestyle. 
Additional details are provided in Section 11.2.1. 
8. Documentation of current vaccinations against Neisseria meningitidis types A, C, W, and Y, 
and Streptococcus pneumoniae, or willingness to start vaccination series at least 14 days prior 
to Day 1. 
(Note: Vaccination for N. meningitidis type B and for Haemophilus influenzae type B [Hib] is 
strongly encouraged where authorized and available.) 
9. In the opinion of the investigator, the subject is expected to adequately comply with all 
required study procedures and restrictions for the study, including compliance with the BID 
dosing schedule for BCX9930. 
10. Willing and able to provide written informed consent. 
Subjects must not meet any of the following exclusion criteria to be eligible for participation in the 
study: 
1. Known history of or existing diagnosis of hereditary complement deficiency. 
2. History of hematopoietic cell transplant or solid organ transplant or anticipated candidate for 
transplantation during the study. 
3. Myocardial infarction or cerebrovascular accident within 30 days prior to screening, or current 
and uncontrolled clinically significant cardiovascular or cerebrovascular condition, including 
unstable angina, severe congestive heart failure, unexplained syncope, arrhythmia, and critical 
aortic stenosis. 
4. History of malignancy within 5 years prior to the screening visit, with exception of adequately 
treated non-melanoma skin or superficial bladder cancer, curatively treated carcinoma in situ of 
the cervix, or other curatively treated solid tumor deemed by the investigator and medical 
monitor to be at low risk for recurrence. 
5. Active bacterial, viral, or fungal infection or any other serious infection within 14 days prior to 
screening. 
(Note: Suspected or confirmed coronavirus disease [COVID-19]; persistent or recurrent 
positive test(s) for severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] nucleic 
acids or antigens; and worsening of dyspnea not due to PNH, vasculitic rash, and persistent 
fever or other symptoms consistent with multisystem inflammatory syndrome in adults 
[MIS-A] are exclusionary.) 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
12 
 
CONFIDENTIAL 
6. Current participation in any other investigational drug study or participation in an 
investigational drug study within 30 days prior to the screening visit, or 5.5 half-lives of the 
investigational drug, whichever is longer. 
7. Treatment with anti-thymocyte globulin within 180 days prior to the screening visit. 
8. Initiation of treatment with an erythropoiesis-stimulating agent (eg, erythropoietin), a 
thrombopoietin receptor agonist (eg, eltrombopag), or danazol within 28 days prior to the 
screening visit. 
(Note: Treatment with these medications initiated > 28 days prior to the screening visit is not 
exclusionary, if the dose is stable and there is a reasonable expectation that treatment will be 
continued.) 
9. Receiving iron with an unstable dose in the 28 days prior to the screening visit. 
10. Clinically significant abnormal electrocardiogram (ECG) at the screening visit. 
(Note: This includes, but is not limited to, a QT interval corrected using Fridericia’s method 
[QTcF] of > 450 msec in males or > 470 msec in females, or ventricular and/or atrial premature 
contractions that are more frequent than occasional, and/or as couplets or higher in grouping.) 
11. Subjects with any of the following results at the screening visit: 
a. Alanine aminotransferase (ALT; also serum glutamic-pyruvic transaminase [SGPT]) 
> 3 × ULN. 
b. AST (SGOT) > 3 × ULN. 
(Note: Subjects may be enrolled with AST > 3 × ULN if explained by hemolysis.) 
c. Total serum bilirubin > 2 × ULN. 
(Note: Subjects may be enrolled with total serum bilirubin > 2 × ULN if explained by 
hemolysis or Gilbert’s syndrome. In the case of hemolysis, total serum bilirubin must be 
< 5 × ULN and in the case of Gilbert’s syndrome, total serum bilirubin must be 
< 11 × ULN.) 
12. Current use of a prohibited concomitant medication within 7 days prior to Day 1 as detailed in 
Section 9.8.1. 
13. Positive serology for human immunodeficiency virus, or active infection with hepatitis B virus 
or hepatitis C virus, unless receiving antiviral therapy and viral load is undetectable. 
14. Positive drugs of abuse screen, unless by prescription. 
15. Pregnant, planning to become pregnant, or breastfeeding. 
16. Known hypersensitivity to BCX9930 or any of its formulation excipients. 
17. History of severe hypersensitivity to any medicinal product, which was associated with 
swelling, severe rash requiring treatment/hospitalization, or anaphylaxis. 
18. Any other clinically significant medical or psychiatric condition that, in the opinion of the 
investigator or sponsor, would interfere with the subject’s ability to participate in the study or 
increase the risk of participation for that subject. 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
13 
 
CONFIDENTIAL 
Investigational Product, Dosage, and Mode of Administration: 
Subjects who previously received 500 mg BID and remain on study treatment will be dose adjusted to 
400 mg BID. For all newly enrolled subjects, at the initiation of BCX9930 dosing, subjects will take a 
dose of 200 mg BID for the first 14 days of treatment before increasing the dose to 400 mg BID. The 
appropriate quantity of BCX9930 tablets will be taken orally, twice a day, approximately 12 hours 
apart, without regard to food. Adequate hydration should be maintained to prevent the formation of 
highly concentrated urine. 
Duration of Treatment: 
In Part 1, either BCX9930 monotherapy or placebo for 12 weeks. In Part 2, all subjects will receive 
BCX9930 for 40 weeks. 
Reference Therapy, Dosage and Mode of Administration:  
For subjects randomized to placebo in Part 1, matched placebo tablets will be administered orally 
BID, approximately 12 hours apart, without regard to food. 
Criteria for Evaluation: 
Safety: TEAEs, laboratory analyses (clinical chemistry, hematology, coagulation, urinalysis 
including microscopy), vital signs, 12-lead ECGs, and physical examination findings. 
Clinical and Laboratory Measurements of PNH: Hb, number of pRBC transfusions and number of 
pRBC units administered, LDH, ARC, haptoglobin, bilirubin, AST; assessment of PNH-associated 
clinical symptoms (eg, fatigue, dyspnea, chest pain/discomfort, dysphagia, abdominal pain, headache, 
erectile dysfunction, hemoglobinuria, and jaundice); acute symptomatic hemolysis; major adverse 
vascular events (MAVEs), including thrombotic events. 
PROs: FACIT-Fatigue scale, QLQ-AA/PNH, modified PRO-AA/PNH, EQ-5D-5L, TSQM, and 
PGIC/PGIS items for fatigue, impact of fatigue, and physical functioning. 
PK: Plasma BCX9930 concentrations (via sparse sampling in all subjects and via serial sampling for 
0 to 6 hours post-first dose and at steady state in an optional PK/PD substudy) and PK parameter 
estimation. Urine for parent BCX9930/metabolite concentration. 
PD: Blood samples for analysis of ex vivo AP Wieslab; alternative pathway (AP)-activated 
complement biomarkers Factor Bb, C3a, and C5a; and constitutive Factor D (as the pharmacologic 
target), Factor Bb, and sC5b-9. PNH clone size (ie, total PNH RBC, PNH WBC, and the ratio of total 
PNH RBC to PNH WBC) will be assessed. Acute symptomatic hemolysis will be evaluated, where 
possible, with analysis of ex vivo AP Wieslab, constitutive Factor D, Factor Bb, total C3, C3a, total 
C4, C4a, and sC5b-9, and ex vivo AP-activated (multiplex) Factor Bb, C3a, and C5a. 
 
 
Statistical Methods: 
The primary study hypothesis is that the treatment effect, as measured by the CFB in Hb at Week 12 
for BCX9930, will be superior to placebo. The primary efficacy endpoint is the CFB in Hb at 
Week 12 in the intent-to-treat (ITT) population, which includes all randomized subjects, regardless of 
whether study drug was administered. The difference between treatment groups in CFB in Hb at 
Week 12 will be analyzed using an analysis of covariance (ANCOVA) model. The model will include 
treatment and randomization stratum as categorical covariates and baseline Hb as a continuous 
covariate. Missing data will be imputed using the Jump-to-Reference (J2R) method (Carpenter, 
Roger, et al. 2013). Inferential testing for the primary endpoint of interest (CFB in Hb at Week 12) 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
14 
 
CONFIDENTIAL 
will be conducted at the α = 0.05 level of significance. The alpha level for tests of primary and key 
secondary endpoints will be adjusted for multiplicity using hierarchical testing in the order the 
endpoints are specified. All hypothesis tests will be 2-sided. 
Sample Size: Assuming a common standard deviation for Hb of 2.3 g/dL from Lee and colleagues 
(Lee, Peffault de Latour, et al. 2019), and a randomization ratio of 2:1, a sample size of 57 subjects 
(approximately 38 subjects in the BCX9930 200/400 mg arm and approximately 19 subjects in the 
placebo arm) will provide 85.3% power to detect a treatment difference of 2.0 g/dL in change from 
baseline Hb for subjects randomized to BCX9930 200/400 mg compared to subjects randomized to 
placebo. Because missing data will be imputed for the primary analysis, enrollment has not been 
increased to account for drop-outs. 
Safety assessments, data from PNH using clinical measurements, PK, clinical laboratory biomarkers, 
and quality-of-life measurements will be summarized in tables and figures. 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
15 
 
CONFIDENTIAL 
3. 
TABLE OF CONTENTS, LIST OF TABLES, AND LIST OF 
FIGURES  
TABLE OF CONTENTS 
1. 
TITLE PAGE ................................................................................................................1 
SPONSOR SIGNATURE PAGE ....................................................................................................2 
INVESTIGATOR AGREEMENT...................................................................................................3 
STUDY INFORMATION ...............................................................................................................4 
2. 
SYNOPSIS ...................................................................................................................5 
3. 
TABLE OF CONTENTS, LIST OF TABLES, AND LIST OF FIGURES ...............15 
4. 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS.............................22 
5. 
INTRODUCTION ......................................................................................................27 
5.1. 
Background .................................................................................................................27 
5.1.1. 
The Complement System ............................................................................................27 
5.1.2. 
The Role of Factor D ..................................................................................................28 
5.1.3. 
Paroxysmal Nocturnal Hemoglobinuria .....................................................................28 
5.1.3.1. 
Currently Licensed Treatments for PNH ....................................................................29 
5.2. 
BCX9930 ....................................................................................................................30 
5.2.1. 
Nonclinical Findings for BCX9930 ............................................................................31 
5.2.2. 
Clinical Findings for BCX9930 ..................................................................................31 
5.2.2.1. 
Study BCX9930-101 ..................................................................................................31 
5.2.2.2. 
Study BCX9930-201 ..................................................................................................33 
5.2.2.3. 
Study BCX9930-102 ..................................................................................................33 
5.2.2.4. 
Other Clinical Studies .................................................................................................34 
5.3. 
Rationale for Study .....................................................................................................34 
5.3.1. 
Rationale for Study Population ...................................................................................34 
5.3.2. 
Rationale for Placebo Comparator: Ethical Considerations for Study Design ...........35 
5.3.3. 
Rationale for Study Endpoints ....................................................................................37 
5.3.4. 
Rationale for Dose Selection ......................................................................................38 
5.3.4.1. 
Summary of Hematologic Response at 400 and 500 mg BID – Studies 101 
and 201 ........................................................................................................................39 
5.3.4.2. 
Summary of PPK and PK/PD Modeling ....................................................................39 
5.3.4.3. 
Clinical Safety and Tolerability ..................................................................................41 
5.4. 
Benefit-Risk Assessment ............................................................................................42 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
16 
 
CONFIDENTIAL 
5.4.1. 
Potential Risks of Bacterial Infections .......................................................................42 
5.4.2. 
Potential Risks of SARS-CoV-2 Infection and Vaccination While Receiving 
BCX9930 Therapy ......................................................................................................43 
5.4.3. 
Potential Risks for Hemolysis After Discontinuation or Interruption of Study 
Treatment ....................................................................................................................43 
5.4.4. 
Potential Risks of Adverse Events with BCX9930 ....................................................43 
5.4.4.1. 
Potential Risks for Headache ......................................................................................43 
5.4.4.2. 
Potential Risks for Dermatologic Reactions ...............................................................44 
5.4.4.3. 
Potential Risks for Renal or Hepatic Effects ..............................................................44 
5.4.5. 
Overall Benefit-Risk Analysis ....................................................................................45 
6. 
STUDY OBJECTIVES ..............................................................................................45 
6.1. 
Objectives ...................................................................................................................45 
6.1.1. 
Part 1 Primary Objective ............................................................................................45 
6.1.2. 
Part 1 Secondary Objectives .......................................................................................45 
6.1.3. 
Part 2 Primary Objective ............................................................................................46 
6.1.4. 
Part 2 Secondary Objectives .......................................................................................46 
6.2. 
Endpoints ....................................................................................................................46 
6.2.1. 
Part 1 Primary Endpoint .............................................................................................46 
6.2.2. 
Part 1 Key Secondary Endpoints ................................................................................46 
6.2.3. 
Part 1 Other Secondary Endpoints ..............................................................................46 
6.2.4. 
Part 1 Exploratory Endpoints ......................................................................................47 
6.2.5. 
Part 1 Other Health-related Quality of Life Endpoints ...............................................47 
6.2.6. 
Part 1 Safety Endpoints ..............................................................................................48 
6.2.7. 
Part 2 Primary Endpoints ............................................................................................48 
6.2.8. 
Part 2 Secondary Endpoints ........................................................................................48 
6.2.9. 
Part 2 Exploratory Endpoints ......................................................................................49 
6.2.10. 
Part 2 Health-related Quality of Life Endpoints .........................................................49 
6.2.11. 
Pharmacokinetic and Pharmacodynamic Endpoints – Parts 1 and 2 ..........................50 
7. 
INVESTIGATIONAL PLAN .....................................................................................50 
7.1. 
Overall Study Design ..................................................................................................50 
7.2. 
Number of Subjects ....................................................................................................51 
7.3. 
Treatment Assignment ................................................................................................53 
7.4. 
Rescue Criteria for Part 1 ...........................................................................................53 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
17 
 
CONFIDENTIAL 
7.5. 
Individual and Study Termination Criteria .................................................................53 
7.5.1. 
Subject Withdrawal from Study Treatment ................................................................53 
7.5.2. 
Criteria for Study Termination ...................................................................................55 
8. 
SELECTION AND WITHDRAWAL OF SUBJECTS ..............................................55 
8.1. 
Subject Inclusion Criteria ...........................................................................................55 
8.2. 
Subject Exclusion Criteria ..........................................................................................56 
8.3. 
Subject Withdrawal ....................................................................................................58 
8.4. 
End of Study Definition ..............................................................................................58 
8.5. 
BCX9930 Access at Study Completion ......................................................................58 
9. 
TREATMENT OF SUBJECTS ..................................................................................59 
9.1. 
Description of Study Drug and Study Drug Product ..................................................59 
9.2. 
Description of Study Drug Packaging, Labelling, and Storage ..................................59 
9.3. 
Randomization and Blinding of Study Drug ..............................................................59 
9.3.1. 
Blinding ......................................................................................................................59 
9.3.2. 
Randomization ............................................................................................................60 
9.4. 
Study Drug Administration.........................................................................................60 
9.4.1. 
Treatment Interruption or Dose Reduction .................................................................61 
9.4.2. 
Dose Tapering .............................................................................................................61 
9.5. 
Treatment Compliance ................................................................................................61 
9.6. 
Missed Doses and Special Considerations for Dosing ...............................................62 
9.6.1. 
Missed Doses ..............................................................................................................62 
9.6.2. 
Special Considerations for Dosing, Including Inability to Take Medications 
Orally ..........................................................................................................................62 
9.7. 
Study Drug Accountability .........................................................................................63 
9.8. 
Prior and Concomitant Medications ...........................................................................63 
9.8.1. 
Prohibited and Restricted Medications .......................................................................64 
9.9. 
Vaccination Requirements, Vaccinations During Study, and Prophylactic 
Antibiotic Coverage ....................................................................................................65 
10. 
STUDY CONDUCT ...................................................................................................66 
10.1. 
Overview .....................................................................................................................66 
10.2. 
Schedule of Assessments ............................................................................................67 
10.3. 
Study Visits .................................................................................................................76 
10.3.1. 
Screening ....................................................................................................................76 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
18 
 
CONFIDENTIAL 
10.3.2. 
Rescreening/Retesting ................................................................................................77 
10.3.3. 
Baseline Visit (Day 1) ................................................................................................77 
10.3.4. 
On-study Visits for Part 1: Weeks 1, 2, 4, 8, and 12 ..................................................79 
10.3.5. 
On-study Visits for Part 2: Weeks 13, 14, 16, 20, 24, 28, 32, 36, 40, 44, 48, 
and 52 ..........................................................................................................................80 
10.3.6. 
Additional Assessments for Renal and Hepatic Safety Monitoring ...........................82 
10.3.7. 
Unscheduled Visits (Including for Assessment of Acute Symptomatic 
Hemolysis) ..................................................................................................................83 
10.3.8. 
End-of-Study Visit/Early Termination Visit ..............................................................83 
11. 
STUDY ASSESSMENTS ..........................................................................................84 
11.1. 
Chronology of Assessments .......................................................................................84 
11.2. 
Demographic Information, Medical and Medication History ....................................84 
11.2.1. 
Contraception Requirements ......................................................................................85 
11.3. 
Immunity Assessment .................................................................................................86 
11.4. 
Efficacy/Effectiveness Assessments ...........................................................................86 
11.4.1. 
Clinical and Laboratory Measurements of PNH ........................................................86 
11.4.2. 
Blood Transfusions .....................................................................................................87 
11.4.3. 
Clinical Measurements of Iron, Folate, and Vitamin B12 ...........................................87 
11.4.4. 
Patient-reported Outcomes .........................................................................................87 
11.4.4.1. 
FACIT-Fatigue ...........................................................................................................88 
11.4.4.2. 
QLQ-AA/PNH ............................................................................................................88 
11.4.4.3. 
Modified PRO-AA/PNH ............................................................................................89 
11.4.4.4. 
TSQM .........................................................................................................................89 
11.4.4.5. 
EQ-5D-5L ...................................................................................................................89 
11.4.4.6. 
PGIS-Fatigue, PGIS-Impact of Fatigue, and PGIS-Physical Functioning .................90 
11.4.4.7. 
PGIC-Fatigue, PGIC-Impact of Fatigue, and PGIC-Physical Functioning ................90 
11.4.5. 
Optional Exit Interviews .............................................................................................90 
11.5. 
Pharmacokinetic and Pharmacodynamic Assessments ..............................................90 
11.5.1. 
Blood Sampling for Pharmacokinetic Analysis ..........................................................91 
11.5.1.1. 
Optional Pharmacokinetic/Pharmacodynamic Substudy ............................................91 
11.5.2. 
Urine Collection for Measurement of Parent-Metabolite Concentration ...................92 
11.5.3. 
Blood Sampling for Analysis of Pharmacodynamic and Complement 
Biomarkers ..................................................................................................................92 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
19 
 
CONFIDENTIAL 
11.6. 
Optional Pharmacodynamic Analyses ........................................................................95 
11.7. 
Safety Assessments .....................................................................................................95 
11.7.1. 
Vital Signs ..................................................................................................................95 
11.7.2. 
Body Weight, Height, and Body Mass Index .............................................................95 
11.7.3. 
Physical Examination .................................................................................................95 
11.7.4. 
Electrocardiogram .......................................................................................................95 
11.7.5. 
Clinical Chemistry, Hematology, Urinalysis, and Other Laboratory 
Assessments ................................................................................................................96 
11.7.5.1. 
Urine Collections for Urinalysis, Microscopy, and Biomarker Testing .....................98 
11.7.6. 
Menopause and Pregnancy Testing ............................................................................99 
12. 
ADVERSE EVENTS..................................................................................................99 
12.1. 
Definition of Adverse Events .....................................................................................99 
12.1.1. 
Adverse Event .............................................................................................................99 
12.1.2. 
Serious Adverse Event ..............................................................................................101 
12.1.3. 
Events of Special Monitoring ...................................................................................101 
12.2. 
Definition of Severity ...............................................................................................102 
12.3. 
Relationship to Study Drug ......................................................................................102 
12.4. 
Method, Frequency, and Time Period for Detecting Adverse Events and 
Reporting Serious Adverse Events ...........................................................................103 
12.4.1. 
Serious Adverse Events and Suspected Unexpected Serious Adverse 
Reactions ...................................................................................................................104 
12.4.2. 
Pregnancy .................................................................................................................105 
12.4.3. 
Emergency Unblinding Procedures ..........................................................................105 
12.5. 
Adverse Event Management .....................................................................................105 
12.5.1. 
Potential Drug-induced Liver Injury: Monitoring, Evaluation, and 
Discontinuation Criteria ............................................................................................105 
12.5.2. 
Renal Events .............................................................................................................106 
12.5.2.1. 
Monitoring, Evaluation, and Subject Discontinuation Criteria ................................106 
12.5.2.2. 
Study Stopping Rule .................................................................................................107 
12.5.3. 
Risk of Hemolysis After Missed Doses, Treatment Interruption, or 
Permanent Discontinuation of BCX9930 .................................................................107 
12.5.4. 
Acute Symptomatic Hemolysis ................................................................................108 
12.6. 
Overdose ...................................................................................................................109 
12.7. 
Data Monitoring Committees ...................................................................................109 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
20 
 
CONFIDENTIAL 
13. 
STATISTICS ............................................................................................................109 
13.1. 
Hypotheses ................................................................................................................109 
13.1.1. 
Controlling for Multiplicity ......................................................................................111 
13.2. 
Sample Size Considerations .....................................................................................111 
13.3. 
Sample Size Re-estimation .......................................................................................111 
13.4. 
Stratification .............................................................................................................111 
13.5. 
Statistical Methods ....................................................................................................111 
13.5.1. 
Analysis Populations ................................................................................................111 
13.5.1.1. 
Screen Failures ..........................................................................................................112 
13.5.1.2. 
Intent-to-Treat Population ........................................................................................112 
13.5.1.3. 
Safety Population ......................................................................................................112 
13.5.1.4. 
Per Protocol Population ............................................................................................112 
13.5.1.5. 
Completers Population ..............................................................................................112 
13.5.1.6. 
Pharmacokinetic Population .....................................................................................112 
13.5.1.7. 
Pharmacodynamic Population ..................................................................................112 
13.5.2. 
General Considerations for Data Analysis ...............................................................113 
13.5.3. 
Subject Demographic and Disposition Data .............................................................113 
13.5.4. 
Analysis of Efficacy Variables .................................................................................113 
13.5.4.1. 
Primary Efficacy Analysis ........................................................................................113 
13.5.4.2. 
Analyses of Key Secondary, Other Secondary, and Exploratory Efficacy 
Endpoints ..................................................................................................................114 
13.5.5. 
Analysis of Safety Variables ....................................................................................119 
13.5.6. 
Acute Symptomatic Hemolysis ................................................................................120 
13.5.7. 
Breakthrough Hemolysis ..........................................................................................120 
13.5.8. 
Major Adverse Vascular Events ...............................................................................120 
13.5.9. 
Pharmacokinetic Analyses ........................................................................................120 
13.5.10. 
Pharmacodynamic and Biomarker Analyses ............................................................121 
14. 
STUDY ADMINISTRATION .................................................................................121 
14.1. 
Study Monitoring ......................................................................................................121 
14.2. 
Audits and Inspections ..............................................................................................122 
14.3. 
Ethics Committee ......................................................................................................122 
14.4. 
Serious Breaches of GCP ..........................................................................................122 
15. 
QUALITY CONTROL AND QUALITY ASSURANCE .......................................122 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
21 
 
CONFIDENTIAL 
16. 
ETHICS ....................................................................................................................123 
16.1. 
Ethics Review ...........................................................................................................123 
16.2. 
Ethical Conduct of the Study ....................................................................................123 
16.3. 
Written Informed Consent ........................................................................................123 
17. 
DATA HANDLING AND RECORDKEEPING .....................................................124 
17.1. 
Inspection of Records ...............................................................................................124 
17.2. 
Retention of Records ................................................................................................124 
17.3. 
Confidentiality of Information and Data ..................................................................124 
18. 
PUBLICATION POLICY ........................................................................................125 
19. 
LIST OF REFERENCES ..........................................................................................126 
 
LIST OF TABLES 
Table 1: 
List of Abbreviations and Specialist Terms ................................................................22 
Table 2: 
Study 101 Part 3/Study 201: Key Efficacy Parameters at Last Visit for 
400 and 500 mg BID ...................................................................................................39 
Table 3: 
Study BCX9930-203: Part 1 Schedule of Study Assessments/Procedures 
(Screening to Week 12) ..............................................................................................68 
Table 4: 
Study BCX9930-203: Part 2 Schedule of Study Assessments/Procedures 
(Weeks 13 to 52) .........................................................................................................73 
Table 5: 
Summary of Pharmacokinetic and Pharmacodynamic Blood Sampling ....................94 
Table 6: 
Clinical Laboratory Evaluations .................................................................................97 
 
LIST OF FIGURES 
Figure 1: 
The Complement Pathways ........................................................................................27 
Figure 2: 
Comparison of PK/PD Model-Estimated IC Values (95% CI) for 
AP Wieslab, LDH, and C3 Opsonization with Median (10th to 90th 
percentile) PPK Model-Estimated Ctau at 200, 400, and 500 mg BID ........................41 
Figure 3: 
BCX9930-203 Study Schema (Parts 1 and 2) ............................................................52 
 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
22 
 
CONFIDENTIAL 
4. 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
The following abbreviations and specialist terms are used in this study protocol. 
Table 1: 
List of Abbreviations and Specialist Terms 
Abbreviation or 
Specialist Term 
Explanation 
AA 
aplastic anemia 
ACIP 
Advisory Committee on Immunization Practices 
ADL 
Activities of Daily Living 
AE 
adverse event 
aHUS 
atypical hemolytic uremic syndrome 
AKI 
acute kidney injury 
ALP 
alkaline phosphatase 
ALT 
alanine aminotransferase (also SGPT) 
ANC 
absolute neutrophil count 
ANCOVA 
analysis of covariance 
AP 
alternative complement pathway 
ARC 
absolute reticulocyte count 
AST 
aspartate transferase (also SGOT) 
BCRP 
breast cancer resistance protein 
BID 
twice daily 
BMF 
bone marrow failure 
BMI 
body mass index 
BQL 
below the quantification level 
BTH 
breakthrough hemolysis 
C3 
complement component 3 
C3b 
end product of the alternative complement pathway 
C3bB 
Factor B in complex with C3b 
C3G 
complement 3 glomerulopathy 
C4 
complement component 4 
C5 
complement component 5 
CAC 
complement-activating condition 
CDF 
cumulative density function 
CFB 
change from baseline 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
23 
 
CONFIDENTIAL 
Abbreviation or 
Specialist Term 
Explanation 
CI 
confidence interval 
CIOMS 
Council for International Organizations of Medical Sciences 
CKD-EPI 
Chronic Kidney Disease Epidemiology Collaboration equation 
COS 
Clinical Outcomes Solutions 
CMH 
Cochran-Mantel-Haenszel 
COVID-19 
coronavirus disease 2019 
CP 
classical complement pathway 
CSR 
clinical study report 
Ctau 
trough concentration 
CTCAE 
Common Terminology Criteria for Adverse Events 
CYP 
cytochrome P450 
DDI 
drug-drug interaction 
DMC 
Data Monitoring Committee 
ECG 
electrocardiogram 
eCRF 
electronic case report form 
eGFR 
estimated glomerular filtration rate 
EOS 
end of study 
EOSM 
events of special monitoring 
EQ-5D-5L 
EuroQoL 5-dimension, 5-level questionnaire 
E-R 
exposure-response 
ET 
early termination 
EU 
European Union 
EVH 
extravascular hemolysis 
FACIT 
Functional Assessment of Chronic Illness Therapy 
FDA 
US Food and Drug Administration 
FIH 
first in human 
 
 
FSH 
follicle-stimulating hormone 
FXa 
activated Factor X 
FXIIa 
activated Factor XII 
GCP 
Good Clinical Practice 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
24 
 
CONFIDENTIAL 
Abbreviation or 
Specialist Term 
Explanation 
Hb 
hemoglobin 
HBV 
hepatitis B virus 
HCV 
hepatitis C virus 
Hib 
Haemophilus influenzae type B 
HIPAA 
US Health Insurance Portability and Accountability Act 
HIV 
human immunodeficiency virus 
HRQoL 
health-related quality of life 
IB 
Investigator’s Brochure 
IC50 
50% of maximal inhibitory concentration 
IC90 
90% of maximal inhibitory concentration 
ICF 
informed consent form 
ICH 
International Council for Harmonisation 
IMP 
investigational medicinal product 
INR 
international normalized ratio 
ITT 
intent-to-treat 
IV 
intravenous 
IVH 
intravascular hemolysis 
IWRS 
interactive web-based response system 
J2R 
Jump-to-Reference 
LDH 
lactate dehydrogenase 
LLN 
lower limit of normal (reference range) 
LP 
lectin complement pathway 
LSM 
least-squares mean 
MAC 
membrane attack complex 
MAD 
multiple ascending dose 
MAVE 
major adverse vascular event 
MedDRA 
Medical Dictionary for Regulatory Activities 
MMRM 
mixed model repeated measures 
N, n 
number of subjects or events (uppercase is total population; lowercase is 
subgroup population) 
NCI 
US National Cancer Institute 
NRMWG 
Nephrology Risk Mitigation Working Group 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
25 
 
CONFIDENTIAL 
Abbreviation or 
Specialist Term 
Explanation 
NSAID 
non-steroidal anti-inflammatory drug 
PD 
pharmacodynamic(s) 
PDF 
probability density function 
P-gp 
P-glycoprotein 
PGIC 
Patient Global Impression of Change 
PGIS 
Patient Global Impression of Severity 
PK 
pharmacokinetic(s) 
PK/PD 
pharmacokinetic/pharmacodynamic 
PNH 
paroxysmal nocturnal hemoglobinuria 
PP 
per-protocol 
PPK 
population pharmacokinetic(s) 
pRBC 
packed red blood cell 
PRO-AA/PNH 
Patient-Reported Outcome Questionnaire for Aplastic Anemia/Paroxysmal 
Nocturnal Hemoglobinuria 
Q12h 
every 12 hours 
Q24h 
every 24 hours 
QLQ-AA/PNH 
Quality of Life Questionnaire for patients with Aplastic Anemia and Paroxysmal 
Nocturnal Hemoglobinuria 
QoL 
quality-of-life 
QTcF 
QT interval corrected using Fridericia’s method 
RBC 
red blood cell 
SAD 
single ascending dose 
SAE 
serious adverse event 
SAP 
statistical analysis plan 
SARS-CoV-2 
severe acute respiratory syndrome coronavirus 2 
sC5b-9 
soluble C5b-9 
sCr 
serum creatinine 
SD 
standard deviation 
SGOT 
serum glutamic-oxaloacetic transaminase (also AST) 
SGPT 
serum glutamic-pyruvic transaminase (also ALT) 
SOC 
system organ class 
SUSAR 
suspected unexpected serious adverse reaction 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
26 
 
CONFIDENTIAL 
Abbreviation or 
Specialist Term 
Explanation 
t1/2 
half-life 
TEAE 
treatment-emergent adverse event 
TESAE 
treatment-emergent serious adverse event 
TSQM 
Treatment Satisfaction Questionnaire for Medication 
uACR 
urine albumin to creatinine ratio 
ULN 
upper limit of normal (reference range) 
uNGAL 
urine neutrophil gelatinase-associated lipocalin 
US 
United States 
VAS 
visual analog scale 
VZV 
varicella-zoster virus 
WBC 
white blood cell 
WHO 
World Health Organization 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
28 
 
CONFIDENTIAL 
The complement system is activated to high levels by the 3 complement pathways (ie, the CP, 
the LP, or the AP) and amplified by the AP amplification loop. Activation of the complement 
system by any of the 3 pathways results in production of C3b fragments, which can covalently 
attach to available surfaces (ie, opsonization) (Holers 2008, Brodsky 2014, Zipfel, Skerka, et al. 
2015, Ricklin, Reis, et al. 2016). Deposited C3b fragments trigger a positive feedback loop, 
called the AP amplification loop, by pairing with Factor B to form C3bB, which then is cleaved 
by Factor D to generate a second form of AP C3 convertase, C3bBb. Membrane-bound C3bBb 
then cleaves additional C3 to generate further C3b fragments, which bind additional Factor B 
molecules to repeat and amplify the cycle. Ultimately, activation of the AP amplification loop, 
whether initially by the AP, LP, or CP, leads to opsonization with C3b, release of the 
anaphylatoxins C3a and C5a, and assembly of the terminal membrane attack complex (MAC, 
also known as C5b-9) on the target surface, resulting in cell lysis (Ricklin, Reis, et al. 2016). 
Several studies have shown that the AP amplification loop may account for up to 80% of the C5a 
and MAC generated via CP or LP activation, substantially more than previously appreciated 
(Thurman and Holers 2006, Ekdahl, Mohlin, et al. 2019). 
In summary, regardless of whether complement is initially activated via the AP, CP, or LP, 
activation of the AP amplification loop results in opsonization of cell surfaces by C3b, formation 
of the C5 convertase C3bBb(3b)n, cleavage of C5, release of the anaphylatoxins C3a and C5a, 
and assembly of the terminal MAC on the target surface resulting in cell lysis (Ricklin, Reis, et 
al. 2016). 
5.1.2. 
The Role of Factor D 
Factor D is the rate-limiting enzyme of the AP (Volanakis and Narayana 1996) and the AP 
amplification loop and is made constitutively by adipocytes (White, Damm, et al. 1992). The 
only natural substrate for Factor D is complement Factor B bound to C3b (Volanakis and 
Narayana 1996). Factor D cleaves Factor B only after the latter is bound to C3b or C3(H2O) at 
the bond between Factor B amino acid residues 259 and 260, releasing the 30kD N-terminal Ba 
fragment and retention of the 60kD C-terminal Bb fragment that is required for production of the 
C3 convertases of the AP [ie, C3bBb and C3(H2O)Bb] (Torreira, Tortajada, et al. 2009). In 
addition, Factor D is essential for the AP amplification loop following generation of C3b by the 
AP, LP, or CP (Lesavre and Muller-Eberhard 1978, Volanakis and Narayana 1996, Xu, 
Narayana, et al. 2001). Based on in vitro studies using human serum, this AP amplification loop 
appears to account for up to 80% of the C5a and MAC generated from initial activation of 
complement by the CP or LP, or other proteolytic enzymes (eg, renin) in the plasma or other 
body fluids (Thurman and Holers 2006, Ekdahl, Mohlin, et al. 2019) (BioCryst internal data on 
file). As such, Factor D plays a central role in the activation and amplification of the AP, as well 
as in the amplification of the LP and the CP. 
5.1.3. 
Paroxysmal Nocturnal Hemoglobinuria 
PNH is an acquired, rare, serious, and potentially life-threatening disorder characterized by 
destruction of red blood cells (RBCs) resulting from uncontrolled activity of complement. PNH 
is caused by a somatic mutation in the phosphatidylinositol glycan anchor biosynthesis class A 
(PIG-A) gene in hematopoietic stem cells that leads to a deficiency of the membrane-displayed 
complement regulatory proteins CD55 and CD59 that normally protect RBCs from effective 
opsonization and lysis by the complement system. These deficiencies result in unrestrained 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
29 
 
CONFIDENTIAL 
complement activity that attacks RBCs leading to episodes of intravascular hemolysis (IVH), 
extravascular hemolysis (EVH), chronic hemolytic anemia, bone marrow failure (BMF), and 
thrombosis (Parker 2009, Pu and Brodsky 2011, Parker 2012), and EVH in patients treated with 
C5 inhibitors (Risitano, Notaro, et al. 2009). PNH affects men and women equally, and is more 
common in people of Asian than Caucasian ethnicity (Hill, DeZern, et al. 2017, Jalbert, 
Chaudhari, et al. 2019). The onset of PNH can occur at any age. The median (interquartile range) 
age of patients with PNH at diagnosis reported in a large series was 44 years (30 to 60 years) 
(Curran, Kernan, et al. 2012, Ge, Shi, et al. 2015, Mercuri, Farruggia, et al. 2017, Narita, 
Muramatsu, et al. 2017, Cannizzo, Raia, et al. 2019, Griesser, Myskiw, et al. 2020). 
IVH in PNH is associated with gastrointestinal, cardiovascular, pulmonary, neurological, and 
urogenital symptoms, as well as clotting disorders (Rother, Bell, et al. 2005, Savage and Brodsky 
2007). A classic symptom experienced by patients with PNH is discoloration of the urine due to 
hemoglobinuria following hemolysis. Patients report attacks of abdominal pain, difficulty 
swallowing, and pain during swallowing, as well as erectile dysfunction in men (Borowitz, 
Craig, et al. 2010, Rachidi, Musallam, et al. 2010). Other common symptoms related to anemia 
of patients with PNH are those such as debilitating fatigue, shortness of breath, and palpitations 
(Parker, Omine, et al. 2005). 
Patients with PNH have an increased risk for splanchnic, portal, and hepatic vein thrombosis, the 
latter leading to Budd-Chiari syndrome (Graham, Rosse, et al. 1996, Hauser, Brichta, et al. 2003, 
Yin, Liu, et al. 2009, Jain 2010, Torres, De Vroey, et al. 2010). 
Other nonhematological clinical findings include acute or chronic renal failure (Sechi, 
Marigliano, et al. 1988, Jackson, Noble, et al. 1992, Chow, Lai, et al. 2001, Nair, Khaira, et al. 
2008, Guasch 2010, Hillmen, Elebute, et al. 2010) and pulmonary hypertension (Heller, 
Grinberg, et al. 1992). 
PNH is associated with significant morbidity and mortality (Harris, Koscick, et al. 1999, Rachidi, 
Musallam, et al. 2010). Median survival in the era prior to use of C5 inhibitors was reported in 
one study as 10 years (Hillmen, Lewis, et al. 1995); a retrospective analysis found that 
approximately 20% of patients with only supportive care died within 6 years of diagnosis 
(Loschi, Porcher, et al. 2016). Thrombosis was the leading cause of death in PNH patients, 
accounting for up to 67% of deaths (Loschi, Porcher, et al. 2016). While thrombosis is relatively 
rare as a presenting symptom, it has historically occurred in up to 40% of patients during the 
course of disease (Pu and Brodsky 2011); a history of major adverse vascular events (MAVEs), 
including thromboembolism, was reported in 19% of patients with PNH in a large series 
(Schrezenmeier, Roth, et al. 2020). Visceral thrombosis, cerebrovascular events, and pulmonary 
embolism predict a poor outcome (Ziakas, Poulou, et al. 2008). 
5.1.3.1. 
Currently Licensed Treatments for PNH 
There are currently three therapeutic agents approved for the treatment of PNH in various parts 
of the world: eculizumab, ravulizumab, and pegcetacoplan. 
Eculizumab (approved in the United States [US] and European Union [EU] in 2007 and in Japan 
in 2010) and ravulizumab (approved in the US in 2018 and in the EU and Japan in 2019) were 
the only therapeutic agents approved for the treatment of PNH. Both eculizumab and 
ravulizumab are monoclonal antibodies directed against C5 and each is administered by 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
30 
 
CONFIDENTIAL 
intravenous (IV) infusion (Alexion Pharmaceuticals Soliris PI 2020, Alexion Pharmaceuticals 
Ultomiris PI 2020). 
Although survival has improved with the introduction of C5 inhibitors, significant unmet need 
remains (Marti-Carvajal, Anand, et al. 2014, Risitano, Marotta, et al. 2019). The hematological 
benefits among patients during C5 inhibitor treatment for PNH are heterogeneous. Complete 
normalization of hemoglobin (Hb) is seen in no more than one-third of patients, while the 
remaining patients continue to experience some degree of anemia, in some cases requiring 
regular RBC transfusions (Lee, Sicre de Fontbrune, et al. 2019). Different factors contribute to 
residual anemia during eculizumab treatment, including underlying bone marrow dysfunction, 
residual IVH, and C3-mediated EVH (Risitano, Marotta, et al. 2019). Therefore, there exists a 
significant unmet need for an efficacious and safe alternative therapeutic option that addresses 
the shortcomings of the available therapies, including dependence on lifelong IV infusion, 
ongoing EVH, and for those that do not respond adequately to available therapies, persistent 
anemia, PNH symptoms, and transfusion dependence. 
On 14 May 2021, the US Food and Drug Administration (FDA) granted approval for 
pegcetacoplan for the treatment of PNH. In December 2021, the European Commission granted 
approval for pegcetacoplan for the treatment of adult patients with PNH who are anemic after 
treatment with a C5 inhibitor for at least 3 months. Pegcetacoplan, which is administered by 
subcutaneous administration twice a week, is a synthetic cyclic peptide conjugated to a 
polyethylene glycol polymer that binds specifically to C3 and C3b (Apellis Pharmaceutical 
Empaveli PI 2021). 
5.2. 
BCX9930 
BioCryst Pharmaceuticals, Inc. (“BioCryst”) is developing BCX9930, a potent and selective, 
orally bioavailable, small-molecule inhibitor of complement Factor D. 
 
 
 
 
 
 
 
indicating that BCX9930 has the potential to inhibit both IVH and EVH. 
Targeting Factor D with a pharmacologic inhibitor is expected to block the formation of MAC 
and also inhibit the formation of C3 fragments, opsonization and, therefore, prevent both IVH 
and EVH in patients with PNH. 
Inhibiting Factor D with BCX9930 as a treatment strategy for PNH has at least 2 potential 
clinical advantages over C5 inhibitors: 1) C3b opsonization is blocked by Factor D inhibition, 
whereas it is not blocked by C5 inhibitors, with the result that opsonized PNH RBCs undergo 
EVH despite C5 inhibitor therapy; and 2) small molecule therapeutics inhibiting Factor D could 
be administered orally, abrogating the need for lifelong IV infusions of C5 inhibitors. 
Therefore, targeting Factor D is a promising therapeutic strategy to inhibit AP activation for the 
treatment of AP-mediated diseases such as PNH. 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
31 
 
CONFIDENTIAL 
 
 
 
 
5.2.1. 
Nonclinical Findings for BCX9930 
The results of nonclinical pharmacology, pharmacokinetics (PK), and toxicology studies of 
BCX9930 are described briefly below; additional details can be found in the Investigator’s 
Brochure (IB). 
 
 
 
 
 
In rats and dogs, BCX9930 is rapidly absorbed. Increases in exposure of BCX9930 were 
approximately proportional to increases in dose in both species. 
 
 
 
 
 
 
The data from safety pharmacology studies indicate that BCX9930 has a low potential to affect 
the respiratory, cardiovascular, and central nervous systems. 
 
 BCX9930 has a low risk to prolong the QT 
interval. 
 
 
 
 
 
The weight of evidence suggests BCX9930 has a low risk for genotoxicity. BCX9930 is not 
fetotoxic and is not teratogenic in pregnant rats and rabbits. There is a low concern for 
phototoxicity. 
5.2.2. 
Clinical Findings for BCX9930 
5.2.2.1. 
Study BCX9930-101 
The multipart first-in-human (FIH) study (Study 101) of single ascending dose (SAD) and 
multiple ascending dose (MAD) oral treatment with BCX9930 in 152 healthy subjects (Parts 1 
and 2) and ascending doses in 16 PNH subjects (Part 3) commenced in 2019 and has fully 
enrolled. 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
32 
 
CONFIDENTIAL 
Safety and tolerability were evaluated through assessments of treatment-emergent adverse events 
(TEAEs), laboratory analyses (clinical chemistry, hematology, and urinalysis), vital signs, 
electrocardiograms (ECGs; 12-lead and telemetry), and physical examinations. 
5.2.2.1.1. Healthy Subjects (Study 101, Parts 1 and 2) 
Part 1 of Study 101, a SAD study in 56 healthy subjects, has completed enrollment. No clinically 
significant dose-related trends in laboratory values, vital signs, or ECGs were noted in subjects 
receiving single doses ranging from 10 to 2000 mg. The most frequently reported TEAE 
assessed as possibly related to study drug was headache. 
Part 2 of Study 101, a MAD study in 96 healthy subjects, has completed enrollment. No 
clinically significant dose-related trends in laboratory values, vital signs, or ECGs were noted in 
any cohort. BCX9930 was safe and generally well tolerated following multiple doses of 
BCX9930 50 to 500 mg administered every 12 hours (Q12h) and 1000 to 2000 mg every 
24 hours (Q24h). The most frequently reported TEAE assessed as possibly related to study drug 
was rash that was self-limiting and not associated with mucosal involvement. No clinically 
significant dose-related trends in adverse events (AEs), laboratory values, vital signs, or ECGs 
were noted. 
In healthy subjects, BCX9930 exposure was linear and dose-proportional, with no evidence of 
dose- or time-dependent PK. Food effect (of a high-fat meal) on exposure was modest with an 
approximate 30% increase in exposure. Steady state was reached within 48 hours after repeat 
dosing, with modest accumulation (approximately 1.5-fold for Q12h regimens). The effective 
half-life (t1/2) was approximately 6 to 8 hours. 
BCX9930 showed rapid and dose-related suppression of the AP. After multiple doses of 
BCX9930 at dose levels ≥ 100 mg Q12h and ≥ 1000 mg Q24h, AP Wieslab activity was 
inhibited by > 95%. 
5.2.2.1.2. Subjects with PNH (Study 101, Part 3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
33 
 
CONFIDENTIAL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.2.2.2. 
Study BCX9930-201 
 
 
 
 
 
5.2.2.3. 
Study BCX9930-102 
 
 
 
 
 
 
  
 
 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
34 
 
CONFIDENTIAL 
 
 
 
 
5.2.2.4. 
Other Clinical Studies 
Four additional Phase 1 clinical studies in adult subjects have been initiated. Enrollment has 
completed for an absorption, distribution, metabolism, and excretion (ADME) study 
(Study BCX9930-103), a renal impairment study (Study BCX9930-104), an ethnobridging study 
to evaluate the safety, PK, and pharmacodynamics (PD) of SAD and MAD of BCX9930 in 
healthy subjects of Japanese origin (Study BCX9930-105), and a relative bioavailability study of 
BCX9930 tablet and capsule formulations in healthy subjects (Study 106). Results from these 
studies are described in the current version of the IB. 
5.3. 
Rationale for Study 
BCX9930 blocks the initiation of the AP and the C3 amplification loop via potent inhibition of 
Factor D, resulting in downstream inhibition of both proximal and terminal complement activity. 
Therefore, BCX9930 monotherapy has the potential to treat patients with PNH whether or not 
they have received treatment with C5 inhibitors and whether or not C3 opsonization associated 
with C5 inhibitor treatment is contributing to inadequate responses to those treatments. The 
clinical development plan for BCX9930 in PNH will evaluate BCX9930 in patients with PNH 
who have inadequate responses to C5 inhibitor treatment and patients who are not being treated 
with C5 inhibitor therapies in two complementary studies. Study BCX9930-202 will evaluate the 
efficacy, safety, and tolerability of BCX9930 monotherapy over a 24-week treatment period 
versus an active control of continued C5 inhibitor therapy in subjects with an inadequate 
response to that therapy, while the current study, BCX9930-203 (Study 203), will evaluate the 
efficacy, safety, and tolerability of BCX9930 monotherapy over a 12-week treatment versus 
placebo in subjects not currently receiving complement inhibitor therapy. 
Study 203 is divided into two parts, conducted on the same population of subjects. Part 1 of the 
study is designed to evaluate the efficacy, safety, and tolerability of treatment with oral 
BCX9930 monotherapy for 12 weeks versus placebo in subjects with PNH who are not currently 
receiving treatment with complement inhibitor therapy. Subjects will be randomized to receive 
BCX9930 monotherapy or placebo under double-blind conditions for the 12-week randomized 
treatment period. The primary efficacy and safety analyses will be based on Part 1. Part 2 of the 
study is designed to evaluate the long-term safety, tolerability, and effectiveness of BCX9930 
monotherapy when administered through Week 52. All subjects in Part 2 will receive BCX9930. 
Subjects who are randomized to BCX9930 monotherapy in Part 1 will continue to receive 
BCX9930 in Part 2. Subjects who are randomized to placebo in Part 1 will discontinue placebo 
at the Week 12 visit and receive BCX9930 in Part 2. 
5.3.1. 
Rationale for Study Population 
The current study will evaluate a single dose regimen of BCX9930 in subjects not currently 
receiving treatment with complement inhibitor therapy. For the purposes of this study, 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
35 
 
CONFIDENTIAL 
“complement inhibitor therapy” includes both approved therapies and investigational 
medications, and both proximal complement inhibitors, such as C3 inhibitors and inhibitors of 
Factor B or Factor D, and terminal complement inhibitors such as C5 inhibitors. In addition to 
patients naïve to complement inhibitor therapy, who are expected to make up the majority of 
study participants, for reasons of equity, individuals who have previously received complement 
inhibitor therapy may also be allowed to enroll in the study. To avoid inadvertently biasing the 
results of the current study, any prior complement inhibitor therapy must have been stopped at 
least 12 months prior to screening for this study. This will include individuals whose prior 
treatment was for a prescribed period only, eg, women who were indicated for treatment with 
eculizumab during pregnancy only, or individuals who may have participated in a clinical trial 
with an investigational medication where treatment either was not continued after the study 
completed or access to the study or study drug was stopped for reasons not directly related to the 
study drug (eg, travel restrictions related to coronavirus disease [COVID-19]). 
All participants must demonstrate ongoing IVH and anemia, as evidenced by an LDH of 
≥ 2 × ULN and a Hb ≤ 10.5 g/dL at screening. In addition to anemia, prospective subjects must 
show evidence of reticulocytosis (defined as an absolute reticulocyte count [ARC] of 
≥ 100,000 cells/µL) as further evidence of ongoing hemolysis and an ability to mount a 
hematopoietic response to treatment with BCX9930. To exclude patients with evidence of 
significant underlying aplastic anemia (AA) or BMF, who are unlikely to benefit from treatment 
with a complement inhibitor, and to minimize the risk of infection to participants, subjects will 
need to meet minimum thresholds at screening for platelet count (≥ 30,000 /µL) and absolute 
neutrophil counts (≥ 750 cells/µL). 
5.3.2. 
Rationale for Placebo Comparator: Ethical Considerations for Study Design 
Because PNH is such a rare disease, of necessity, the study is being conducted globally across 
multiple countries/regions, including in countries that have approved one or both of the 
commercially available C5 inhibitors and in other countries that have no approved PNH 
therapies beyond supportive care. 
Randomized, controlled clinical trials are recognized as the gold standard, and as described in the 
‘International Ethical Guidelines for Health-related Research Involving Humans,’ prepared by 
the Council for International Organizations of Medical Sciences (CIOMS) in collaboration with 
the World Health Organization (WHO) (CIOMS 2016), placebo is typically used as the 
comparator when there is no established effective intervention for the condition under study, or 
when the placebo is added on to an established effective intervention. For countries in which 
C5 inhibitor therapies are not currently approved, or approved but not accessible to patients, the 
inclusion of the placebo control is reasonable. Participants in both arms of the study will still be 
able to receive most of the treatments that currently constitute the local standard of care, 
including blood transfusions, growth factors and iron supplementation, and anticoagulant 
therapies for thrombosis prophylaxis. Thus, participants in the study randomized to placebo 
would be no worse off than if they did not participate in the study and will be able to access an 
investigational medicine at the end of the 12 weeks that would otherwise not be available to 
them. 
The CIOMS/WHO guidelines also recognize that the inclusion of a placebo control can be 
considered ethical, even when there is an established effective intervention, if there are 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
36 
 
CONFIDENTIAL 
“compelling scientific reasons for using placebo, and if delaying or withholding the established 
effective intervention, will result in no more than a minor increase above minimal risk to the 
participant and risks are minimized, including through the use of effective mitigation 
procedures”. In this study, including a placebo control allows for the study to be blinded, which 
is not considered a practical option with a C5 inhibitor control, given the need for sham IV 
infusions, thereby reducing the potential bias from an open-label study. Importantly, the 
inclusion of the placebo control allows for an assessment of the absolute benefit-risk of 
BCX9930 therapy in this patient population. 
Based on discussions with the US FDA at the End of Phase 1 meeting, a placebo control was 
considered acceptable if the following “mitigation procedures” are applied: 
1. The duration of the placebo-controlled treatment period is kept short. 
2. Placebo participants have the opportunity to receive active treatment after completing the 
placebo-controlled treatment period. 
3. The study protocol includes prespecified objective criteria that, in the event that the 
participant’s PNH disease was to worsen while receiving placebo, would allow a placebo 
recipient to be transitioned to active treatment early. 
These considerations are addressed as follows: 
1. The duration of blinded study treatment in this study is limited to 12 weeks. Based on 
review of the preliminary data from Study 101 and the results of Phase 2 studies 
performed with other investigational proximal complement inhibitors, including the 
C3 inhibitor, pegcetacoplan (APL-2), and orally administered inhibitors of Factor B, 
iptacopan (LNP 023) and Factor D, danicopan (ACH-0144471), a 12-week blinded 
treatment period is considered sufficient to be able to demonstrate the efficacy of 
treatment and sufficient to observe improvement in Hb after hemolysis is controlled 
(Kulasekararaj, Risitano, et al. 2019, Wong, Ignatova, et al. 2020, Risitano, Roth, et al. 
2021). 
2. At the end of the 12-week blinded treatment period, all placebo recipients are transitioned 
to BCX9930 monotherapy and will receive active treatment through Week 52. 
Thereafter, BioCryst has committed to provide access to BCX9930 to all study 
participants who are continuing to experience clinical benefit at the end of the current 
study. 
3. Importantly, the study protocol allows for blinded treatment to be discontinued and 
treatment with open-label BCX9930 initiated in subjects who demonstrate an immediate 
therapeutic need for active treatment. These criteria are described in detail in Section 7.4 
and include acute kidney injury (AKI) secondary to IVH and MAVEs, including 
thrombosis. Thrombotic events are recognized as the most significant cause of mortality 
in PNH patients (Hill, Kelly, et al. 2013). However, while serious and potentially 
life-threatening, these events are rare, and given the short 12-week duration of the 
placebo-controlled period, the actual risk from a thrombotic event is considered low. 
A cumulative thrombosis incidence of between 23% and 30% over an 8- to 10-year 
period is described by Griffin and Munir for the pre-eculizumab era, ie, representing 
untreated patients, in their 2017 paper [(Griffin and Munir 2017) based on original 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
37 
 
CONFIDENTIAL 
reports (Socie, Mary, et al. 1996, Ray, Burows, et al. 2000, Hall, Richards, et al. 2003, de 
Latour, Mary, et al. 2008)]. All study participants will be allowed to continue 
anticoagulant therapy for thrombosis prophylaxis without interruption during the study. 
Although eculizumab and ravulizumab are the current standard of care for the treatment of PNH 
in countries where one or both drugs have received regulatory approval, there are limitations on 
the availability of these drugs to clinicians treating PNH in many countries. It is recognized that 
these treatments represent some of the most expensive therapies available for the treatment of 
any disease. Because of the cost, the initiation of C5 inhibitor treatment is often limited to 
patients whose disease meets criteria specified by the relevant payers, whether the local health 
authorities and/or third-party healthcare insurers. Thus, there exists a patient population in these 
countries whose disease may not currently meet all of those criteria, who would derive benefit 
from an alternative complement inhibitor and who be willing to participate in this study. 
Similarly, in some jurisdictions, it is reported that the time needed to satisfy a healthcare insurer 
that a patient meets the criteria for treatment, absent a sudden deleterious worsening of the 
patient’s health status, can be as long as or longer than the duration of the placebo control. There 
are also patients who are known to be waiting for alternatives to the established IV treatments, 
who would consider participation in a study of an all oral therapy. 
In summary, there is scientific rationale for the inclusion of placebo to assess the true benefit-risk 
of BCX9930 and the design of the current study is intended to reduce the potential risk to 
participants by keeping the overall duration of placebo short, allowing all placebo patients to 
receive treatment with BCX9930 at the end of the placebo control period, and providing for a 
switch to open-label BCX9930 in the event that a subject should experience signs and symptoms 
consistent with the worsening of their disease. 
5.3.3. 
Rationale for Study Endpoints 
Patients with PNH who are not being treated with a C5 inhibitor or other complement inhibitor 
have uncontrolled IVH, resulting in anemia and fatigue (Risitano 2016). Therefore, the primary 
endpoint selected for this study is the change from baseline (CFB) in the Hb level, which is an 
objective biomarker that has generally been accepted as a surrogate for clinical benefit in this 
patient population, as reflected in its use as an endpoint in randomized controlled trials (Hillmen, 
Szer, et al. 2021) and in the draft hematological response categorization criteria proposed by the 
Severe Aplastic Anaemia Working Party of the European Bone Marrow Transplantation group 
(Risitano, Marotta, et al. 2019). This will be assessed though the end of the placebo-controlled 
treatment period at Week 12. 
Key secondary endpoints include those that characterize the clinical benefit of treatment with 
BCX9930. Secondary endpoints include the proportion of subjects who are transfusion-free over 
the 12-week period and reductions in transfusions as reflected in the number of units of packed 
RBC units (pRBCs) transfused, the percent CFB in LDH, and improvement in subject 
health-related quality of life (HRQoL) as reported using the established Functional Assessment 
of Chronic Illness Therapy (FACIT)-Fatigue scale. Although RBC transfusion criteria vary, 
reductions in RBC transfusion burden, as reflected in the proportion of subjects who remain 
transfusion-free and the number of units of RBCs transfused, is an important benefit of treatment 
of PNH. Fatigue is a key symptom of PNH which is frequently, sometimes constantly, 
experienced by patients and significantly impacts their HRQoL (Escalante, Chisolm, et al. 2019). 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
38 
 
CONFIDENTIAL 
The FACIT-Fatigue scale has been used in prior PNH clinical studies to assess self-reported 
fatigue and its impact upon daily activities and function, including pivotal clinical trials that 
supported the approvals of eculizumab and ravulizumab (Hillmen, Young, et al. 2006, Weitz, 
Meyers, et al. 2013, Kulasekararaj, Hill, et al. 2019, Lee, Sicre de Fontbrune, et al. 2019). 
Additional secondary endpoints will characterize the effects of BCX9930 on IVH by measuring 
the CFB in the total PNH RBC clone size, as well as the change in the ratio of total PNH RBCs 
to PNH white blood cells (WBCs) (ie, percent PNH RBCs/percent PNH WBCs) after 12 weeks. 
Preventing complement-mediated destruction of PNH RBC cells will increase the size of the 
total PNH RBC clone, but not impact the PNH WBC clone size, as WBCs are not materially 
affected by complement, so the total PNH RBC clone size should increase to approximate the 
PNH WBC clone size, as the theoretical maximum. 
Disease-specific instruments to measure HRQoL in patients with PNH are currently lacking and, 
as is often the case with ultra-rare diseases, evaluation of HRQoL is either incomplete or 
assessed using measures designed for other conditions. As a result, symptoms and impacts not 
relevant to patients with PNH are often measured and, most importantly, those that are of 
primary importance to patients are often not captured. The effect of BCX9930 monotherapy on 
HRQoL will be evaluated using a PNH-specific instrument, the Quality of Life Questionnaire for 
patients with Aplastic Anemia/Paroxysmal Nocturnal Hemoglobinuria (QLQ-AA/PNH). This 
instrument is currently being used in the International PNH Registry (Groth, Singer, et al. 2017, 
Niedeggen, Singer, et al. 2019). In addition, improvement on individual PNH symptom items 
(ie, frequency, severity, and/or interference) will be captured using a modified form of the 
PNH-specific symptom measure, the Patient-Reported Outcome Questionnaire for Aplastic 
Anemia and Paroxysmal Nocturnal Hemoglobinuria (PRO-AA/PNH) (Weisshaar, Ewald, et al. 
2020). These disease-specific measures will be supplemented by established patient-reported 
outcome (PRO) measures, including the EuroQoL 5-dimension, 5-level (EQ-5D-5L) 
questionnaire and the Treatment Satisfaction Questionnaire for Medication (TSQM). 
5.3.4. 
Rationale for Dose Selection 
The dose regimen selected for this study is 400 mg BID, modified from 500 mg BID in previous 
versions of this protocol based on efficacy and safety considerations. The following observations 
support this dosing regimen: 
• 
 
 
 
 
 
 
 
 
 
 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
39 
 
CONFIDENTIAL 
5.3.4.1. 
Summary of Hematologic Response at 400 and 500 mg BID – Studies 101 
and 201 
Available clinical efficacy data support the potential for lowering the target dose of BCX9930 
from 500 to 400 mg BID in the ongoing clinical studies. As dosing of BCX9930 was titrated in 
the initial cohort of subjects with PNH enrolled in Study 101 Part 3, that study and the long-term 
extension study (Study 201) provide a comparison of efficacy during at least 6 weeks of initial 
treatment with 400 mg BID and with ongoing treatment at 500 mg BID (Table 2). Nine subjects 
in Studies 101/201 had at least 6 weeks of dosing at 400 mg BID prior to escalating to 500 mg 
BID; 7 of these subjects were naïve to C5 inhibitors and provide a meaningful comparative 
dataset. Mean Hb, CFB in Hb, PNH Type II+III RBC clone size, its CFB, and the CFB in the 
ratio of RBC clone size to WBC clone size were very similar at both dose levels. No subjects 
required red blood cell transfusions during treatment at either dose level. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.3.4.2. 
Summary of PPK and PK/PD Modeling 
The primary efficacy consideration for the dose selection in this study was the development of 
PPK and PK/PD models using data from Studies 101 and 201. 
PD endpoints in these models included AP Wieslab in healthy and PNH subjects, LDH in 
subjects with PNH naïve to C5 inhibitors, and C3 opsonization in PNH subjects with inadequate 
response to ongoing C5 inhibitor therapy. AP Wieslab was used as a real-time marker of overall 
complement activation. LDH was used as a marker of IVH (terminal complement inhibition) and 
C3 opsonization was used as a marker of the potential for EVH (proximal complement 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
40 
 
CONFIDENTIAL 
inhibition) in PNH subjects. Target occupancy of Factor D is not expected to be affected by a 
terminal complement inhibitor, allowing for models of IVH and EVH to be extrapolated to all 
subjects with PNH regardless of C5 inhibitor status. 
 
 
 
 
 
 
Separate PK/PD models were constructed for AP Wieslab, LDH, and C3 opsonization of RBCs. 
Overall, the models performed well and were able to describe trends in the observed data. 
 
 
 
  
The LDH model in C5 inhibitor-naïve PNH subjects was characterized by indirect inhibition, 
 
 
 
 
 
 
  
 
 
 
 
 
Outcomes of PK/PD modeling are summarized in Figure 2 (comparison of predicted inhibitory 
concentrations with PPK-predicted Ctau). 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
41 
 
CONFIDENTIAL 
Figure 2: 
Comparison of PK/PD Model-Estimated IC Values (95% CI) for 
AP Wieslab, LDH, and C3 Opsonization with Median (10th to 90th percentile) 
PPK Model-Estimated Ctau at 200, 400, and 500 mg BID 
Abbreviations: AP = alternative pathway; BID = twice daily; CI = confidence interval; IC = inhibitory 
concentration; LDH = lactate dehydrogenase; PK/PD = pharmacokinetic/pharmacodynamic; PPK = population 
pharmacokinetic(s). 
Notes: Each simulation assumes perfect adherence and optimal spacing of BID doses (ie, every 12 hours). 
Initially, a dose of 500 mg BID was selected due to a small potential benefit relative to 400 mg 
BID in PK/PD model predictions in the absence of any safety signal in humans. Given the 
available safety data and overlapping confidence intervals in model estimates vs. 500 mg BID, a 
BCX9930 dose of 400 mg BID is supported by PPK and PK/PD modeling predictions to reach a 
similar clinical efficacy in PNH subjects. 
5.3.4.3. 
Clinical Safety and Tolerability 
In Study 101 Part 3/Study 201, administration of BCX9930 50 to 500 mg has been generally 
well tolerated for up to 746 days (approximately 107 weeks) in subjects with PNH. There have 
been no discontinuations due to drug-related TEAEs. The most common TEAEs related to 
BCX9930 have been headache and events consistent with a drug rash. 
 
 
 
 
 As of the data cutoff, 11 of the 16 subjects with PNH enrolled in Study 101 
Part 3 remain on treatment with BCX9930 at doses of 500 mg BID. 
 
 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
42 
 
CONFIDENTIAL 
 
 
 
 
 
 
 
 
5.4. 
Benefit-Risk Assessment 
The development of BCX9930 may be of benefit to patients with PNH and other 
complement-mediated diseases that are serious, associated with chronic morbidity, and are 
potentially life-threatening. In Study 101, administration of BCX9930 at doses of 400 mg or 
500 mg BID, both in subjects who are naïve to C5 inhibitors and in those who are receiving 
C5 inhibitors and had an inadequate response, resulted in sustained clinical responses, as 
measured by improvement in Hb levels, and decreases in LDH and C3 opsonization of RBC 
cells. Subjects participating in this study may similarly derive a benefit with BCX9930 in 
controlling the symptoms and/or improving laboratory parameters related to their PNH disease. 
Thorough monitoring and assessment of AEs will be performed for subjects enrolled in this 
study, and protocol-mandated safety assessments include vital sign measurements, physical 
examinations, ECGs, and clinical laboratory testing. 
Potential risks associated with complement inhibitors for the treatment of PNH, as well as 
potential risks associated with BCX9930 based on nonclinical and clinical data to date are 
described in the IB for BCX9930 and summarized below. 
5.4.1. 
Potential Risks of Bacterial Infections 
The most significant risk associated with complement inhibitor therapies is the risk of 
life-threatening or fatal meningococcal infections (Figueroa and Densen 1991, Hillmen, Young, 
et al. 2006). This risk is well-known and included as a warning in the relevant labels for both 
Soliris (eculizumab) and Ultomiris (ravulizumab) (Alexion Pharmaceuticals Soliris PI 2020, 
Alexion Pharmaceuticals Ultomiris PI 2020). 
As BCX9930 blocks the AP of complement, subjects may have increased susceptibility to 
bacterial infections, especially infections with encapsulated organisms, such as Neisseria 
meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae, but also with 
unencapsulated strains of N. meningitidis and other bacteria such as N. gonorrhoeae (Ram, 
Lewis, et al. 2010). Study subjects receiving BCX9930 will be monitored closely for signs and 
symptoms of infection; infection risk will be mitigated by requiring subjects to have up-to-date 
vaccinations against appropriate bacterial strains. If required on an individual basis, prophylactic 
antibiotic administration will be allowed. 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
43 
 
CONFIDENTIAL 
5.4.2. 
Potential Risks of SARS-CoV-2 Infection and Vaccination While Receiving 
BCX9930 Therapy 
Complement inhibitors do not inhibit cellular or humoral immunity. Therefore, BCX9930 is not 
expected to increase the risk of contracting COVID-19 following infection with the severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) or to increase the risk of severe illness with 
COVID-19. 
All study activity will be conducted in accordance with relevant local, regional, and national 
guidance around COVID-19. In order to minimize the risk of COVID-19 transmission, additional 
procedures or assessments (which may include but are not limited to symptom assessment, 
temperature, viral ribonucleic acid [RNA] testing, and antibody testing) may be implemented at 
the discretion of the investigator and sponsor medical monitor beyond those required for this 
protocol. 
Vaccination against SARS-CoV-2, the causal agent for COVID-19 infection, is allowed, if 
authorized and available in country or area, and based on investigator’s judgment. 
The sponsor’s current risk assessment, relative to COVID-19 vaccination in clinical trials with 
BCX9930, is that authorized or available COVID-19 vaccinations are unlikely to have any 
potential interaction or added safety risk, if given in combination with BCX9930. Also, 
currently, there is no theoretical concern or data to suggest that complement inhibition with 
ongoing BCX9930 treatment would impact the potential efficacy of vaccinations against 
SARS-CoV-2. While there is a known or expected higher risk of some bacterial infections in 
patients treated with complement inhibition and in patients with certain hereditary complement 
deficiencies, there is no clear known increased or compounded risk with vaccinations in the 
setting of complement inhibition; however, there have been reports of hemolysis in patients with 
PNH after SARS-CoV-2 vaccination (Gerber, Yuan, et al. 2021).  
5.4.3. 
Potential Risks for Hemolysis After Discontinuation or Interruption of Study 
Treatment 
Similar to available complement inhibitors used to treat PNH (Alexion Pharmaceuticals Soliris 
PI 2020, Alexion Pharmaceuticals Ultomiris PI 2020), discontinuation of BCX9930 may result in 
increased risk of hemolysis of PNH RBCs. Subjects receiving blinded study drug or BCX9930 
will be instructed to immediately contact the investigative site if they miss any doses of blinded 
study drug or BCX9930 and experience new or worsening symptoms of hemolysis. In addition, 
subjects who permanently discontinue blinded study drug or BCX9930 will be closely monitored 
for potential hemolysis. Assessments to detect hemolysis should be performed as described in 
Section 12.5.3 and Section 10.3.7. 
5.4.4. 
Potential Risks of Adverse Events with BCX9930 
5.4.4.1. 
Potential Risks for Headache 
In Phase 3 studies of adult patients with PNH who received eculizumab or ravulizumab, 
headache was one of the most frequently reported adverse drug reactions 
(Alexion Pharmaceuticals Soliris PI 2020, Alexion Pharmaceuticals Ultomiris PI 2020). 
Headaches that were considered related to ravulizumab and eculizumab commonly occurred 
early after the initiation of treatment. These headaches may be associated with a transient surge 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
44 
 
CONFIDENTIAL 
in plasma nitric oxide levels induced by the cessation of the depletion of nitric oxide by free 
hemoglobin (Hillmen, Young, et al. 2006, Brodsky 2008, Hillmen, Muus, et al. 2013, Roth, 
Rottinghaus, et al. 2018). In Study 101, early-onset headache was the most common TEAE in 
subjects with PNH treated with BCX9930, likely consistent with restoration of nitric oxide 
homeostasis due to improved control of hemolysis with BCX9930. 
5.4.4.2. 
Potential Risks for Dermatologic Reactions 
A benign maculopapular rash with consistent onset and clinical course has been observed with 
multiple-day dosing of BCX9930 in both healthy subjects and subjects with PNH. Clinical 
experience to date indicates that this rash resolves with no intervention while continuing dosing 
of BCX9930. Although there is no evidence for any systemic hypersensitivity, more severe 
reactions may be possible, and any subject with a rash believed to be related to BCX9930 should 
be evaluated, as deemed medically appropriate. Currently, the risk of discontinuing BCX9930 in 
PNH patients is greater than the potential risk of continuing with treatment; all PNH subjects 
with rash have recovered while continuing dosing and in the same timeframe as healthy subjects 
who stopped dosing of BCX9930. 
5.4.4.3. 
Potential Risks for Renal or Hepatic Effects 
Toxicities identified in nonclinical studies and detailed in the IB for BCX9930 are monitorable 
with standard blood and urine clinical chemistry tests. 
Renal Effects 
 
 
 
 
 
 
 
 
 
Monitoring of renal function will be undertaken in the study using standard measures (eg, sCr, 
estimated glomerular filtration rate [eGFR], and urinalysis including microscopy and biomarker 
analysis). Further information can be found in Section 11.7.5. Based on the timing of the 
early-onset sCr increases, the frequency of laboratory assessments is increased to monitor for any 
changes in renal function. Any renal events occurring on study should be evaluated as detailed in 
Section 12.5.2. 
Hepatic Effects 
Serum chemistries, including liver transaminases, bilirubin, and alkaline phosphatase (ALP), will 
be followed closely in this study to monitor for any hepatocellular and biliary system changes. 
Hepatic synthetic function will be monitored by prothrombin time, international normalized ratio 
(INR), albumin, and total protein levels in blood. The additional laboratory measurements 
performed through the first 12 weeks of BCX9930 treatment include monitoring for hepatic 
toxicities. 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
45 
 
CONFIDENTIAL 
5.4.5. 
Overall Benefit-Risk Analysis 
Treatment-emergent increases in 
 
 Based on the sponsor’s preliminary investigations, reducing 
the BCX9930 dose to 400 mg BID and introducing a step-up regimen (ie, starting dosing at 
200 mg BID for 2 weeks before escalating to 400 mg BID) is anticipated to mitigate the risk of 
 while maintaining the potential for demonstrating clinical benefit in the PNH patient 
population. 
BCX9930 is expected to provide greater efficacy than the currently available C5 inhibitors by 
not only preventing IVH, but also by preventing C3-mediated EVH, thereby reducing symptom 
burden, reducing hemolysis, including EVH and breakthrough hemolysis (BTH), improving 
patient function, changing the administration route from IV to oral, and improving HRQoL. 
Study subject selection criteria, dose selection, and study monitoring assessments have been 
included to optimize benefit and to minimize the risk of toxicities to study participants. Regular 
monitoring of safety parameters, including AEs, clinical laboratory abnormalities, vital signs 
measurements, ECGs, and physical examination findings, will ensure that the benefit-risk profile 
supports continued dosing. In addition, an independent, program-wide data monitoring 
committee (DMC) will provide oversight of the ongoing exposure of subjects to BCX9930 in 
this and other clinical studies. The overall benefit-risk balance is, therefore, considered to be 
acceptable. 
6. 
STUDY OBJECTIVES 
6.1. 
Objectives 
6.1.1. 
Part 1 Primary Objective 
The primary objective of Part 1 of this study is: 
• To determine the efficacy of oral BCX9930 monotherapy administered for 12 weeks, 
as compared to placebo, in subjects with PNH 
6.1.2. 
Part 1 Secondary Objectives 
The secondary objectives of Part 1 of this study are: 
• To evaluate the safety and tolerability of BCX9930 monotherapy administered for 
12 weeks, as compared to placebo, in subjects with PNH 
• To characterize the effects of BCX9930 monotherapy administered for 12 weeks, as 
compared to placebo, using clinical and laboratory measurements, including 
complement and thrombosis biomarkers, and PNH clone size, in subjects with PNH 
• To evaluate the effects of BCX9930 monotherapy administered for 12 weeks, as 
compared to placebo, on the FACIT-Fatigue scale and other PROs in subjects with 
PNH 
• To characterize BCX9930 plasma concentrations and PK parameters in subjects with 
PNH 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
46 
 
CONFIDENTIAL 
6.1.3. 
Part 2 Primary Objective 
The primary objective of Part 2 of this study is: 
• To evaluate the long-term safety and tolerability of oral BCX9930 monotherapy 
administered for up to 52 weeks in subjects with PNH 
6.1.4. 
Part 2 Secondary Objectives 
The secondary objectives of Part 2 of this study are: 
• To assess the effectiveness of BCX9930 monotherapy administered for up to 
52 weeks in subjects with PNH 
• To characterize the effects of BCX9930 monotherapy administered for up to 
52 weeks using clinical and laboratory measurements, including complement and 
thrombosis biomarkers, and PNH clone size, in subjects with PNH 
• To evaluate the effects of BCX9930 monotherapy administered for up to 52 weeks on 
FACIT-Fatigue scale and other PROs 
• To characterize BCX9930 plasma concentrations and PK parameters over time in 
subjects with PNH 
6.2. 
Endpoints 
In Part 1 of this study, unless indicated otherwise, all endpoints will be assessed at Week 12. In 
Part 2, unless indicated otherwise, all endpoints will be assessed at Week 52. For subjects who 
are switched from placebo to BCX9930 monotherapy at the end of Part 1, the baseline for 
treatment with BCX9930 will be defined as the last value prior to first dose of active treatment. 
6.2.1. 
Part 1 Primary Endpoint 
The primary endpoint of Part 1 of this study is: 
• CFB in Hb [at Week 12] 
6.2.2. 
Part 1 Key Secondary Endpoints 
The key secondary endpoints of Part 1 of this study are: 
1. Proportion of subjects who are transfusion-free [from Week 4 to Week 12] 
2. Number of units of pRBCs transfused [from Week 4 to Week 12] 
3. Percent CFB in LDH [at Week 12] 
4. CFB in FACIT-Fatigue scale score [at Week 12] 
6.2.3. 
Part 1 Other Secondary Endpoints 
Other secondary endpoints for Part 1 of the study are: 
• Percent reduction in the rate of pRBC units transfused [from Week 4 to Week 12 vs. 
prestudy transfusion rate] 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
47 
 
CONFIDENTIAL 
• Proportion of subjects with Hb ≥ 12 g/dL [at Week 12] 
• Hb stabilization, defined as avoidance of a > 2 g/dL decrease in the absence of 
transfusion [from Week 4 to Week 12] 
• CFB in total PNH RBC clone size [at Week 12] 
• CFB in ratio of total PNH RBC clone size to PNH WBC clone size (ie, percent PNH 
RBCs / percent PNH WBCs) [at Week 12] 
• CFB in absolute reticulocyte count (ARC) [at Week 12] 
• Proportion of subjects with ARC in the normal range [at Week 12] 
• CFB in haptoglobin [at Week 12] 
• Proportion of subjects with haptoglobin ≥ lower limit of normal reference range 
(LLN) [at Week 12] 
• CFB in total bilirubin [at Week 12] 
• CFB in aspartate aminotransferase (AST; also serum glutamic-oxaloacetic 
transaminase [SGOT]) [at Week 12] 
6.2.4. 
Part 1 Exploratory Endpoints 
The exploratory endpoints of Part 1 of this study are: 
• 
 
 
6.2.5. 
Part 1 Other Health-related Quality of Life Endpoints 
Other HRQoL endpoints for Part 1 of the study are: 
• Proportion of subjects achieving a within-subject meaningful change for the 
FACIT-Fatigue scale [at Week 12] 
• CFB in QLQ-AA/PNH Physical Functioning and other domain scores [at Week 12] 
• Proportion of subjects with improvement on individual PNH symptom items 
(ie, frequency, severity, and/or interference) from baseline as assessed using the 
modified PRO-AA/PNH symptom collection tool [at Week 12] 
• CFB in individual PNH symptom items on the modified PRO-AA/PNH scores 
[at Week 12] 
• CFB in EQ-5D-5L utility and visual analog scale (VAS) scores [at Week 12] 
• TSQM scale score [at Week 12] 
• Patient global impression of change in fatigue, impact of fatigue, and physical 
functioning as assessed using the PGIC-Fatigue, PGIC-Impact of Fatigue, and 
PGIC-Physical Functioning scores, respectively [at Week 12] 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
48 
 
CONFIDENTIAL 
• CFB in patient global impression of severity of fatigue, impact of fatigue, and 
physical functioning as assessed using the PGIS-Fatigue, PGIS-Impact of Fatigue, 
and PGIS-Physical Functioning scores, respectively [at Week 12] 
6.2.6. 
Part 1 Safety Endpoints 
The safety endpoints of Part 1 of this study are: 
• Number and proportion of subjects with a TEAE 
• Number and proportion of subjects who discontinue treatment due to a TEAE 
• Number and proportion of subjects who experience a treatment-emergent serious 
adverse event (TESAE) 
• Number and proportion of subjects who experience a Grade 3 or Grade 4 TEAE 
assessed using the US National Cancer Institute (NCI) Common Terminology Criteria 
for Adverse Event (CTCAE) grading scales 
• Number and proportion of subjects who experience a treatment-emergent CTCAE 
Grade 3 or Grade 4 laboratory abnormality 
6.2.7. 
Part 2 Primary Endpoints 
The primary endpoints of Part 2 of this study are: 
• Number and proportion of subjects with a TEAE 
• Number and proportion of subjects who discontinue due to a TEAE 
• Number and proportion of subjects who experience a TESAE 
• Number and proportion of subjects who experience a CTCAE Grade 3 or Grade 4 
TEAE 
• Number and proportion of subjects who experience a treatment-emergent CTCAE 
Grade 3 or Grade 4 laboratory abnormality 
6.2.8. 
Part 2 Secondary Endpoints 
The secondary endpoints in Part 2 of this study are: 
• CFB in Hb [mean of values from Weeks 12 to 52 for subjects randomized to 
BCX9930 in Part 1 and from Weeks 24 to 52 for subjects randomized to placebo] 
• Proportion of subjects with Hb ≥ 12 g/dL [at Week 52] 
• Proportion of subjects with Hb stabilization (avoidance of a > 2 g/dL decrease in the 
absence of transfusion) [from Weeks 12 to 52 for subjects randomized to BCX9930 
in Part 1 and from Weeks 16 to 52 for subjects randomized to placebo] 
• Proportion of subjects who are transfusion-free [from Weeks 12 to 52 for subjects 
randomized to BCX9930 in Part 1 and from Weeks 16 to 52 for subjects randomized 
to placebo] 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
49 
 
CONFIDENTIAL 
• Number of units of pRBCs transfused [from Weeks 12 to 52 for subjects randomized 
to BCX9930 in Part 1 and from Weeks 16 to 52 for subjects randomized to placebo] 
• Percent reduction in the rate of pRBC units transfused [from Weeks 12 to 52 for 
subjects randomized to BCX9930 in Part 1 and from Weeks 16 to 52 for subjects 
randomized to placebo vs. prestudy transfusion rate] 
• Percent CFB in LDH [mean of values from Weeks 12 to 52 for subjects randomized 
to BCX9930 in Part 1 and from Weeks 24 to 52 for subjects randomized to placebo] 
• CFB in ARC [mean of values from Weeks 12 to 52 for subjects randomized to 
BCX9930 in Part 1 and from Weeks 24 to 52 for subjects randomized to placebo] 
• Proportion of subjects with ARC in the normal range [at Week 52] 
• CFB in haptoglobin [mean of values from Weeks 12 to 52 for subjects randomized to 
BCX9930 in Part 1 and from Weeks 24 to 52 for subjects randomized to placebo] 
• Proportion of subjects with haptoglobin ≥ LLN [at Week 52] 
• CFB in total PNH RBC clone size [mean of values from Weeks 12 to 52 for subjects 
randomized to BCX9930 in Part 1 and from Weeks 24 to 52 for subjects randomized 
to placebo] 
• CFB in ratio of total PNH RBC clone size to PNH WBC clone size [mean of values 
from Weeks 12 to 52 for subjects randomized to BCX9930 in Part 1 and Weeks 24 to 
52 for subjects randomized to placebo] 
6.2.9. 
Part 2 Exploratory Endpoints 
• 
 
 
 
 
 
6.2.10. 
Part 2 Health-related Quality of Life Endpoints 
HRQoL endpoints in Part 2 of this study are: 
• Durability of FACIT-Fatigue scale, QLQ-AA/PNH domain, modified PRO-AA/PNH, 
EQ-5D-5L utility and VAS, and TSQM scale scores 
• Proportion of subjects achieving a within-subject meaningful change for 
FACIT-Fatigue scale 
• Proportion of subjects with improvement in individual PNH symptom items 
(ie, frequency, severity, and/or interference) on the modified PRO-AA/PNH as 
compared to baseline 
• Patient global impression of change in fatigue, impact of fatigue, and physical 
functioning since the start of open-label treatment as assessed using the 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
50 
 
CONFIDENTIAL 
PGIC-Fatigue, PGIC-Impact of Fatigue, and PGIC-Physical Functioning scores, 
respectively 
• CFB in patient global impression of severity of fatigue, impact of fatigue, and 
physical functioning as assessed using the PGIS-Fatigue, PGIS-Impact of Fatigue, 
and PGIS-Physical Functioning scores, respectively 
6.2.11. 
Pharmacokinetic and Pharmacodynamic Endpoints – Parts 1 and 2 
The PK and PD endpoints of Parts 1 and 2 of this study are: 
• PK data will be used to estimate PK parameters using appropriate PK analyses based 
on the sampling collection approaches 
• PD data will be used to estimate PD parameters as well as in combination with PK 
data to perform PKPD analyses 
• CFB in PD and complement biomarker measurements, including constitutive 
complement levels and ex vivo stimulation assays 
PK and PD data may be analyzed in combination with data from other clinical studies as 
appropriate. 
7. 
INVESTIGATIONAL PLAN 
7.1. 
Overall Study Design 
This is a randomized, placebo-controlled, double-blind, multicenter, parallel-group, 2-part study 
conducted in the same subjects. 
Part 1: Evaluation of efficacy, safety, and tolerability of BCX9930 monotherapy vs. placebo 
Part 1 of the study is designed to evaluate the efficacy, safety, and tolerability of treatment with 
oral BCX9930 monotherapy for 12 weeks versus placebo in subjects with PNH who are not 
currently receiving treatment with a complement inhibitor. Eligible subjects will be randomized 
in a 2:1 ratio to receive either BCX9930 monotherapy or placebo for 12 weeks under 
double-blind conditions. After completion of all baseline procedures, the first dose of study drug 
(ie, BCX9930 or placebo) will be administered on Day 1 under the supervision of clinic staff. 
Depending on the time of the first dose administration, the second dose of study drug may be 
taken at home later that day. Subsequent doses of study drug are taken BID, approximately 
12 hours apart, through Week 12. Subjects will be required to return to the clinic at Weeks 1, 2, 
4, 8, and 12 for study assessments. Additional safety assessments will be performed at Weeks 3, 
5, 6, 7, and 10. At the Week 12 visit, the treatment assignment for Part 1 will be unblinded. 
During the blinded treatment phase of the study, any subject who experiences a qualifying event 
reflecting a significant worsening of their PNH may be allowed to switch to open-label 
BCX9930. This is described in more detail in Section 7.4. 
Data collected through Week 12 will constitute the primary data set for the study; hence, the 
primary database will be locked and analyzed following capture of available data for all subjects 
through Week 12. 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
51 
 
CONFIDENTIAL 
Part 2: Evaluation of the long-term safety, tolerability, and effectiveness of BCX9930 
monotherapy 
Part 2 of the study is designed to evaluate the long-term safety, tolerability, and effectiveness of 
BCX9930 monotherapy when administered through Week 52. All subjects will receive 
BCX9930 in Part 2. Subjects randomized to placebo during Part 1 will discontinue placebo at the 
Week 12 visit and be switched to open-label BCX9930 monotherapy in Part 2, so that all 
subjects receive BCX9930 monotherapy in Part 2. All subjects will be required to return to the 
clinic at Weeks 13, 14, and 16, and then every 4 weeks thereafter through Week 52. Additional 
safety assessments will be performed at Weeks 15, 17, 18, 19, and 22 for subjects randomized to 
placebo who are newly switched to BCX9930 for Part 2. Data collected through Week 52 will be 
used to assess the long-term safety of BCX9930. 
After completion of Part 2, all subjects continuing to derive clinical benefit will be allowed to 
continue treatment with BCX9930 through enrollment in a separate long-term extension study, 
or via another access mechanism, where available (see Section 8.5). Subjects who do not 
continue BCX9930 therapy after Week 52, or who are prematurely discontinued from BCX9930 
treatment prior to Week 52, will be monitored for potential hemolysis and may be required to 
return to the clinic for an additional visit(s) to assess for acute symptomatic hemolysis, if and 
when symptoms occur, as described in Section 12.5.3. Subsequently, they will return to the clinic 
approximately 3 weeks after the date of last dose of BCX9930 for end of study assessments. 
A study schema is shown in Figure 3. 
7.2. 
Number of Subjects 
This study will enroll approximately 57 subjects with PNH who are not currently receiving 
treatment with a complement inhibitor. In Part 1, approximately 38 subjects will be randomized 
to BCX9930 monotherapy and approximately 19 subjects will be randomized to placebo under 
double-blind conditions. 
 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
52 
 
CONFIDENTIAL 
Figure 3: 
BCX9930-203 Study Schema (Parts 1 and 2) 
 
Abbreviations: BID = twice daily; D1 = Day 1. 
Note: Assessments occurring below the x-axis require a visit to the investigational site; assessments shown above the x-axis may be completed at the 
investigational site, at a laboratory local to the subject, or via a home health service (where permitted and available). 
 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
53 
 
CONFIDENTIAL 
7.3. 
Treatment Assignment 
In Part 1, eligible subjects will be randomized in a 2:1 ratio through an interactive web-based 
response system (IWRS) to receive BCX9930 monotherapy or placebo through Week 12: 
• BCX9930 to be administered orally BID (experimental arm) 
OR 
• Matched placebo administered orally BID (control arm) 
Randomization will be stratified based on receipt of a pRBC transfusion within the 6 months 
prior to baseline (yes vs. no). 
In Part 2, all subjects will receive BCX9930 monotherapy through Week 52: 
• BCX9930 to be administered orally BID (experimental arm) 
7.4. 
Rescue Criteria for Part 1 
In Part 1, subjects who meet either of the following criteria will be discontinued from blinded 
study drug, and at the investigator’s discretion, may be switched to open-label BCX9930 for the 
remainder of the treatment period in Part 1: 
• AKI, defined as an eGFR decrease of ≥ 50% or doubling of serum creatinine, 
secondary to IVH; or 
• MAVE, defined as one of the following: deep vein thrombosis; pulmonary embolus; 
myocardial infarction; transient ischemic attack; unstable angina; renal vein 
thrombosis; acute peripheral vascular occlusion; mesenteric/visceral vein thrombosis 
or infarction; mesenteric/visceral arterial thrombosis or infarction; hepatic/portal vein 
thrombosis (Budd-Chiari syndrome); cerebral arterial occlusion/cerebrovascular 
accident; cerebral venous occlusion; renal arterial thrombosis; gangrene 
(nontraumatic; nondiabetic); amputation (nontraumatic; nondiabetic); dermal 
thrombosis. 
Subjects should receive treatment with local standard of care appropriate for the event, as 
determined by the investigator or treating physician, based on available therapies. 
The subject’s treatment assignment will be unblinded after confirmation that the AKI or MAVE 
criterion has been met and prior to initiating treatment with open-label BCX9930. For subjects 
who were randomized to placebo, treatment with open-label BCX9930 should begin at 200 mg 
BID for the first 14 days before escalating to the 400 mg BID target dose. Subjects randomized 
to BCX9930 will continue on their current dose regimen. 
7.5. 
Individual and Study Termination Criteria 
7.5.1. 
Subject Withdrawal from Study Treatment 
A subject will be permanently discontinued from study drug in either study part for any of the 
following reasons: 
• Subject request to discontinue for any reason. 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
54 
 
CONFIDENTIAL 
• Pregnancy in a female subject. 
• Emergence of an AE, including a laboratory abnormality, or other unacceptable 
toxicity that, in the judgment of the investigator, compromises the ability of the 
subject to continue study-specific procedures or it is considered not to be in the 
subject’s best interest to continue due to an altered benefit-risk profile. 
• Intercurrent illness or the emergence of a new medical condition that would, in the 
judgment of the investigator, affect assessments of clinical status to a significant 
degree. 
• Treatment-emergent ALT (also serum glutamic-pyruvic transaminase [SGPT]) 
> 3 × ULN (confirmed by repeat testing) combined with either: 
− laboratory abnormalities indicative of significant hepatic toxicity (ie, meeting 
Hy’s law, total bilirubin > 2 × ULN OR with a new increase in INR > 1.5 in the 
absence of warfarin therapy) 
OR 
− symptomatology of acute hepatitis (ie, severe fatigue, nausea, vomiting, right 
upper quadrant pain and tenderness, fever, rash, and/or eosinophilia [> 5%] that 
has not been part of the subject’s history of PNH symptomatology) 
AND 
− assessed as probably or definitely related to BCX9930 
AND 
− without clinical and/or laboratory evidence of hemolysis or any other potential 
alternative etiology. 
• Treatment-emergent increase in sCr ≥ 3 × ULN (confirmed by repeat testing) without 
clinical and/or laboratory evidence of hemolysis or any other potential cause of renal 
dysfunction. 
• Invasive meningococcal infection or invasive encapsulated bacterial infection. 
Discontinuation may occur after subject stabilization to prevent uncontrolled 
hemolysis. 
• In the investigator’s opinion it is in the best interest of the subject to discontinue from 
further dosing. 
• Subject noncompliance (eg, protocol deviation), as assessed by the sponsor or 
investigator, to be detrimental to study or subject benefit-risk profile. 
• Discontinuation at the request of the sponsor, relevant competent authority, or the 
governing institutional review board (IRB), research ethics board (REB), or 
independent ethics committee (IEC), collectively referred to as “ethics committee”. 
Whenever possible, the investigator will consult with the sponsor medical monitor (or designee) 
before discontinuing study treatment. The reason for discontinuation of study treatment will be 
recorded in the source documents and electronic case report form (eCRF). 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
55 
 
CONFIDENTIAL 
Subjects who interrupt or discontinue study drug for any reason will be monitored for hemolysis 
as described in Section 12.5.3 and Section 10.3.7. 
7.5.2. 
Criteria for Study Termination 
The following study stopping criteria will be used to terminate either the study or the 
participation of a particular investigational site: 
• Request of the relevant competent authority or ethics committee 
• Emergence of unacceptable risk, toxicity, or negative change in the benefit-risk 
assessment 
• Non-compliance with the study protocol, including inaccurate or incomplete 
recordkeeping, that jeopardizes the scientific integrity of the study or subject safety 
BioCryst reserves the right to discontinue the study prior to inclusion of the planned number of 
subjects but intends only to exercise this right for valid scientific or administrative reasons. If 
BioCryst does discontinue the study, the investigator must contact all participating subjects 
immediately after notification of study termination. 
If the study is halted due to safety concerns, re-start of the study will occur only following the 
appropriate authorization via a substantial amendment. 
8. 
SELECTION AND WITHDRAWAL OF SUBJECTS 
8.1. 
Subject Inclusion Criteria 
Subjects must meet all of the following criteria, as applicable, to be eligible for participation in 
this study: 
1. Male or female, aged ≥ 18 years old. 
2. Body weight ≥ 40 kg. 
3. Documented diagnosis of PNH confirmed by flow cytometry with a PNH granulocyte or 
monocyte clone size of ≥ 10% during screening. 
4. Are either: (a) naïve to treatment with a complement inhibitor, or (b) have received no 
treatment with a complement inhibitor for at least 12 months prior to the screening visit. 
5. Do not have access to or have a contraindication (ie, have had a serious adverse reaction) 
to approved complement, C5 or C3, inhibitor therapies. 
6. Recorded the following results during screening: 
a. Hb ≤ 105 g/L (≤ 10.5 g/dL). 
b. LDH ≥ 2 × ULN. 
c. ARC of ≥ 100 × 109 cells/L (≥ 100,000 cells/µL; ≥ 100 G/L). 
d. ANC of ≥ 0.75 × 109 cells/L (≥ 750 cells/µL; or ≥ 0.75 G/L). 
e. Platelet count of ≥ 30 × 109/L (≥ 30,000 /µL; or ≥ 30 G/L). 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
56 
 
CONFIDENTIAL 
f. eGFR of ≥ 60 mL/min/1.73 m2 using the Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) equation (Levey and Stevens 2010) and no evidence of 
clinically relevant abnormal renal function unrelated to underlying PNH disease. 
7. Contraception requirements: 
Female participants must meet at least one of the following requirements: 
a. Be a woman of nonchildbearing potential. 
b. Be a woman of childbearing potential who agrees to use a highly effective 
contraceptive method throughout the study and for a duration of 30 days after the last 
dose of study drug. 
c. Alternatively, true abstinence is acceptable for women of childbearing potential when 
it is in line with the subject’s preferred and usual lifestyle. 
Male participants must meet at least one of the following requirements: 
a. Males with a female partner of childbearing potential must use condoms throughout 
the study and for a duration of 90 days after the last dose of study drug unless their 
partner is using a highly effective contraceptive method independent of the study. 
b. Alternatively, true abstinence is acceptable when it is in line with the subject’s 
preferred and usual lifestyle. 
Additional details are provided in Section 11.2.1. 
8. Documentation of current vaccinations against N. meningitidis types A, C, W, and Y, and 
S. pneumoniae, or willingness to start vaccination series at least 14 days prior to Day 1. 
(Note: Vaccination for N. meningitidis type B and for H. influenzae type B (Hib) is 
strongly encouraged where authorized and available.) 
9. In the opinion of the investigator, the subject is expected to adequately comply with all 
required study procedures and restrictions for the study, including compliance with the 
BID dosing schedule for BCX9930. 
10. Willing and able to provide written informed consent. 
8.2. 
Subject Exclusion Criteria 
Subjects must not meet any of the following exclusion criteria to be eligible for participation in 
the study: 
1. Known history of or existing diagnosis of hereditary complement deficiency. 
2. History of hematopoietic cell transplant or solid organ transplant or anticipated candidate 
for transplantation during the study. 
3. Myocardial infarction or cerebrovascular accident within 30 days prior to screening, or 
current and uncontrolled clinically significant cardiovascular or cerebrovascular 
condition, including unstable angina, severe congestive heart failure, unexplained 
syncope, arrhythmia, and critical aortic stenosis. 
4. History of malignancy within 5 years prior to the screening visit, with exception of 
adequately treated non-melanoma skin or superficial bladder cancer, curatively treated 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
57 
 
CONFIDENTIAL 
carcinoma in situ of the cervix, or other curatively treated solid tumor deemed by the 
investigator and medical monitor to be at low risk for recurrence. 
5. Active bacterial, viral, or fungal infection or any other serious infection within 14 days 
prior to screening. 
(Note: Suspected or confirmed COVID-19; persistent or recurrent positive test(s) for 
SARS-CoV-2 nucleic acids or antigens; and worsening dyspnea not due to PNH, 
vasculitic rash, and persistent fever or other symptoms consistent with multisystem 
inflammatory syndrome in adults [MIS-A] are exclusionary.) 
6. Current participation in any other investigational drug study or participation in an 
investigational drug study within 30 days prior to the screening visit, or 5.5 half-lives of 
the investigational drug, whichever is longer. 
7. Treatment with anti-thymocyte globulin within 180 days prior to the screening visit. 
8. Initiation of treatment with an erythropoiesis-stimulating agent (eg, erythropoietin), a 
thrombopoietin receptor agonist (eg, eltrombopag), or danazol within 28 days prior to the 
screening visit. 
(Note: Treatment with these medications initiated > 28 days prior to the screening visit is 
not exclusionary, if the dose is stable and there is a reasonable expectation that treatment 
will be continued.) 
9. Receiving iron with an unstable dose in the 28 days prior to the screening visit. 
10. Clinically significant abnormal ECG at the screening visit. 
(Note: This includes, but is not limited to, a QT interval corrected using Fridericia’s 
method [QTcF] of > 450 msec in males or > 470 msec in females, or ventricular and/or 
atrial premature contractions that are more frequent than occasional, and/or as couplets or 
higher in grouping.) 
11. Subjects with any of the following results at the screening visit: 
a. ALT (SGPT) > 3 × ULN. 
b. AST (SGOT) > 3 × ULN. 
(Note: Subjects may be enrolled with AST > 3 × ULN if explained by hemolysis.) 
c. Total serum bilirubin > 2 × ULN. 
(Note: Subjects may be enrolled with total serum bilirubin > 2 × ULN if explained by 
hemolysis or Gilbert’s syndrome. In the case of hemolysis, total serum bilirubin must 
be < 5 × ULN and in the case of Gilbert’s syndrome, total serum bilirubin must be 
< 11 × ULN.) 
12. Current use of a prohibited concomitant medication within 7 days prior to Day 1 as 
detailed in Section 9.8.1. 
13. Positive serology for human immunodeficiency virus (HIV), or active infection with 
hepatitis B virus (HBV) or hepatitis C virus (HCV), unless receiving antiviral therapy and 
viral load is undetectable. 
14. Positive drugs of abuse screen, unless by prescription. 
15. Pregnant, planning to become pregnant, or breastfeeding. 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
58 
 
CONFIDENTIAL 
16. Known hypersensitivity to BCX9930 or any of its formulation excipients. 
17. History of severe hypersensitivity to any medicinal product, which was associated with 
swelling, severe rash requiring treatment/hospitalization, or anaphylaxis. 
18. Any other clinically significant medical or psychiatric condition that, in the opinion of the 
investigator or sponsor, would interfere with the subject’s ability to participate in the 
study or increase the risk of participation for that subject. 
8.3. 
Subject Withdrawal 
Participation in the study is strictly voluntary; a subject may withdraw consent to contribute 
additional study information at any point. Subjects have the right to withdraw from the study at 
any time and for any reason. In addition, a subject’s participation may be terminated for any of 
the reasons described in Section 7.5.1. Whenever possible, the investigator will consult with the 
sponsor medical monitor before halting a subject’s participation in the study. 
Although a subject may withdraw from the study at any time without specifying a reason for 
withdrawal, the reason for withdrawal, if provided by the subject, will be recorded in the 
subject’s medical records (source documents) and also in the eCRF. If the reason for subject 
withdrawal is not known, attempts to contact the subject must be documented to establish 
whether the reason was due to an AE, and if so, this must be reported in accordance with the 
procedures outlined in Section 12.4.1. Vigorous attempts will be made for follow-up of all 
subjects who miss a study visit, given the potential for acute symptomatic hemolysis if BCX9930 
dosing is interrupted. If at any point in the study the clinic is unable to contact the subject after 
appropriate attempts have been made, the subject will be considered lost to follow-up. If a 
subject’s participation in this study is terminated, the responsible investigator/clinical staff 
member will document termination in the source documents.  
Unless consent is withdrawn, subjects who discontinue study treatment in Parts 1 or 2 will be 
monitored for potential hemolysis and may be required to return to the clinic for an additional 
visit(s) to assess for acute symptomatic hemolysis, if and when symptoms occur. An early 
termination (ET) visit will be completed approximately 3 weeks after the date of last dose of 
BCX9930. See Section 10.3.7 and Section 10.3.8, respectively. 
Once subjects have withdrawn from the study, the sponsor will no longer provide treatment with 
BCX9930 through the study. 
Subjects are not eligible for treatment with BCX9930 in Part 2 if they discontinue study 
treatment in Part 1 unless they meet the criteria for discontinuation of blinded treatment 
described in Section 7.4. 
8.4. 
End of Study Definition 
The end of the study will be defined as the date when the last subject completes the last 
protocol-scheduled visit. 
8.5. 
BCX9930 Access at Study Completion 
Subjects who are assessed as deriving clinical benefit from BCX9930 will be offered continued 
access to BCX9930 through participation in a separate long-term extension study, or via another 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
59 
 
CONFIDENTIAL 
treatment access mechanism, where available and approved by the relevant competent authority. 
Assuming continued approval of the competent authority, it is anticipated that BCX9930 will 
continue to be made available in each country until such time as BCX9930 is available through 
another means (eg, commercial approval) or until BioCryst discontinues development of the 
product for this indication. 
9. 
TREATMENT OF SUBJECTS 
9.1. 
Description of Study Drug and Study Drug Product 
The investigational medicinal product (IMP) for this study consists of BCX9930 and matched 
placebo tablets. 
BCX9930 is a small-molecule inhibitor of Factor D and will be supplied by BioCryst as tablets 
for oral administration. The active ingredient is BCX9930 drug substance. 
 
 
 
 
Dosage forms include BCX9930 tablets of 100-, 200-, and 250-mg strength, which are all from a 
dose-proportional blend compressed into tablets of the desired weight. 
The matching placebo will also be provided as tablets to match the BCX9930 tablets. The 
matching placebo tablets contain microcrystalline cellulose, mannitol, and magnesium stearate, 
and are film-coated with Opadry white. 
Additional details of the chemical and physical characteristics of BCX9930 may be found in the 
IB for BCX9930 and the IMP manual for the study. 
9.2. 
Description of Study Drug Packaging, Labelling, and Storage 
The study drug (BCX9930 tablets or matched placebo) will be packaged in bottles. 
Each bottle of study drug will be labeled with the information required per local law, which may 
include sponsor name, study protocol number, description of the contents, a statement regarding 
the investigational (clinical study) use of the study drug and expiry date. 
The bottles of study drug should be stored at 15°C to 25°C (59ºF to 77ºF). 
Details on the study drug packaging, labeling, shipment, storage, and dispensing will be provided 
in the IMP manual for the study. 
9.3. 
Randomization and Blinding of Study Drug 
9.3.1. 
Blinding 
In Part 1 of the study, the study drug assignment (BCX9930 or placebo) will be double-blinded 
(ie, the investigator, study staff, study subjects, and clinical research organization staff will be 
blinded). Sponsor employees will also be blinded to the treatment allocation of individual 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
60 
 
CONFIDENTIAL 
subjects, with the exception of sponsor staff responsible for managing study drug/IMP supplies. 
Other exceptions are described in the separate Blinding and Unblinding Plan for the study. 
Part 2 of the study will be open-label (ie, no blinding will be used). At the Week 12 visit, all 
subjects will be unblinded as to Part 1 treatment assignment and dispensed open-label BCX9930 
for Part 2. 
Information on unblinding in the event of an SAE is provided in Section 12.4.3. 
9.3.2. 
Randomization 
In Part 1 of the study, approximately 57 subjects will be randomized in a 2:1 ratio to the 
following treatments using a computer-generated randomization schedule prepared by an 
unblinded statistician: 
• Treatment 1: BCX9930 administered orally BID for 12 weeks (n = 38) 
• Treatment 2: Matched placebo administered orally BID for 12 weeks (n = 19) 
Details on the processes to be followed for randomization will be provided in a separate manual. 
Day 1 for purposes of analysis in Part 1 is defined as the day on which subjects take their first 
dose of study drug. Randomization will be scheduled such that it occurs on the same day that the 
subject is scheduled to receive the first dose of study drug, after completion of all baseline study 
procedures and confirmation of subject eligibility. If required by site procedures (ie, dispensing 
of randomized study drug must occur through a pharmacy), the subject may be randomized on 
the business day prior to the planned baseline (Day 1) visit. 
Randomization will be stratified based on whether a subject has received a pRBC transfusion 
within the 6 months prior to baseline (yes vs. no). There will be 2 strata as shown below. 
Stratum No. 
Stratum Description 
1 
Received pRBC transfusion within previous 6 months 
2 
Did not receive pRBC transfusion within previous 6 months 
9.4. 
Study Drug Administration 
Subjects who previously received 500 mg BID and remain on study treatment will be dose 
adjusted to 400 mg BID. 
For newly enrolled subjects randomized to BCX9930 in Part 1, and subjects switched to 
BCX9930 for Part 2, BCX9930 will be taken at a dose of 200 mg BID for the first 14 days of 
treatment before increasing to 400 mg BID. For subjects randomized to placebo in Part 1, an 
equivalent number of matched placebo tablets will be taken. Subjects will be instructed to take 
the BCX9930 or matched placebo tablets orally, twice a day at approximately the same times 
each day (ie, at intervals of approximately 12 hours) without regard to food. Adequate hydration 
should be maintained to prevent the formation of highly concentrated urine. 
No additional study drug preparation is required. BCX9930 or matched tablets will be taken 
from the provided bottles. 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
61 
 
CONFIDENTIAL 
Subjects will be dispensed a sufficient number of bottles of BCX9930 or matched tablets to 
cover the dosing period until the next study visit. 
Drug dispensation will occur in-clinic but may be delivered to subjects by other means 
(eg, traceable courier) if warranted due to extenuating circumstances (eg, COVID-19 
restrictions) which will be determined individually for each site and/or subject taking into 
account applicable local law or regulation. 
Subjects will be instructed to bring all bottles of study drug (both unused and used bottles) with 
them for each study visit, including any unscheduled visits, where possible. Accountability and 
adherence will be reviewed at these visits. 
9.4.1. 
Treatment Interruption or Dose Reduction 
Treatment interruption or dose reduction as a result of investigator management of AEs 
potentially related to study drug is permissible with appropriate monitoring for potential 
hemolysis as described in Section 12.5.3. Any treatment interruption or dose reduction will be 
recorded in the eCRF and source documents, including the reason for the interruption or 
reduction. Resumption of study drug administration is also permissible upon resolution of the 
event, as assessed by the investigator, with a plan for monitoring of the subject for recurrence of 
the AE, as appropriate. See Section 9.4.2 for potential dose reduction options. 
9.4.2. 
Dose Tapering 
In the event of permanent discontinuation of BCX9930, 
 
 
 
 
 
 
The decision to taper the dose and duration of any taper should be based on the investigator’s 
medical judgement, taking into account the reason for discontinuation of the drug, the severity of 
any reported signs or symptoms, and/or any reported worsening of signs or symptoms. The 
tapering schedule should be discussed with the sponsor medical monitor (or designee), ideally 
prior to implementation, and adjusted, as appropriate, for the individual subject. 
9.5. 
Treatment Compliance 
The first dose of study drug will be administered in the clinic on Day 1 under supervision. All 
subsequent doses can be taken at home; subjects do not need to withhold any doses on clinic 
days or take a dose at the clinic, unless the clinic visit falls during the subject’s normal time of 
dosing, or the subject is participating in the optional PK/PD substudy on a given visit. Subjects 
will be provided instructions for taking the twice-daily doses of BCX9930 at home, including 
frequency and time of administration. Where possible, the BCX9930 doses should be taken at the 
same times each day as close as possible to 12 hours apart (eg, 8:00 AM and 8:00 PM). 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
62 
 
CONFIDENTIAL 
It is anticipated that subject compliance with the BID dosing schedule for BCX9930 is critical to 
the success of this study. Missing more than 2 consecutive doses of BCX9930 increases the risk 
of subjects experiencing a hemolytic episode. Therefore, participants must be educated about and 
understand the importance of compliance with the dosing schedule, be reminded about the risks 
associated with breakthrough hemolysis, and the need to promptly report new or worsening signs 
and symptoms of potential hemolysis to staff, especially when associated with missed doses. 
Once enrolled in this study, each participant will need to be responsible for taking the study drug 
or BCX9930 doses twice a day, at approximately the same times and as close as possible to 
12 hours apart. Investigators are requested to meet with each participant and discuss with them 
the importance of treatment compliance prior to qualifying the participant for the study. 
Consideration should be given to strategies that will help reinforce these behaviors, such as 
asking subjects to voluntarily set up reminder alarms on their mobile phones or at their homes to 
remind them to take their doses, at least until they become adjusted to their new treatment 
regimen. BioCryst will provide materials that can be used to communicate the importance of 
compliance. Subjects will be asked to report new or worsening signs or symptoms of hemolysis 
to staff. Subjects will be required to bring the bottles of study drug or BCX9930 to clinic visits, 
including any unscheduled visit to assess for potential hemolysis, when possible. Investigators 
should remind participants who regularly miss doses about the importance of treatment 
compliance. 
9.6. 
Missed Doses and Special Considerations for Dosing 
If study drug needs to be withheld (eg, to assess a potentially drug-related TEAE), consideration 
for potential hemolysis as described in Section 12.5.3 should be given. 
9.6.1. 
Missed Doses 
Ideally, BCX9930 doses should be taken 12 hours apart at the same times each day without 
missing doses. If a subject does not take a BCX9930 dose at the scheduled time, the missed dose 
can be taken up to 6 hours after the scheduled dose time. If more than 6 hours has passed, the 
missed dose should not be taken. Regardless of whether the missed dose was made up, dosing 
should resume with the next dose taken at the scheduled time. For example, a subject who 
normally takes the BCX9930 doses at 8:00 AM/PM each day can take a missed morning dose as 
late as 2:00 PM with the evening dose administered on schedule at 8:00 PM. A missed evening 
dose can be taken as late as 2:00 AM the next day, with the next dose taken on schedule at 
8:00 AM. 
Subjects should be instructed to immediately contact the investigator if they miss any BCX9930 
doses and have new or worsening signs or symptoms consistent with acute symptomatic 
hemolysis (see Section 12.5.3). 
9.6.2. 
Special Considerations for Dosing, Including Inability to Take Medications 
Orally 
It is imperative that study subjects take study medication as scheduled without missing doses. 
Under certain circumstances, when a subject cannot take or absorb BCX9930 (including acute 
illness with vomiting, dysphagia due to symptomatic hemolysis, and unplanned circumstances 
requiring hospitalization), there are provisions that can be taken. 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
63 
 
CONFIDENTIAL 
For acute vomiting, treatment of nausea and/or vomiting with an oral, orally dissolving, or rectal 
suppository anti-emetic 30 minutes to an hour (as a suggestion) before attempting to swallow the 
BCX9930 tablets could be attempted. If a subject vomits after receiving a dose of BCX9930, the 
subject may be re-dosed (take two new tablets) if the intact tablets or pieces of the tablets are 
seen in the vomitus. 
Please refer also to the IMP manual for specific instructions. 
9.7. 
Study Drug Accountability 
Accountability of study drug dispensed and returned (as applicable) will be performed at Day 1 
and at each subsequent study visit (including at unscheduled visits, where possible). Returned 
study drug bottles must be retained and reviewed during monitoring visits by the study monitor. 
The investigator or designee (eg, pharmacist) must maintain accurate records of the disposition 
of all study drugs received from the sponsor, directly administered to the subject (including date 
and time) or dispensed to the subject. At the end of the study, information describing study drug 
accountability must be maintained at the site. 
All study drug not administered and any returned study drug (including empty bottles) will be 
returned to the sponsor or destroyed on site as instructed by the sponsor following IMP 
accountability by the study monitor, abiding by appropriate standard operating procedure(s) at 
the participating institution. 
9.8. 
Prior and Concomitant Medications 
Details of all prior treatments for PNH (ie, C5 and other complement inhibitors) will be recorded 
in the source documentation and eCRF, where known; all other medications will be documented 
beginning 30 days prior to the screening visit. All concomitant medication use, beginning with 
the screening visit, will be recorded in the source documentation and eCRF. 
Prior to enrollment, the investigator should review the subject’s medication list for potentially 
nephrotoxic medications and consider, when medically feasible, whether these medications may 
be stopped or substituted with non- or less nephrotoxic medications. Caution should be exercised 
with the chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) while taking BCX9930. 
With the exception of any changes to nephrotoxic medications and prohibited and restricted 
medications detailed below (Section 9.8.1), subjects should continue their normal medications. 
Medications that increase infection risk (including oral corticosteroids and other 
immunosuppressants) and erythropoietin (and analogs) should remain stable until at least the 
Week 12 visit, and then tapered as per the investigator’s judgement, unless taper or 
discontinuation during Part 1 needs to be done for safety reasons (eg, hemosiderosis). 
Prophylactic use of antibacterial and antiviral medications, other than those expressly prohibited 
on the prohibited medication list, may be considered if clinically indicated (eg, acyclovir for 
varicella-zoster virus [VZV]) and after discussion with the sponsor medical monitor (or 
designee), with consideration of the list of prohibited and restricted medications separate from 
this protocol (Section 9.8.1). 
Please refer to inclusion criterion 7 and Section 9.9 for vaccination requirements. 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
64 
 
CONFIDENTIAL 
9.8.1. 
Prohibited and Restricted Medications 
Drug interactions with concomitant medications (including supplements) may affect plasma 
concentrations of that medication or of BCX9930. Adjustments in the dosing regimen of 
concomitant medications and/or increased safety monitoring may be necessary based on the 
potential for interaction. Additional detail regarding potential for interaction with specific 
medications may be found in the prohibited and restricted medications list. 
All subjects should observe the prohibitions and restrictions on concomitant use described in 
Section 8.2 and in the following text for the appropriate window prior to screening or Day 1. All 
subjects must have discontinued all prohibited medications for a minimum of 7 days prior to 
Day 1 and have an agreed plan in place for monitoring any restricted medications that will be 
continued. Similarly, dose adjustments to restricted medications that are necessary for enrollment 
should be completed at least 7 days prior to Day 1. 
Use of the following medications is currently excluded while subjects are receiving treatment 
with study drug or BCX9930, beginning 7 days prior to Day 1, as is the planned initiation of 
treatment with such medications during the study: 
• 
 
 
 
 
 
 
 
 
 
 
• 
 
 
 
 
 
 
 
 
 
 
 
The sponsor will provide a list separate from the protocol of prohibited and restricted 
medications for which there may be a drug interaction with BCX9930 based upon regulatory 
labeling for individual medications, regulatory guidances, peer-reviewed literature, and regularly 
updated drug interaction reference databases (eg, University of Washington School of Pharmacy 
Drug Interaction Database, Pharmapendium). The sponsor may modify this list of prohibited 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
65 
 
CONFIDENTIAL 
medications based upon available PK and safety data on concomitant medications, ongoing 
clinical findings, and continued review of labeling, regulatory guidances, literature, and 
reference databases. A memorandum of any such changes to this list will be provided to all 
clinical sites. 
Phase 1 DDI studies may be conducted and resulted during the conduct of this study. Should the 
guidance for individual medications change, the use of currently prohibited medications may be 
subsequently allowed based upon the quantitative data generated in the DDI study. A summary 
and justification of the updated allowance/guidance will be provided to all clinical sites along 
with a revised list of prohibited medications. 
 
 
 
Throughout the course of the study, investigators should inquire about newly initiated, daily 
chronic-use medications; the investigator should compare these medications to the prohibited 
medication list. 
Similarly, subjects should be aware that there may be restricted medications in this study and 
should inform all treating physicians of their participation in this study and the possibility of 
potential interactions with BCX9930. 
Please contact the sponsor medical monitor for specific questions regarding prohibited and 
restricted medications if needed. 
9.9. 
Vaccination Requirements, Vaccinations During Study, and 
Prophylactic Antibiotic Coverage 
BCX9930 blocks the alternative pathway of complement activation; therefore, subjects may have 
increased susceptibility to bacterial infections, especially infections with encapsulated organisms 
such as N. meningitidis, S. pneumoniae, and H. influenzae, but also with unencapsulated strains 
of N. meningitidis and other bacteria such as N. gonorrhoeae (Ram, Lewis, et al. 2010). Effective 
and current vaccination coverage must be documented for N. meningitidis types A, C, W, and Y, 
and for S. pneumoniae. Vaccination for N. meningitidis type B and for H. influenzae type B (Hib) 
is strongly encouraged where authorized and available. 
For those who have not received all of the required vaccines (including boosters) or vaccine 
series, administration of any needed vaccines should start no later than 14 days prior to Day 1. 
If the recommended vaccination coverage requires more than a single dose, then the additional 
dose(s) may be administered after Day 1 to complete the recommended vaccination coverage. 
If a vaccine is not available, the sponsor medical monitor (or designee) should be contacted to 
discuss potential options in order to satisfy eligibility requirement prior to completing the Day 1 
visit. 
Antibiotic prophylaxis must be given from Day 1 until a subject is considered fully vaccinated 
(ie 2 weeks after a booster and 2 weeks after the last vaccination in a series) for those who 
receive a N. meningitidis vaccine less than 14 days before the first dose of study drug. Local 
treatment guidelines should be followed for prophylactic antibiotic therapy for patients with 
PNH at the discretion of the investigator for those receiving treatment with complement 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
66 
 
CONFIDENTIAL 
inhibition. The screening window can be extended for required vaccinations as per 
Section 10.3.2. 
Unless local guidelines are more stringent, the US Centers for Disease Control and Prevention 
Advisory Committee on Immunization Practices (ACIP) recommendations for meningococcal 
vaccination and ACIP guidance for altered immunocompetence (including complement 
inhibition therapy) should be followed (Mbaeyi 2020, Kroger, Bahta, et al. 2021). For vaccines 
against serogroups A, C, W, and Y, a booster vaccine should be given every 5 years while on 
complement inhibitor therapy; the available vaccines are interchangeable. For vaccines against 
serogroup B, a booster vaccine should be given 1 year after the series completion and every 2 to 
3 years thereafter; the available vaccines are not interchangeable (Mbaeyi 2020). 
S. pneumoniae vaccination is also required; vaccination with both conjugate and polysaccharide 
vaccines is preferred. 
Vaccination or a booster vaccine against Hib is strongly encouraged for all study participants 
where authorized and available. 
Prior to randomization, each study participant’s vaccination record will be reviewed by the 
sponsor medical monitor or designee, and a plan for required vaccinations will be made based on 
ACIP guidelines, any national guidance, local practice, authorized vaccines, and vaccine 
availability. Investigators will also review each subject’s vaccination status at periodic intervals 
to ensure that any needed booster vaccinations are administered at the optimal timing during the 
study. Please contact the sponsor medical monitor or designee for any questions. 
If a live vaccine needs to be given during the study, please contact the sponsor medical monitor 
or designee. 
10. 
STUDY CONDUCT 
10.1. 
Overview 
Prospective subjects will be qualified for the study during a screening period of up to 28 days 
prior to Day 1 (baseline). Once randomized, subjects will complete 2 consecutive treatment 
periods with a total duration of approximately 52 weeks. In the first, 12-week treatment period, 
subjects will be randomized to receive BCX9930 or placebo under double-blind conditions 
through Week 12. In the second, 40-week treatment period, subjects who are randomized to 
BCX9930 in Part 1 will continue to receive BCX9930, while those subjects who are randomized 
to placebo will discontinue placebo and receive BCX9930 through Week 52. At the end of the 
study, it is anticipated that subjects who have completed treatment with BCX9930 and, in the 
opinion of the investigator, would benefit from continued treatment with BCX9930 will be 
allowed to do so. Subjects who do not qualify for continued treatment with BCX9930, or who 
choose not to continue treatment, will be required to complete an end-of-study (EOS) visit 
approximately 3 weeks after the last dose of BCX9930. 
During the combined 52-week treatment period, all subjects will be required to attend at least 
18 in-clinic study visits: Day 1 (Baseline), Week 1 (Day 8), Week 2 (Day 15), Week 4 (Day 29), 
Week 8 (Day 57), Week 12 (Day 85), Week 13 (Day 92), Week 14 (Day 99), Week 16 
(Day 113), Week 20 (Day 141), Week 24 (Day 169), Week 28 (Day 197), Week 32 (Day 225), 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
67 
 
CONFIDENTIAL 
Week 36 (Day 253), Week 40 (Day 281), Week 44 (Day 309), Week 48 (Day 337), and Week 52 
(Day 365). Additional visits will be required for subjects who experience acute symptomatic 
hemolysis on-study and/or require additional post-treatment hemolysis assessment at the end of 
treatment, or who require unscheduled visits for additional or repeat evaluations. 
Additional safety assessments will also be required as part of the renal and hepatic safety 
monitoring program for all subjects at Weeks 3, 5, 6, 7, and 10 during the blinded treatment 
phase and at Weeks 15, 17, 18, 19, and 22 for subjects randomized to placebo after switching to 
BCX9930 for Part 2. These additional assessments may be performed at the investigational site, 
at a laboratory local to the subject, or via a home health service (where permitted and available) 
and will be continued until sufficient data are available to allow for reduction or elimination of 
the additional assessments. 
Inclusive of the screening and potential post-treatment follow-up periods, each subject’s 
participation in this study is expected to span up to approximately 59 weeks. 
10.2. 
Schedule of Assessments 
The schedule of study assessments/procedures for Part 1 of this study is presented in Table 3 and 
for Part 2 in Table 4. 
Assessments in the study are intended to be conducted in clinic; they may be conducted remotely 
under extenuating circumstances (eg, COVID-19 restrictions), which will be determined 
individually for each site and/or subject. 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
68 
 
CONFIDENTIAL 
Table 3: 
Study BCX9930-203: Part 1 Schedule of Study Assessments/Procedures (Screening to Week 12) 
Assessment/Procedure 
Screening 
(D-28 to 
D-1) 
Baseline 
D1 
Part 1 Treatment (Study Week/Daya) 
Unscheduled 
Visit (including 
for hemolysis 
assessment)b 
ETc 
Wk1 / D8 
Wk2 / D15 
Wk3 / D22 
Wk4 / D29 
Wk5 / D36 
Wk6 / D43 
Wk7 / D50 
Wk8 / D57 
Wk10 / D71 
Wk12 / D85 
Site visit 
X 
X 
X 
X 
 
X 
 
 
 
X 
 
X 
 
X 
Site visit or remote 
assessmentd 
 
 
 
 
X 
 
X 
X 
X 
 
X 
 
X 
 
Written informed consente 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
Review eligibility criteria 
X 
X 
 
 
 
 
 
 
 
 
 
 
 
 
Demographics 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medical & medication historyf 
X 
X 
 
 
 
 
 
 
 
 
 
 
 
 
Height, body weight & BMIg 
X 
X 
 
 
 
X 
 
 
 
X 
 
X 
 
X 
Physical examinationh 
X 
X 
X 
X 
 
X 
 
 
 
X 
 
X 
X 
X 
12-lead ECGi 
X 
X 
X 
X 
 
X 
 
 
 
X 
 
X 
 
X 
Vital signsj 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Hematology 
X 
X 
X 
X 
 
X 
 
 
 
X 
 
X 
X 
X 
Clinical chemistry 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Urinalysis including 
microscopyk 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Coagulation & haptoglobin 
X 
X 
X 
X 
 
X 
 
 
 
X 
 
X 
X 
X 
Drugs of abuse screen 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pregnancy testl 
X 
X 
 
 
 
X 
 
 
 
X 
 
X 
 
X 
FSHm 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
69 
 
CONFIDENTIAL 
Assessment/Procedure 
Screening 
(D-28 to 
D-1) 
Baseline 
D1 
Part 1 Treatment (Study Week/Daya) 
Unscheduled 
Visit (including 
for hemolysis 
assessment)b 
ETc 
Wk1 / D8 
Wk2 / D15 
Wk3 / D22 
Wk4 / D29 
Wk5 / D36 
Wk6 / D43 
Wk7 / D50 
Wk8 / D57 
Wk10 / D71 
Wk12 / D85 
HBV, HCV, HIV, VZV 
testingn 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
Urine for biomarkerso 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Optional exit interviewp 
 
 
 
 
 
 
 
 
 
 
 
X 
 
 
PRO questionnaireq 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FACIT-Fatigue scale 
 
X 
 
X 
 
X 
 
 
 
X 
 
X 
 
 
QLQ-AA/PNH 
 
X 
 
 
 
X 
 
 
 
X 
 
X 
 
 
Modified PRO-AA/PNH 
 
X 
X 
X 
 
X 
 
 
 
X 
 
X 
 
 
TSQM 
 
 
 
 
 
X 
 
 
 
 
 
X 
 
 
EQ-5D-5L 
 
X 
 
 
 
 
 
 
 
 
 
X 
 
 
PGIS-Fatigue/Impact of 
Fatigue/Physical 
Functioning 
 
X 
 
 
 
 
 
 
 
 
 
X 
 
 
PGIC-Fatigue/Impact of 
Fatigue/Physical 
Functioning 
 
 
 
 
 
 
 
 
 
 
 
X 
 
 
PK blood sample collectionr 
 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
PD blood sample collections 
X 
X 
X 
X 
 
X 
 
 
 
X 
 
X 
X 
X 
Optional PK/PD substudyt 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
PK urine collectionu 
 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Iron assessmentsv 
X 
X 
 
 
 
 
 
 
 
 
 
X 
 
X 
Subject randomizationw 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
Study drug dispensingx 
 
X 
 
X 
 
X 
 
 
 
X 
 
Xy 
 
 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
70 
 
CONFIDENTIAL 
Assessment/Procedure 
Screening 
(D-28 to 
D-1) 
Baseline 
D1 
Part 1 Treatment (Study Week/Daya) 
Unscheduled 
Visit (including 
for hemolysis 
assessment)b 
ETc 
Wk1 / D8 
Wk2 / D15 
Wk3 / D22 
Wk4 / D29 
Wk5 / D36 
Wk6 / D43 
Wk7 / D50 
Wk8 / D57 
Wk10 / D71 
Wk12 / D85 
Drug accountability 
 
 
X 
X 
 
X 
 
 
 
X 
 
X 
X 
X 
Record AEs, concomitant 
medications & transfusionsz 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: AE = adverse event; BMI = body mass index; ECG = electrocardiogram; EQ-5D-5L = EuroQoL 5-dimension, 5-level; ET = early termination; 
; FACIT = Functional Assessment of Chronic Illness Therapy; FSH = follicle-stimulating hormone; Hb = hemoglobin; HBV = hepatitis B 
virus; HCV = hepatitis C virus; HIV = human immunodeficiency virus; ICF = informed consent form; IWRS = interactive web response system; 
PD = pharmacodynamic(s); PGIC = Patient Global Impression of Change; PGIS = Patient Global Impression of Severity; PK = pharmacokinetic(s); 
pRBC = packed red blood cells; PRO = patient-reported outcome; PRO-AA/PNH = Patient-Reported Outcome Questionnaire for Aplastic Anemia/Paroxysmal 
Nocturnal Hemoglobinuria symptom collection tool; QLQ-AA/PNH = Quality of Life Questionnaire for patients with Aplastic Anemia/Paroxysmal Nocturnal 
Hemoglobinuria; TSQM = Treatment Satisfaction Questionnaire for Medication; VZV = varicella-zoster virus. 
Note: X = procedure to be performed only at visits to investigational site. 
a Visits may be performed within a window of ± 1 days for Week 1 and Week 2, and ± 3 days thereafter. 
b Subjects should be instructed to immediately contact the investigator if they have new or worsening symptoms of hemolysis. Following the permanent 
discontinuation of BCX9930, subjects may be required to complete an additional visit(s) to assess for acute symptomatic hemolysis if and when symptoms 
occur. 
c Subjects who discontinue the study for any reason will be asked to complete an early termination visit approximately3 weeks (± 3 days) after their last dose of 
study drug. 
d For subjects required to complete additional assessments for enhanced renal and hepatic safety monitoring purposes. These assessments may be performed at 
the investigational site or remotely using a laboratory more convenient for the subject or via a home health service (where permitted and available); results 
from local laboratory testing must be provided to the investigational site. 
e Signing of the written ICF may occur in advance of the screening visit and must be obtained from the subject as required by national or local law and 
institutional practice, prior to conducting any study-related assessments/procedures. 
f Medical history will include baseline PNH clinical characteristics and disease burden and review of current and prior renal health. Medication history will 
include all medications administered specifically for PNH (including C5 and other complement inhibitors) and within 30 days prior to screening visit for all 
other medications taken. 
g Body weight will be captured at all assessments; height will be measured and BMI calculated at screening only. 
h A full physical examination will be completed at screening; all other physical examinations may be abbreviated (ie, symptom-driven) examinations, targeted to 
new or worsening signs and symptoms. 
i Bedside 12-lead ECGs will be conducted in triplicate pre-dose on Day 1 and Week 12; all other ECGs may be single assessments. Subjects should rest quietly 
for 10 minutes in a supine position prior to the ECGs being performed. Any blood draws scheduled at the same time should occur after obtaining the ECG. 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
71 
 
CONFIDENTIAL 
j Vital signs (to include blood pressure, pulse rate, and temperature) will be performed at investigational site visits only (ie, excluding remote visits). Prior to 
obtaining blood pressure and pulse rate, subjects should rest quietly for a brief period. 
k Urine microscopy will be performed on urine collected at investigational site visits (and, where possible, at remote visits where the laboratory has appropriate 
on-site testing capability). Urine microscopy should be performed using the site’s local laboratory (assuming appropriate on-site testing capability exists) in lieu 
of the central laboratory. 
l A serum pregnancy test will be administered to women of childbearing potential or who are postmenopausal for ≤ 2 years at screening. All other pregnancy 
tests performed during the study may be urine pregnancy tests (for women of childbearing potential only, or as required by normal institutional practice). The 
subject’s continued use of contraception should be reviewed throughout the study. 
m FSH will be measured at screening to confirm postmenopausal state in women who report being postmenopausal for< 2 years. 
n Tests for HIV serology and active HBV and HCV infection – to include hepatitis B surface antigen, hepatitis B core antibody, hepatitis C antibody, 
HIV antibody – and VZV immunoglobulin G titer. 
o Urine will be collected at investigational site visits (ie, excluding remote visits) and aliquots frozen for possible future analysis of urine biomarkers. 
p Optional one-on-one qualitative exit interviews will be conducted by Clinical Outcomes Solutions or a third-party vendor over the telephone or by 
videoconference in a subset of subjects. The exit interview will be conducted for individual subjects as soon as possible (ideally within 2 weeks) after the end 
of blinded treatment (ie, Week 12 visit). A separate consent for the exit interview will be obtained at the screening or later visit. 
q All PRO instruments will be administered electronically using a tablet or equivalent device; QLQ-AA/PNH will be administered in paper form. 
r Single venous blood samples for analysis of plasma BCX9930 concentration will be collected from all subjects at each scheduled study visit, beginning at 
Week 1, and at any unscheduled visits to the investigational site to assess for acute symptomatic hemolysis or perform additional safety assessments. The blood 
sample may be drawn without regard to study drug dosing. 
s Blood samples for analysis of PD and clinical laboratory biomarkers will be collected at each study visit (including screening and Day 1) from all subjects 
regardless of treatment, including any unscheduled visit to assess for acute symptomatic hemolysis. On Day 1, the samples will be collected prior to 
administration of the first dose of study drug; at all other visits the blood sample may be drawn without regard to study drug dosing. 
t For subjects who participate in the optional PK/PD substudy, 4 blood samples for analysis of plasma BCX9930 concentration will be collected on Day 1 at 
0.5 (± 0.25), 1.5 (± 0.5), 3.5 (± 0.5), and 6 (± 1) hours post-dose. In addition, where possible, 5 blood samples for analysis of PD and clinical laboratory 
biomarkers will be collected on Day 1; the first sample will be collected prior to study drug dosing (≤ 2 hours) with subsequent samples collected at 
0.5 (± 0.25), 1.5 (± 0.5), 3.5 (± 0.5), and 6 (± 1) hours post-dose. As applicable, PD blood samples will be collected at the same time as the corresponding PK 
blood sample (ie, excluding the pre-dose sample). 
u Spot urine samples will be collected for analysis of the concentration of BCX9930 and metabolites at investigational site visits only (ie, excluding remote 
visits). 
v Iron, vitamin B12, and folate levels will be measured at screening. At baseline (Day 1), Week 12, and any ET visit performed, blood will be collected for 
assessment of iron, total iron binding capacity, transferrin, ferritin, hepcidin, and erythroferrone; urine will be collected for hemosiderin. 
w Subjects will be randomized on Day 1 to receive BCX9930 or placebo using an interactive web-based response system (IWRS). If required by site procedures 
(ie, dispensing of randomized study drug must occur through a pharmacy), the subject may be randomized on the business day prior to the planned baseline 
(Day 1) visit. 
x Study drug (BCX9930 or matched placebo) will be taken orally twice-daily, approximately 12 hours apart and at approximately the same times each day, 
without regard to food. 
y At the Week 12 visit, all subjects will be subjects will be unblinded as to Part 1 treatment assignment and dispensed open-label BCX9930 for Part 2. 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
72 
 
CONFIDENTIAL 
z AEs will be assessed and recorded from the time of signing of the ICF through the appropriate follow-up period. At each visit, subjects should be assessed for 
new or worsening signs and symptoms of PNH, including acute symptomatic hemolysis. Starting at randomization, subjects will be assessed for possible pRBC 
transfusion as described in Section 11.4.2. 
 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
73 
 
CONFIDENTIAL 
Table 4: 
Study BCX9930-203: Part 2 Schedule of Study Assessments/Procedures (Weeks 13 to 52) 
Assessment/Procedure 
Part 2 Treatment (Study Week/Daya) 
Unscheduled 
Visit 
(including for 
hemolysis 
assessment)b 
EOS/ 
ETc 
Wk13 / D92 
Wk14 / D99 
Wk15 / D106 
Wk16 / D113 
Wk17 / D120 
Wk18 / D127 
Wk19 / D134 
Wk20 / D141 
Wk22 / D155 
Wk24 / D169 
Wk28 / D197 
Wk32 / D225 
Wk36 / D253 
Wk40 / D281 
Wk44 / D309 
Wk48 / D337 
Wk52 / D365 
Site visit 
X 
X 
 
X 
 
 
 
X 
 
X 
X 
X 
X 
X 
X 
X 
X 
 
X 
Site visit or remote assessmentd 
 
 
X 
 
X 
X 
X 
 
X 
 
 
 
 
 
 
 
 
X 
 
Body weight 
 
 
 
X 
 
 
 
X 
 
X 
X 
X 
X 
X 
X 
X 
X 
 
X 
Physical examinatione 
X 
X 
 
X 
 
 
 
X 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
12-lead ECGf 
X 
X 
 
X 
 
 
 
X 
 
X 
X 
X 
X 
X 
X 
X 
X 
 
X 
Vital signsg 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Hematology 
X 
X 
 
X 
 
 
 
X 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Clinical chemistry 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Urinalysis including microscopyh 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Coagulation & haptoglobin 
X 
X 
 
X 
 
 
 
X 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Pregnancy testi 
 
 
 
X 
 
 
 
X 
 
X 
X 
X 
X 
X 
X 
X 
X 
 
X 
Urine for biomarker testingj 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
PRO questionnairesk 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FACIT-Fatigue scale 
 
X 
 
X 
 
 
 
X 
 
X 
 
 
X 
 
 
 
X 
 
 
QLQ-AA/PNH 
 
 
 
X 
 
 
 
X 
 
X 
 
 
X 
 
 
 
X 
 
 
Modified PRO-AA/PNH 
X 
X 
 
X 
 
 
 
X 
 
X 
 
 
X 
 
 
 
X 
 
 
TSQM 
 
 
 
X 
 
 
 
 
 
X 
 
 
X 
 
 
 
X 
 
 
EQ-5D-5L 
 
 
 
 
 
 
 
 
 
X 
 
 
 
 
 
 
X 
 
 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
75 
 
CONFIDENTIAL 
c Subjects who complete the study through Week 52 and who do not continue into the long-term extension study, and any subject who discontinues the study 
prior to Week 52 (for any reason), will be asked to complete an end-of-study or early termination visit, as applicable, approximately3 weeks (± 3 days) after 
last dose of BCX9930. 
d For subjects randomized to placebo who are newly switched to BCX9930 for Part 2 and who are required to complete additional assessments for enhanced 
renal and hepatic safety monitoring purposes. These assessments may be performed at the investigational site or remotely using a laboratory more convenient 
for the subject or via a home health service (where permitted and available); results from local laboratory testing must be provided to the investigational site. 
e Abbreviated (ie, symptom-driven) physical examinations, targeted to new or worsening signs and symptoms. 
f Subjects should rest quietly for 10 minutes in a supine position prior to the ECGs being performed. Any blood draws scheduled at the same time should occur 
after obtaining the ECG. 
g Vital signs (to include blood pressure, pulse rate, and temperature) will be performed at investigational site visits only (ie, excluding remote visits). Prior to 
obtaining blood pressure and pulse rate, subjects should rest quietly for a brief period. 
h Urine microscopy will be performed on urine collected at investigational site visits (and, where possible, at remote visits where the laboratory has appropriate 
on-site testing capability). Urine microscopy should be performed using the site’s local laboratory (assuming appropriate on-site testing capability exists) in lieu 
of the central laboratory. 
i Urine pregnancy tests (for women of childbearing potential only, or as required by normal institutional practice). The subject’s continued use of contraception 
should be reviewed throughout the study. 
j Urine will be collected at investigational site visits (ie, excluding remote visits) and aliquots frozen for possible future analysis of urine biomarkers. 
k All PRO instruments except QLQ-AA/PNH will be administered electronically using a tablet or equivalent device; QLQ-AA/PNH will be administered in 
paper form. 
l Single venous blood samples for analysis of plasma BCX9930 concentration will be collected at each scheduled study visit, and at any unscheduled visits to the 
investigational site to assess for acute symptomatic hemolysis or perform additional safety assessments. 
m Blood samples for analysis of clinical laboratory biomarkers will be collected at each scheduled study visit and any unscheduled visit to assess for acute 
symptomatic hemolysis. In addition, for subjects participating in the optional PK/PD substudy, time-matched blood samples for analysis of PD and clinical 
laboratory biomarkers will be collected at the same timepoints as the PK samples. 
n For subjects who participate in the optional PK/PD substudy, 5 blood samples for analysis of plasma BCX9930 concentration will be collected at Week 14 or a 
later visit, beginning prior to BCX9930 dosing (≤ 15 minutes) and continuing at 0.5 (± 0.25), 1.5 (± 0.5), 3.5 (± 0.5), and 6 (± 1) hours post-dose. In addition, 
where possible, 5 blood samples for analysis of PD and clinical laboratory biomarkers will be collected at the same time as the corresponding PK blood 
samples. 
o Spot urine samples will be collected for analysis of the concentration of BCX9930 and metabolites at investigational site visits (ie, excluding remote visits). 
p At Week 24, Week 52, and at any EOS/ET visit performed, blood will be collected for assessment of iron, total iron binding capacity, transferrin, ferritin, 
hepcidin, and erythroferrone; urine will be collected for hemosiderin. 
q BCX9930 doses will be taken orally, approximately 12 hours apart and at approximately the same times each day, without regard to food. 
r At each visit, the investigator (or designee) will assess the subject for new or worsening signs and symptoms of PNH, including acute symptomatic hemolysis. 
The need for pRBC transfusion will be assessed as described in Section 11.4.2. 
 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
76 
 
CONFIDENTIAL 
10.3. 
Study Visits 
10.3.1. 
Screening 
Subjects who are either naïve to complement inhibitor treatment or have not been treated with a 
complement inhibitor in the past ≥ 12 months may be screened for this study. 
Written informed consent must be obtained from each subject before initiation of any screening 
assessments or procedures. Signing of the informed consent form (ICF) may occur prior to the 
first on-study visit, which is defined as the visit where site-conducted procedures are first 
performed. 
A 28-day window is provided to qualify subjects for the study. All screening procedures do not 
need to be completed on the same day, but all screening procedures must be completed and the 
results reviewed and approved by the investigator (or designee) prior to randomizing a subject. 
An important consideration for the timing of the screening visit is the collection of blood for 
hematological testing relative to any pRBC transfusion that may have been administered or is 
planned to be administered. Where possible, the screening visit should be scheduled such that the 
hematology sample is drawn prior to any planned pRBC transfusion, or at least 14 days after the 
subject’s last pRBC transfusion, as applicable. 
The following assessments will be performed at the screening visit(s): 
• Obtain written informed consent 
• Discuss optional Exit Interview (by Clinical Outcomes Solutions [COS] or a 
third-party vendor) and obtain written informed consent for exit interview, if 
applicable. Note: A Subject Contact Form must be completed and sent to COS or the 
third-party vendor upon receipt of an executed informed consent. 
• Obtain demographic information 
• Review of inclusion-exclusion criteria 
• Medical history, including collection of PNH history, current and prior renal health, 
and confirmation of adequate vaccination status and either providing any 
protocol-required vaccinations and/or scheduling with local health care provider to 
have the subject vaccinated, as needed, where vaccination status cannot be confirmed; 
see Section 11.3. 
• Review medication history, including prohibited and restricted medications (see 
Section 9.8.1). All medications administered specifically for PNH (including C5 and 
other complement inhibitors) and within 30 days prior to screening visit for all other 
medications will be recorded. 
• Record all blood transfusions administered in at least the 12 months prior to the 
screening visit 
• Full physical examination 
• 12-lead ECG 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
77 
 
CONFIDENTIAL 
• Height, weight, and body mass index (BMI) estimation 
• Vital signs (resting blood pressure and pulse rate, and temperature) 
• Blood collection for clinical laboratory evaluations (see Table 3 and Table 6): 
− Blood for hematology, clinical chemistry (including haptoglobin), coagulation 
testing, and iron, folate, and vitamin B12 
− Blood for HBV, HCV, HIV, and VZV testing 
− Serum pregnancy test for female subjects of childbearing potential or who are 
postmenopausal for ≤ 2 years at screening 
− Blood collection for follicle-stimulating hormone (FSH) to confirm 
postmenopausal state in women who are postmenopausal for ≤ 2 years at 
screening 
• Blood collection for PD and clinical laboratory biomarkers 
• Blood collection for 
 
• Urine collection for clinical laboratory evaluations (see Table 3 and Table 6): 
− Urinalysis including microscopy 
− Urine drug screen 
A screening failure eCRF page will be completed for those subjects who do not proceed with 
study dosing, recording the reason for screening failure. 
10.3.2. 
Rescreening/Retesting 
Rescreening of ineligible subjects, where there is a reasonable expectation that the subject will 
become eligible, is permitted up to 2 times. If a subject is unable to be qualified in the 28-day 
window, eg, due to recent pRBC transfusion or acute illness, the screening window may be 
extended up to 14 additional days. Retesting of specific assessments without entirely rescreening 
a subject may be permitted with the approval of the sponsor medical monitor (or designee). 
10.3.3. 
Baseline Visit (Day 1) 
Where possible, the baseline (Day 1) visit should be scheduled such that the hematology sample 
is drawn prior to any planned pRBC transfusion, or at least 14 days after the subject’s last pRBC 
transfusion, as applicable. 
Before any study drug is administered, the following assessments will be completed: 
• Administer PRO questionnaires; where possible, the questionnaires should be 
completed by the subject prior to other assessments to prevent influencing subject 
perceptions: 
− FACIT-Fatigue scale 
− QLQ-AA/PNH 
− Modified PRO-AA/PNH 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
78 
 
CONFIDENTIAL 
− EQ-5D-5L 
− PGIS-Fatigue, PGIS-Impact of Fatigue, and PGIS-Physical Functioning 
• Review and update medical history, including PNH history, as needed 
• Review and update medication history, including prohibited and restricted 
medications. Record all medications administered specifically for PNH and all other 
medications since screening visit. 
• 12-lead ECG (triplicate ECGs) 
• Targeted physical examination 
• Body weight 
• Vital signs (resting blood pressure and pulse rate, and temperature) 
• Blood collection for clinical laboratory evaluations (see Table 3 and Table 6): 
− Blood for hematology, clinical chemistry (including haptoglobin), and 
coagulation testing 
− Blood for iron, total iron binding capacity, transferrin, ferritin, hepcidin, and 
erythroferrone 
• Blood collection for PK if participating in the optional PK/PD substudy, a total 
4 samples will be drawn through 6 hours post-dose as described in Section 11.5.1.1. 
• Blood collection for PD and clinical laboratory biomarkers (all subjects). 
Note: If participating in the optional PK substudy, where possible, a total of 
5 samples will be drawn through 6 hours post-dose as described in Section 11.5.1.1. 
• Blood collection for 
 
• Urine collection for clinical laboratory evaluations (see Table 3 and Table 6): 
− Urinalysis including microscopy 
− Urine collection for biomarker testing 
− Urine collection for hemosiderin 
• Urine pregnancy test for female subjects of childbearing potential (or as required by 
local or institutional practice). A negative pregnancy test result must be recorded in 
order for the subject to receive study drug. 
• Review of inclusion-exclusion criteria (to confirm study eligibility) 
• Randomization (if not done previously). 
Note: If required by site procedures (eg, dispensing of randomized study drug must 
occur through a pharmacy), the subject may be randomized on the business day prior 
to the planned baseline (Day 1) visit. 
• Review/record AEs since screening visit 
• Record any blood transfusions administered since the screening visit 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
79 
 
CONFIDENTIAL 
After completion of all baseline procedures, subjects will receive the first dose of blinded study 
drug administered under the supervision of clinic staff. Subjects participating in the optional 
PK/PD substudy will remain in the clinic for approximately 6 hours post-dose to allow for the 
collection of the additional post-dose PK and PD blood samples as described in Section 11.5.1.1. 
10.3.4. 
On-study Visits for Part 1: Weeks 1, 2, 4, 8, and 12 
In Part 1, all subjects will return to the clinic during Week 1 (Day 8 ± 1 day), Week 2 
(Day 15 ± 1 day), Week 4 (Day 29 ± 3 days), Week 8 (Day 57 ± 3 days), and Week 12 
(Day 85 ± 3 days). [Note: If the subject attends the clinic for an unscheduled visit, including for 
pRBC transfusion, at any time within the 14-day period prior to the scheduled Week 12 visit, 
where possible, a blood sample for hematology should be collected for analysis by the 
designated central laboratory.] 
Subjects do not need to withhold any doses on clinic days or take a dose in the clinic unless the 
clinic visit falls during the subject’s normal time of dosing. 
The following assessments will be performed at each visit unless otherwise indicated: 
• Administer PRO questionnaires; where possible, the questionnaires should be 
completed by the subject prior to other assessments to prevent influencing subject 
perceptions: 
− FACIT-Fatigue scale at Weeks 2, 4, 8, and 12 
− QLQ-AA/PNH at Weeks 4, 8 and 12 
− Modified PRO-AA/PNH at Weeks 1, 2, 4, 8, and 12 
− TSQM at Weeks 4 and 12 
− EQ-5D-5L at Week 12 
− PGIS-Fatigue, PGIS-Impact of Fatigue, and PGIS-Physical Functioning at 
Week 12 
− PGIC-Fatigue, PGIC-Impact of Fatigue, and PGIC-Physical Functioning at 
Week 12 
• 12-lead ECG (single ECGs, except at Week 12 when triplicate ECGs are required) 
• Targeted physical examination 
• Body weight at Weeks 4, 8, and 12 
• Vital signs (resting blood pressure and pulse rate, and temperature) 
• Blood collection for clinical laboratory evaluations (see Table 3 and Table 6): 
− Blood for hematology, clinical chemistry (including haptoglobin), and 
coagulation testing 
− Blood for iron, total iron binding capacity, transferrin, ferritin, hepcidin, and 
erythroferrone at Week 12 
• Blood collection for PK 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
80 
 
CONFIDENTIAL 
• Blood collection for PD and clinical laboratory biomarkers 
• Blood collection for 
 
• Urine collection for clinical laboratory evaluations (see Table 3 and Table 6): 
− Urinalysis including microscopy 
− Urine collection for biomarker testing 
− Urine collection for hemosiderin at Week 12 
• Urine collection for PK 
• Urine pregnancy test for female subjects of childbearing potential (or as required by 
local or institutional practice) at Weeks 4, 8, and 12. A negative pregnancy test result 
must be recorded in order for the subject to continue receiving study drug. 
• Study drug dispensing and drug accountability review 
• Review/record AEs, concomitant medication use, including prohibited and restricted 
medications, and blood transfusions 
At Week 8, subjects participating in the optional Exit Interview should be reminded that they 
will be contacted by COS or a third-party vendor about scheduling the interview. 
At Week 12, all subjects will receive a new treatment allocation, reflecting the transition to 
open-label BCX9930. After completion of all Week 12 procedures, subjects will be unblinded so 
staff can advise participants of the need to complete additional safety assessments if previously 
randomized to placebo. Subjects will receive the first dose of open-label BCX9930 administered 
under the supervision of clinic staff. Where appropriate, subjects will be reminded about the 
optional Exit Interview. 
10.3.5. 
On-study Visits for Part 2: Weeks 13, 14, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 
In Part 2, all subjects will return to the clinic during Week 13 (Day 92 ± 1 day), Week 14 
(Day 99 ± 1 day), Week 16 (Day 113 ± 3 days), Week 20 (Day 141 ± 3 days), Week 24 
(Day 169 ± 3 days), Week 28 (Day 197 ± 3 days), Week 32 (Day 225 ± 3 days), Week 36 
(Day 253 ± 3 days), Week 40 (Day 281 ± 3 days), Week 44 (Day 309 ± 3 days), Week 48 
(Day 337 ± 3 days), and Week 52 (Day 365 ± 3 days). 
Subjects do not need to withhold any BCX9930 doses on clinic days or take a dose in the clinic, 
unless the clinic visit falls during the subject’s normal time of dosing or the subject is 
participating on the optional PK/PD substudy on that day. 
The following assessments will be performed at each visit unless otherwise indicated: 
• Administer PRO questionnaires; where possible, the questionnaires should be 
completed by the subject prior to other assessments to prevent influencing subject 
perceptions: 
− FACIT-Fatigue scale at Weeks 14, 16, 20, 24, 36, and 52 
− QLQ-AA/PNH at Weeks 16, 20, 24, 36, and 52 
− Modified PRO-AA/PNH at Weeks 13, 14, 16, 20, 24, 36, and 52 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
81 
 
CONFIDENTIAL 
− TSQM at Weeks 16, 24, 36, and 52 
− EQ-5D-5L at Weeks 24 and 52 
− PGIS-Fatigue, PGIS-Impact of Fatigue, and PGIS-Physical Functioning at 
Week 52 
− PGIC-Fatigue, PGIC-Impact of Fatigue, and PGIC-Physical Functioning at 
Week 52 
• 12-lead ECG 
• Targeted physical examination 
• Body weight at Weeks 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 
• Vital signs (resting blood pressure and pulse rate, and temperature) 
• Blood collection for clinical laboratory evaluations (see Table 4 and Table 6): 
− Blood for hematology, clinical chemistry (including haptoglobin), and 
coagulation testing 
− Blood for iron, total iron binding capacity, transferrin, ferritin, hepcidin, and 
erythroferrone at Weeks 24 and 52 
• Blood collection for PK. A single sample will be collected on each visit unless the 
subject is participating in the optional PK/PD substudy. If participating in the optional 
PK/PD substudy, a total of 5 samples will be drawn over an approximately 6-hour 
period at the optional substudy visit as described in Section 11.5.1.1 (Week 14 or 
later). 
• Blood collection for PD and clinical laboratory biomarkers. If participating in the 
optional PK/PD substudy, where possible, a total of 5 samples will be drawn over an 
approximately 6-hour period at the optional PK/PD substudy visit as described in 
Section 11.5.1.1 (Week 14 or later). 
• Urine collection for clinical laboratory evaluations (see Table 4 and Table 6): 
− Urinalysis including microscopy 
− Urine collection for biomarker testing 
− Urine collection for hemosiderin at Weeks 24 and 52 
• Urine collection for PK 
• Urine pregnancy test for female subjects of childbearing potential (or as required by 
local or institutional practice) at Weeks 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52. A 
negative pregnancy test result must be recorded in order for the subject to continue 
receiving BCX9930. 
• BCX9930 dispensing and drug accountability 
• Review/record AEs, concomitant medication use, including prohibited and restricted 
medications, and blood transfusions 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
82 
 
CONFIDENTIAL 
10.3.6. 
Additional Assessments for Renal and Hepatic Safety Monitoring 
Additional assessments to monitor for potential renal and hepatic toxicity will be performed 
during the first 12 weeks of study treatment for all subjects in Part 1 and for subjects newly 
switched to BCX9930 for Part 2 as specified in the schedule of events specified in Table 3 for 
Part 1 and Table 4 for Part 2. The assessments may be performed at the investigational site, at a 
remote laboratory more convenient for the subject, or via a home health service (where permitted 
and available) and will be continued until sufficient data are available to allow for reduction or 
elimination of the additional assessments. 
The minimum procedures to be completed at each assessment will depend on whether the subject 
is assessed at the investigational site or assessed remotely. 
For subjects assessed at the investigational site: 
• Review/record AEs, concomitant medication use, and blood transfusions 
• Vital signs (resting blood pressure, pulse rate, and temperature) 
• Blood collection for clinical laboratory evaluations: 
− Clinical chemistry 
• Blood collection for PK 
• Urine collection for clinical laboratory evaluations: 
− Urinalysis including microscopy 
− Urine collection for biomarker testing 
• Urine collection for PK 
These assessments will also be performed for subjects identified with potential renal 
events and required to return to the investigational site on a weekly basis (see 
Section 12.5.2). 
For subjects assessed remotely: 
• Blood collection for clinical laboratory evaluations: 
− Clinical chemistry (to include at a minimum: sCr, eGFR, blood urea nitrogen, 
ALT, AST, ALP, and bilirubin [total and direct]) 
• Urine collection for clinical laboratory evaluations: 
− Urinalysis (to include at a minimum specific gravity, pH, protein, and blood) 
− Urine microscopy (only if the facility is deemed sufficiently qualified to perform 
this analysis) 
− Urine albumin to creatinine ratio (uACR) 
The enhanced safety assessments described in this amendment (ie, the additional assessments to 
be completed during the first 12 weeks of BCX9930 therapy) will be revisited and reviewed with 
the DMC after an additional approximately 15 subjects with PNH have completed through the 
first 8 weeks of monitoring between the current study and Study 202. 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
83 
 
CONFIDENTIAL 
10.3.7. 
Unscheduled Visits (Including for Assessment of Acute Symptomatic Hemolysis) 
At the investigator’s discretion, an unscheduled visit may be completed at any time during the 
study prior to the EOS visit. Depending on the reason for the visit, any of the below assessments 
may be performed, as appropriate. 
Following the discontinuation of study treatment in Part 1 or BCX9930 in Part 2, subjects may 
be required to complete an additional visit(s) to assess for acute symptomatic hemolysis if and 
when symptoms occur (see Section 12.5.3). 
If subjects attend an unscheduled visit to assess acute symptomatic hemolysis, all of the 
following assessments should be performed. If applicable, dosing compliance should also be 
reviewed to ensure that the subject is taking the drug correctly. Any missed doses should be 
recorded. 
• Review/record AEs, concomitant medication use, including prohibited and restricted 
medications, and blood transfusions since the most recent visit 
• Vital signs (resting blood pressure, pulse rate, and temperature) 
• Targeted physical examination 
• Blood collection for clinical laboratory evaluations (see Table 3 [Part 1] or Table 4 
[Part 2] and Table 6): 
− Blood for hematology, clinical chemistry (including haptoglobin), and 
coagulation testing 
• Blood collection for PK 
• Blood collection for PD and clinical laboratory biomarkers 
• Urine collection for clinical laboratory evaluations (see Table 3 [Part 1] or Table 4 
[Part 2] and Table 6): 
− Urinalysis including microscopy 
− Urine collection for biomarker testing 
• Urine collection for PK 
• Any additional testing needed to evaluate for etiology of hemolysis (including acute 
symptomatic hemolysis), if applicable. This should include review of recent 
complement-activating conditions (CACs) (eg, infection, trauma, or surgery) that 
could have contributed to the hemolytic event. Consider testing for acute 
SARS-CoV-2 infection (the causative agent of COVID-19) in the correct setting. 
10.3.8. 
End-of-Study Visit/Early Termination Visit 
All subjects who complete the Week 52 visit, and either do not qualify for or choose not to 
continue treatment with BCX9930, will be asked to return to the clinic approximately 3 weeks 
(21 ± 3 days) after the date of the last dose of BCX9930 for an EOS visit. In addition, any 
subject who discontinues study treatment prior to Week 52 will be asked to complete the same 
procedures at an ET visit approximately 3 weeks (21 ± 3 days) after the date of the last dose of 
blinded study drug or BCX9930. 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
84 
 
CONFIDENTIAL 
The following assessments will be performed at the EOS/ET visit: 
• 12-lead ECG 
• Targeted physical examination 
• Body weight 
• Vital signs (resting blood pressure and pulse rate, and temperature) 
• Blood collection for clinical laboratory evaluations (see Table 3 [Part 1] or Table 4 
[Part 2] and Table 6): 
• Blood collection for clinical laboratory evaluations (see Table 4 and Table 6): 
− Blood for hematology, clinical chemistry (including haptoglobin), and 
coagulation testing 
− Blood for iron, total iron binding capacity, transferrin, ferritin, hepcidin, and 
erythroferrone 
• Blood collection for 
 
• Blood collection for PD and clinical laboratory biomarkers 
• Urine collection for clinical laboratory evaluations (see Table 3 [Part 1] or Table 4 
[Part 2] and Table 6): 
− Urinalysis including microscopy 
− Urine collection for biomarker testing 
− Urine collection for hemosiderin 
• Urine pregnancy test for female subjects of childbearing potential (or as required by 
local or institutional practice) 
• Drug accountability (if not completed earlier) 
• Review/record AEs, concomitant medication use, and blood transfusions 
If an AE, including a clinically significant laboratory abnormality, is ongoing at the end of study 
visit, additional clinic visit(s) or telephone contact(s) may be warranted (see Section 12.4). 
11. 
STUDY ASSESSMENTS 
11.1. 
Chronology of Assessments 
It is preferred that the PRO questionnaires be administered prior to other study procedures and 
clinic procedures, such as ECGs, physical examinations, and vital signs measurements, should be 
completed prior to specimen collection. 
11.2. 
Demographic Information, Medical and Medication History 
Demographic information, and medical and medication history will be captured for each subject 
participating in the study at the screening visit. The medical and medication history review 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
85 
 
CONFIDENTIAL 
should include review of the subject’s current and prior renal health, and potential risk factors, 
including pre-existing chronic kidney disease, renal complications of PNH, inter-current illness, 
including the potential for renal tuberculosis in areas where the disease is endemic, vaccinations, 
and the use of potentially nephrotoxic medications. Medical history, medication review, and 
review of inclusion and exclusion criteria, potentially nephrotoxic medications, and prohibited 
and restricted medications will also be updated and rechecked at baseline (Day 1) as outlined in 
Section 10. 
A PNH history will be taken to document PNH clinical characteristics and disease burden, 
including time since diagnosis and history of MAVEs (including thrombotic events), bone 
marrow failure, pRBC transfusions, and PNH-related symptoms. Medication history will include 
details of all treatments administered specifically for PNH (including any prior complement 
inhibitor therapies); all other medications will be documented beginning 30 days prior to 
screening. 
11.2.1. 
Contraception Requirements 
The following represents the minimum contraception that should be used by study participants 
and their partners. Additional contraceptive requirements (eg, requiring the female partners of 
male subjects to additionally use highly effective contraception) may be required by local site 
practice and/or the governing ethics committee. It is anticipated that that not all contraceptive 
methods may be available in all countries/regions, so the list should be modified accordingly. 
For the purposes of this study, females are considered fertile following menarche and until 
becoming postmenopausal, unless permanently sterile (ie, premenopausal with one of the 
following: documented hysterectomy, documented bilateral salpingectomy, or documented 
bilateral oophorectomy). Documentation can come from site personnel’s review of the subject’s 
medical records, medical examination, or medical history interview. 
Female participants must meet at least one of the following requirements: 
1. Be a woman of nonchildbearing potential, either postmenopausal (defined as without 
menses for ≥ 12 months without an alternative medical cause with an FSH > 40 mIU/mL) 
or had a hysterectomy, bilateral salpingectomy, or bilateral oophorectomy. 
2. Be a woman of childbearing potential (defined as a female following menarche and prior 
to becoming post-menopausal who has not had a hysterectomy, bilateral salpingectomy, 
or bilateral oophorectomy) who agrees to use a highly effective contraceptive method 
while enrolled in the study and for a duration of 30 days after last dose of study drug. The 
following methods are acceptable: 
− surgical sterilization (ie, bilateral tubal occlusion or vasectomy of the sole male 
partner and the vasectomized partner has received medical assessment of surgical 
success) 
− intrauterine device (IUD) or intrauterine system (IUS) 
− combined (estrogen and progestogen containing) hormonal contraception 
associated with inhibition of ovulation (oral, intravaginal, transdermal) 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
86 
 
CONFIDENTIAL 
− progestogen only hormonal contraception associated with inhibition of ovulation 
(oral, injectable, implantable) 
Women of childbearing potential who declare themselves sexually abstinent or exclusively 
having female sexual partners do not need to use highly effective contraception. Abstinence in 
this study is defined as true abstinence when it is in line with the subject’s preferred and usual 
lifestyle. If a subject is usually not sexually active but becomes active, she, with her partner, 
must meet the requirements listed above. 
Female subjects must abstain from egg donation throughout the study and for a duration of 
30 days after last dose of study drug. 
Male participants must meet at least one of the following requirements:  
1. Males with a female partner of childbearing potential (as defined above) must agree to 
use condoms while enrolled in the study and for at least 90 days after the last dose of 
study drug unless their partner is using a highly effective contraceptive method as defined 
above independent of the study. 
2. Males who declare themselves sexually abstinent or having exclusively male partners are 
not required to use contraception. Abstinence in this study is defined as true abstinence 
when it is in line with the subject’s preferred and usual lifestyle. If a subject is usually not 
sexually active but becomes active, the criteria listed above must be met. 
Male subjects must abstain from sperm donation throughout the study and for a duration of 
90 days after last dose of study drug. 
Methods of contraception, as applicable, for both male and female participants should be 
documented in the source documentation. 
11.3. 
Immunity Assessment 
In Study 101, a subject with PNH and multiple risk factors including occupation, concomitant 
corticosteroids, and additional immunosuppression developed disseminated varicella infection as 
an unrelated SAE. Antibodies to VZV will be tested in all subjects at screening. If an exposure to 
VZV occurs during the study, this will help the investigator assess the risk for developing 
primary varicella for non-immune subjects. Any subject who has an exposure to someone with 
primary varicella (chickenpox) or herpes-zoster (shingles), or who has recently received a live 
varicella vaccine should contact the investigator, and administration of varicella zoster immune 
globulin or other medications should be considered, where available. 
11.4. 
Efficacy/Effectiveness Assessments 
11.4.1. 
Clinical and Laboratory Measurements of PNH 
Clinical measurements of PNH include clinical laboratory testing for Hb, LDH, ARC, 
haptoglobin, bilirubin, and AST; number of pRBC transfusions and number of pRBC units 
administered; assessment of PNH-associated clinical symptoms (eg, fatigue, dyspnea, chest 
pain/discomfort, dysphagia, abdominal pain, headache, erectile dysfunction, hemoglobinuria, and 
jaundice); and the incidence of acute symptomatic hemolysis and MAVEs, including thrombotic 
events. 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
87 
 
CONFIDENTIAL 
At each visit, the investigator (or designee) will assess the subject for new or worsening signs 
and symptoms of PNH, including acute symptomatic hemolysis. Starting at randomization, 
subjects will be assessed for possible pRBC transfusion as described in Section 11.4.2. 
11.4.2. 
Blood Transfusions 
At screening, the number and type of blood transfusions administered within at least the prior 
12 months will be recorded. During the study, all blood transfusions will be documented, 
including the number of units and the type of blood product administered. 
In order to standardize the approach to transfusions on-study, beginning at randomization 
through completion of the Week 52 visit, it is recommended that pRBC transfusion be 
administered to subjects who meet either of the following criteria: 
• Hb value of ≤ 9 g/dL and, in the opinion of the investigator, with symptoms 
warranting transfusion, or 
• Hb value of ≤ 7 g/dL regardless of symptoms 
Transfusions will be administered based on the results of local laboratory testing of Hb (or 
central laboratory testing if local laboratory results are not available) and, as applicable, the 
investigator’s assessment of the subject’s PNH symptoms. The investigator (or designee) will 
determine the appropriate number of units of pRBCs to be transfused. Administration of each 
pRBC transfusion, including the date of transfusion, the Hb result and source (ie, local or central 
laboratory, as applicable) and associated symptoms warranting transfusion (if applicable) that 
triggered the transfusion and the number of units transfused, will be documented in the eCRF. 
11.4.3. 
Clinical Measurements of Iron, Folate, and Vitamin B12 
Most patients with PNH who are not receiving C5 inhibitor therapy are iron‐depleted due to IVH 
and loss through the kidneys. When treated with eculizumab, C5 blockade results in increased 
C3 levels upstream in the complement cascade. The resulting increase in EVH, in combination 
with chronic blood transfusion, is reported to contribute to iron load in some patients over time 
(Risitano, Notaro, et al. 2012, Roth, Rottinghaus, et al. 2018). 
All subjects will have blood samples drawn for assessment of iron, total iron binding capacity, 
transferrin, ferritin, hepcidin, and erythroferrone at baseline, Weeks 12, 24, and 52, and the 
EOS/ET visit; urine collected at these visits will be analyzed for hemosiderin. Iron, vitamin B12, 
and folate levels will also be measured at screening to assess the status of these analytes. 
11.4.4. 
Patient-reported Outcomes 
The following PRO instruments will be used during this study, where translations into the local 
language are available: 
• FACIT-Fatigue scale 
• QLQ-AA/PNH 
• Modified PRO-AA/PNH 
• TSQM 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
88 
 
CONFIDENTIAL 
• EQ-5D-5L 
• PGIS-Fatigue, PGIS-Impact of Fatigue, and PGIS-Physical Functioning 
• PGIC-Fatigue, PGIC-Impact of Fatigue, and PGIC-Physical Functioning 
With the exception of the QLQ-AA/PNH, the available PRO instruments will be administered 
electronically using a tablet or equivalent device; the QLQ-AA/PNH will be administered in 
paper form. For all subject-completed forms, clinic staff should ensure the subject reads the 
instructions and completes the questionnaire in full. The investigator and clinic staff are not 
permitted to provide any assistance, interpretation, or clarification of information or questions 
contained in the questionnaires. Where possible, the questionnaires should be completed by the 
subject prior to other assessments for that visit to prevent assessments from influencing subject 
perceptions (Section 11.1). 
11.4.4.1. FACIT-Fatigue 
The FACIT-Fatigue scale was derived from instrument development work conducted in 1994 
and 1995 to evaluate fatigue associated with anemia in cancer patients (Yellen, Cella, et al. 
1997). It contains 13 items which assess self-reported tiredness, weakness, and difficulty 
conducting usual activities due to fatigue. Items are measured on a 5-point Likert-type scale of 
0 to 4 from “Not at all” to “Very much”, respectively. The FACIT-Fatigue total score is derived 
by summing all items and ranges from 0 to 52; items are reverse scored, when appropriate, to 
provide a scale in which a higher score indicates better functioning or less fatigue (Cella, Lai, et 
al. 2002). Experience and Impact scores may also be obtained by aggregating the 5 Experience 
items and the 8 Impact items separately (Cella, Lai, et al. 2011). The recall period for each 
question is the past 7 days. Content validation of the FACIT-Fatigue scale was examined in a 
cross-sectional validation study involving cognitive debrief interviews with patients with PNH 
(Weitz, Meyers, et al. 2013). The FACIT-Fatigue scale total score has been shown to be 
responsive to change in both clinical and observational studies. Using both anchor- and 
distribution-based methods, the minimal important difference (MID) for the FACIT-Fatigue 
scale total score is 3 points. Currently, there are no published interpretation thresholds for the 
FACIT-Fatigue Experience and Impact scores (Cella, Lai, et al. 2002). 
The FACIT-Fatigue scale will be administered at baseline (Day 1) and at Weeks 2, 4, 8, 12, 14, 
16, 20, 24, 36, and 52. 
11.4.4.2. QLQ-AA/PNH 
The QLQ-AA/PNH is a 54-item patient-reported instrument developed to assess symptom 
burden and HRQoL in patients with AA and/or PNH (Groth, Singer, et al. 2017, Niedeggen, 
Singer, et al. 2019). It consists of 10 preliminary hypothesized domains including: 1) Social 
Support, 2) Fear of Progression and Illness Intrusiveness, 3) Fatigue, 4) Other Symptoms, 
5) Infections, 6) Physical Functioning, 7) Role Functioning, 8) Emotional Functioning, 
9) Stigmatization, and 10) Body Image. The recall period varies by items with a recall of 7 days 
for items 1 to 52, and a recall period of 6 months for items 53 and 54. Response options for all 
items are “Not at all”, “A little”, “Moderately”, and “Very” or “A lot”. 
The QLQ-AA/PNH will be administered at baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 
36, and 52. 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
89 
 
CONFIDENTIAL 
11.4.4.3. Modified PRO-AA/PNH 
The PRO-AA/PNH is modified from the patient-centered version of the PRO-AA/PNH 
questionnaire developed by Weisshaar and colleagues (Weisshaar, Ewald, et al. 2020). As 
modified, the questionnaire includes the 11 PNH symptom questions from the original 
PRO-AA/PNH patient-centered questionnaire (ie, excluding the 3 AA-specific questions): 
1) Fatigue, 2) Bleeding, 3) Shortness of Breath, 4) Mood, 5) Memory and Concentration, 
6) Heart Palpitations, 7) Gastrointestinal Problems, 8) Pain, 9) Dark Urine [Hemoglobinuria], 
10) Difficulty Swallowing [Dysphagia], and 11) Itching) plus the Erectile Dysfunction question 
from the physician-centered version of the PRO-AA/PNH questionnaire. For symptoms other 
than Bleeding and Dark Urine, additional questions assess the frequency, severity and/or impact 
of the symptoms on the subject’s usual or daily activities. The bleeding-related questions follow 
the modified WHO bleeding scale for locations and severity grading. The recall period is the last 
7 days. 
The modified PRO-AA/PNH will be administered at baseline (Day 1) and at Weeks 1, 2, 4, 8, 
12, 13, 14, 16, 20, 24, 36, and 52. 
11.4.4.4. TSQM 
The TSQM (version 1.4) consists of 14 items of which 13 items are made up of 3 specific scales 
(effectiveness, side effects, and convenience) and a global satisfaction scale (global satisfaction). 
In addition, 1 item (Item 4) questions whether the subject experienced any side effects at all as a 
result of taking this medication, which can be answered by yes or no. Scale scores are calculated 
for each scale and are transformed into scores ranging from 0 to 100, with higher scores 
indicating higher satisfaction. The recall period is the last 2 to 3 weeks, or since the medication 
was last used. 
The TSQM will be administered at Weeks 4, 12, 16, 24, 36, and 52. 
11.4.4.5. EQ-5D-5L 
The EQ-5D-5L consists of the EQ-5D descriptive system and the EQ visual analogue scale 
(EQ VAS). The descriptive system (EQ-5D-5L) comprises five dimensions: mobility, self-care, 
usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no 
problems, slight problems, moderate problems, severe problems, and extreme problems. The 
patient is asked to indicate his/her health state by ticking the box next to the most appropriate 
statement in each of the 5 dimensions. This decision results in a 1-digit number that expresses 
the level selected for that dimension. The digits for the five dimensions can be combined into a 
5-digit number that describes the patient’s health state. There is no recall period; the health status 
captured by EQ-5D-5L reflects the respondent’s status at the time of completion. 
The EQ VAS records the respondent’s self-rated health on a 20-cm vertical VAS. The VAS is 
numbered from 0 to 100 with 0 meaning “the worst health you can imagine” and 100 meaning 
“the best health you can imagine”. This information can be used as a quantitative measure of 
health as judged by the individual respondents. The EQ VAS asks respondents to simply “mark 
an X on the scale to indicate how your health is TODAY” and then to “write the number you 
marked on the scale in the box below”. 
The EQ-5D-5L will be administered at baseline (Day 1) and at Weeks 12, 24, and 52. 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
90 
 
CONFIDENTIAL 
11.4.4.6. PGIS-Fatigue, PGIS-Impact of Fatigue, and PGIS-Physical Functioning 
Subjects will be asked to rate the severity of their fatigue, the impact of their fatigue on their 
usual activities, and how much their PNH symptoms interfere with physical functioning 
(eg, walking, climbing stairs, standing) using the PGIS-Fatigue, PGIS-Impact of Fatigue, and 
PGIS-Physical Functioning, respectively. The recall period is the past 7 days. The severity and 
impact of fatigue will both be assessed on a 4-point scale with responses ranging from 
1 = “None” to 4 = “Severe”. Interference will be assessed using a 5-point scale with responses 
ranging from 1 = “Not at all” to 5 = “Very much”. 
The PGIS-Fatigue, PGIS-Impact of Fatigue, and PGIS-Physical Functioning will be administered 
at baseline (Day 1) and at Weeks 12 and 52. 
11.4.4.7. PGIC-Fatigue, PGIC-Impact of Fatigue, and PGIC-Physical Functioning 
Subjects will be asked to rate changes in the severity of their fatigue, the impact of their fatigue 
on their usual activities, and how much their PNH symptoms interfere with physical functioning 
using the PGIC-Fatigue, PGIC-Impact of Fatigue, and PGIC-Physical Functioning, respectively. 
At Week 12, all subjects will be asked to assess how the severity and impact of their fatigue, and 
interference of their PNH symptoms with physical functioning have changed since the start of 
the study. At Week 52, subjects will be asked how the severity and impact of their fatigue, and 
interference of their PNH symptoms with physical functioning have changed since the start of 
the open-label study (ie, since being told they were on active drug). All changes will be assessed 
on a 7-point Likert scale ranging from 1 = “Very much improved” to 7 = “Very much worse”. 
The PGIC-Fatigue, PGIC-Impact of Fatigue, and PGIC-Physical Functioning will be 
administered at Weeks 12 and 52. 
11.4.5. 
Optional Exit Interviews 
One-on-one qualitative exit interviews will be conducted by COS or a third-party vendor over 
the telephone or by videoconference in a subset of approximately 15 subjects. The exit 
interviews will be conducted to explore participants’ overall experience with the study drug and 
what constitutes a meaningful change in terms of symptoms to better understand the relevance of 
the FACIT-Fatigue items and cognitive debriefing of the Physical Function domain of the 
QLQ-AA/PNH. Participants will also be asked to rate and explain their perception of meaningful 
change in fatigue and physical function. The interviews will be conducted for individual subjects 
as soon as possible (ideally within 2 weeks) after the end of blinded treatment (ie, Week 12 visit) 
using a semi-structured interview guide. Subjects will sign a separate ICF, which provides 
further information about the exit interviews. A separate communication will be provided to sites 
about the exit interviews. 
11.5. 
Pharmacokinetic and Pharmacodynamic Assessments 
Detailed instructions for collection, processing, storage, and shipment of PK and PD samples 
will be provided in a separate laboratory manual. 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
91 
 
CONFIDENTIAL 
11.5.1. 
Blood Sampling for Pharmacokinetic Analysis 
Single venous blood samples for measurement of plasma BCX9930 concentrations (“sparse 
sampling” to support PPK and PK/PD modeling) will be collected from all subjects receiving 
study drug at each scheduled study visit to the investigational site, beginning at Week 1, and at 
any visits to the investigational site to assess for acute symptomatic hemolysis or perform 
additional safety assessments. PK samples will not be collected at the baseline (Day 1) visit 
unless subjects participate in the optional PK/PD substudy. 
Sparse PK blood samples may be drawn at any time without regard to study drug/BCX9930 
dosing. However, where feasible, investigators are requested to vary the timing of non-PK/PD 
substudy visits to facilitate PK sampling at different times relative to the previous dose. It is 
preferred that the cumulative sparse PK data for each subject will contain samples drawn within 
each of the following intervals (all relative to the previous dose for BID dosing): 0.5 to 2 hours, 
2 to 5 hours, and 10 to 12 hours post-dose. 
Subjects do not need to withhold any study drug/BCX9930 doses on clinic days or take a dose in 
the clinic, unless the clinic visit falls during the subject’s normal time of dosing or the subject is 
participating in the optional PK/PD substudy on that day (see Section 11.5.1.1). 
For each sample collected, the actual date and time of sample collection, the actual date and time 
of the last two BCX9930 doses taken prior to the blood draw (where applicable), and whether 
those doses were taken with or without food will be recorded in the eCRF. 
Plasma samples for determination of BCX9930 will be analyzed using validated liquid 
chromatography-mass spectrometry assays. The plasma concentration of BCX9930 metabolites 
may also be analyzed using these samples. 
PK samples collected from subjects receiving placebo will not be analyzed except if required. 
Any unused portion of the plasma samples collected for PK purposes will be retained for 
possible repeat or future PK analysis of BCX9930 and/or identified metabolites. Subjects can 
request for these samples to be destroyed at the end of the study, but any data previously 
collected will be retained. 
11.5.1.1. Optional Pharmacokinetic/Pharmacodynamic Substudy 
At study centers with appropriate facilities for the collection and processing of serial plasma 
samples, an optional PK/PD substudy will be performed to characterize the single-dose and 
steady-state PK parameters of BCX9930 in this patient population and contribute to PPK and 
PK/PD models. 
At these centers, subjects consenting to participate in the optional PK/PD substudy will be asked 
to complete up to two serial PK sample collections. The first sample collection will assess the 
single-dose PK of BCX9930, with samples collected on Day 1 in Part 1. The second sample 
collection will assess the PK of BCX9930 at steady state, with samples collected during the 
Week 14 or any later visit in Part 2. Four blood samples will be collected on Day 1, and 5 blood 
samples will be collected during the Week 14 or later visit. On Day 1, samples will be collected 
at 0.5 (± 0.25), 1.5 (± 0.5), 3.5 (± 0.5), and 6 (± 1) hours post-dose. At the Week 14 or later visit, 
samples will be collected immediately (≤ 15 minutes) prior to dosing and at 0.5 (± 0.25), 
1.5 (± 0.5), 3.5 (± 0.5), and 6 (± 1) hours post-dose. For the second sample collection (on or after 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
92 
 
CONFIDENTIAL 
Week 14), the subject’s scheduled dose of BCX9930 should not be taken at home, but 
administered in the clinic after collection of the pre-dose sample, as close as possible to the 
subject’s regularly scheduled dose time (and as close as possible to 12 hours after the previous 
dose). On both occasions, the actual date and time of each blood sample collection and the 
observed BCX9930 dose will be recorded in the eCRF. In addition, for the steady-state collection 
on Week 14 or later, the actual date and time of the last two BCX9930 doses taken prior to the 
pre-dose blood collection (assumed to be the two doses taken the previous day), and whether 
those doses were administered with or without food will also be recorded in the eCRF. 
In addition, where possible, taking into account blood volume requirements, subjects will have 
5 PD samples collected at each substudy visit; the first sample will be collected prior to study 
drug/BCX9930 dosing (≤ 2 hours on Day 1 or ≤ 15 minutes at the Week 14 or later visit), with 
subsequent samples collected at 0.5 (± 0.25), 1.5 (± 0.5), 3.5 (± 0.5), and 6 (± 1) hours post-dose. 
As applicable, PD blood samples will be collected at the same time as the corresponding PK 
blood sample applicable (ie, excluding the pre-dose sample on Day 1). Additional guidance on 
prioritizing sample collections where there are blood volume concerns will be provided in the 
separate laboratory manual. 
Ideally, subjects will participate in both serial PK/PD sample collections. However, subjects who 
do not participate at the Day 1 serial PK/PD sample collection can still participate in the later 
steady-state PK/PD collection in Part 2. 
Plasma concentration and PK parameters of BCX9930 metabolites may also be assessed using 
these samples. Samples collected from subjects receiving placebo on Day 1 will not be analyzed. 
11.5.2. 
Urine Collection for Measurement of Parent-Metabolite Concentration 
Spot urine samples will be collected for analysis of the concentration of BCX9930 and 
metabolites. Because of the study blind, samples will be collected from all subjects during Part 1; 
samples collected from subjects randomized to placebo will not be analyzed. 
Urine samples for determination of BCX9930 will be analyzed using validated liquid 
chromatography-mass spectrometry assays. The concentration of BCX9930 metabolites may also 
be analyzed using these samples. 
For each sample collected, the actual date and time of sample collection, the actual date and time 
of the last two BCX9930 doses taken prior to the urine collection (where applicable), and 
whether those doses were taken with or without food will be recorded in the eCRF. 
11.5.3. 
Blood Sampling for Analysis of Pharmacodynamic and Complement 
Biomarkers 
Blood samples will be analyzed for concentrations of complement cleavage products 
(eg, Factor Bb and sC5b-9). The capacity of the complement system will be assessed by 
measuring these analytes or the activity of the AP using ex vivo stimulation assays, such as 
AP Wieslab, that activate the AP in blood samples using a specific stimulus. Additional 
exploratory assays (eg, for chemokines or cytokines) may be evaluated. Samples collected may 
be run in more than one assay to elucidate the PD effects of BCX9930. The analyses variously 
need serum, plasma, and whole blood. 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
93 
 
CONFIDENTIAL 
Blood samples for analysis of PD and complement biomarkers will be collected at each study 
visit (including screening and baseline [prior to dosing on Day 1]) from all subjects regardless of 
treatment, including any visit to assess for acute symptomatic hemolysis or hemolysis 
monitoring following discontinuation of therapy. Where feasible, and as applicable, blood 
samples for PD analyses should be collected at the same time as sparse PK samples. 
The plasma PD and complement biomarkers for assessment may include, but are not limited to: 
• Ex vivo AP activity (as assessed by AP Wieslab assay) 
• Ex vivo AP-activated complement biomarkers: Factor Bb, C3a, and C5a 
• Constitutive complement biomarkers: Factor D (as the pharmacologic target), 
Factor Bb, and sC5b-9 
Acute symptomatic hemolysis will be evaluated, where possible. The PD and complement 
biomarkers for assessment of acute symptomatic hemolysis may include, but are not limited to: 
• Ex vivo AP activity (as assessed by AP Wieslab) 
• Ex vivo AP-activated complement biomarkers: Factor Bb, C3a, and C5a 
• Constitutive complement biomarkers: Factor D (as the pharmacologic target), 
Factor Bb, total C3*, C3a*, total C4*, C4a*, and sC5b-9 
* In subjects experiencing acute symptomatic hemolysis, as applicable, these additional analytes 
will also be evaluated in previously collected samples to provide internal reference values for the 
acute symptomatic hemolysis values. 
The following are considered key clinical laboratory blood biomarkers of AP activity: 
AP Wieslab and constitutive levels of Factor Bb and sC5b-9. Not all PD and complement 
biomarkers will be assessed at all timepoints. The plans for analysis of other biomarkers may be 
modified based on emerging data, eg, if data show that a particular biomarker is redundant or the 
assay is of poor quality. 
PNH clone size (total PNH RBC [Type II plus Type III], PNH WBC, and the ratio of total PNH 
RBC to PNH WBC) will be assessed at each visit.  
 
 
Any unused portion of the whole blood, plasma, or serum collected for PD purposes will be 
retained for possible repeat or future analysis of biomarkers related to PNH and other 
complement-mediated disease. Subject can request for these samples to be destroyed at the end 
of the study, but any data previously collected will be retained. 
A tabular summary of the PD sampling is provided in Table 5. 
(Note: Some PD and complement biomarkers may not be analyzed, depending on the availability 
of validated assays at the designated regional bioanalytical laboratory.) 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
94 
 
CONFIDENTIAL 
Table 5: 
Summary of Pharmacokinetic and Pharmacodynamic Blood Sampling 
PK or PD 
Sampling 
Screening 
Day 1 
Study Week 
Hemolysis 
Assessment/ 
Monitoring 
Wk1 
Wk2 
Wk4 
Wk8 
Wk12 
Wk13 
Wk14 
Wk16 
Wk20 
Wk24 
Wk28 
Wk32 
Wk36 
Wk40 
Wk44 
Wk48 
Wk52 
All Subjects 
PKa 
- 
- 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
PDb 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Optional PK/PD substudyc 
PK 
- 
4d 
- 
- 
- 
- 
- 
- 
< ------------------------------------------- 5e -------------------------------------------- > 
- 
PD 
- 
5e 
- 
- 
- 
- 
- 
- 
< ------------------------------------------- 5e -------------------------------------------- > 
- 
Abbreviations: PD = pharmacodynamic; PK = pharmacokinetic. 
a Single venous blood samples for measurement of plasma BCX9930 concentrations will be collected at each scheduled study visit, beginning at Week 1, and at 
any visit to the investigational site to assess for acute symptomatic hemolysis (if and when symptoms occur) or to perform additional safety assessments (not shown). 
b Blood samples for analysis of PD and complement biomarkers will be collected at each study visit (including screening and Day 1) from all subjects regardless 
of treatment, including at any visit to assess for acute symptomatic hemolysis or hemolysis monitoring following discontinuation of therapy. 
c The first sample collection will be performed on Day 1 and the second sample collection during the Week 14 or any later visit. 
d Four blood samples will be collected at 0.5 (± 0.25), 1.5 (± 0.5), 3.5 (± 0.5), and 6 (±1) hours after administration of the first dose of study drug/BCX9930. 
e Five blood samples will be collected, where possible; the first sample will be collected prior to study drug/BCX9930 dosing (either ≤ 2 hours on Day 1 or 
≤ 15 minutes at the Week 14 or later visit), with subsequent samples collected at 0.5 (± 0.25), 1.5 (± 0.5), 3.5 (± 0.5), and 6 (±1) hours post-dose. As applicable, 
PD blood samples will be collected at the same time as the corresponding PK blood samples. 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
95 
 
CONFIDENTIAL 
11.6. 
Optional Pharmacodynamic Analyses 
All study participants will be asked to consent to the storage of unused and/or residual PD 
samples collected in the study for possible additional research. The stored PD samples may be 
used for exploratory PD assays to evaluate the PD or PK of BCX9930. If a participant does not 
agree to have his or her PD samples stored, he or she can still participate in this study; all PD 
samples collected during the study will be destroyed upon completion of the study and all 
protocol-mandated analyses. All PD samples for which consent has been obtained will be stored 
for up to 10 years after completion of the study (or according to local regulations) for possible 
additional research. Stored samples will be coded throughout the sample storage and analysis 
process and will not be linked to any personal identifiers. Analysis of these samples is not 
intended for diagnostic or prognostic purposes and results will not be communicated back to the 
investigator or subjects. The research may begin at any time during the study or following 
completion of the study during the post-study storage period. 
11.7. 
Safety Assessments 
11.7.1. 
Vital Signs 
Vital signs comprising blood pressure, pulse rate, and temperature will be obtained per the 
schedule of assessments specified in Table 3 for Part 1 and Table 4 for Part 2. 
Measurements of vital signs should be obtained after the subject has rested for at least 5 minutes 
in a quiet room at a comfortable temperature, with the subject’s arm unconstrained by clothing or 
other material. Blood pressure measurements will be obtained with the appropriate cuff size, 
with the subject’s arm supported at the level of the heart, while the subject is resting in a 
semi-supine position. It is acceptable to obtain a pulse rate from the blood pressure or ECG 
machine. 
11.7.2. 
Body Weight, Height, and Body Mass Index 
Body weight will be recorded per the schedule of assessments specified in Table 3 for Part 1 and 
Table 4 for Part 2; height and BMI will be recorded at screening only. For determination of 
height and body weight, subjects should be clothed with shoes removed. 
11.7.3. 
Physical Examination 
Subjects will undergo a physical examination per the schedule of assessments specified in 
Table 3 for Part 1 and Table 4 for Part 2. 
A full physical examination should be performed per normal site practice as part of the screening 
evaluation (eg, genitourinary and breast examinations may be omitted when not required by 
normal site practice). A targeted (ie, symptom driven) physical examination will be performed at 
subsequent study visits to assess for any changes from the previous examination, including, at a 
minimum, evaluation of new or worsening signs or symptoms. 
11.7.4. 
Electrocardiogram 
A 12-lead ECG will be obtained per the schedule of assessments specified in Table 3 for Part 1 
and Table 4 for Part 2. 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
96 
 
CONFIDENTIAL 
A standard bedside 12-lead ECG machine system that calculates heart rate and measures the PR, 
QRS, QT, RR, and corrected QT (QTc) intervals will be utilized. Twelve-lead ECGs will be 
measured after the subject has rested quietly in the supine position for a minimum of 10 minutes. 
All ECGs will be single assessments, with the exception of the baseline (Day 1) ECG, which will 
be recorded in triplicate. Triplicate ECGs will also be collected at the Week 12 visit. 
Qualified site personnel should review the ECGs and automated findings in real time for gross 
abnormalities and interval measurements of concern (absolute readings and change from 
baseline). An ECG should be repeated after at least an additional 10-minute rest in a supine 
position in the event of a CFB (mean of pre-dose triplicate values on Day 1) in QTcF 
(QT / ³√RR) of > 60 msec or an absolute QTcF interval of > 500 msec. 
For all ECGs, the clinical interpretation of the ECG should be recorded (including 
re-adjudication of any automatic findings) directly on a hard copy of the ECGs. Copies of the 
subject identifier-redacted ECGs may be requested by the sponsor. 
11.7.5. 
Clinical Chemistry, Hematology, Urinalysis, and Other Laboratory Assessments 
Blood and urine samples will be obtained per the schedule of assessments specified in Table 3 
for Part 1 and Table 4 for Part 2. Individual laboratory tests are specified in Table 6. 
In general, laboratory samples collected at visits to the investigational site should be collected 
using kits provided by the designated central laboratory. However, at the investigator’s 
discretion, local laboratories may be used in place of the central laboratory (eg, for logistical 
reasons such as delays in transport due to COVID-19) or for analysis of samples collected for 
assessment of possible AEs (eg, when emergent safety concerns require expedited turnaround 
times for safety laboratory assessments). Urine microscopy for samples collected at the 
investigational site will be performed at the site’s local laboratory, where appropriate on-site 
testing capability exists (see Section 11.7.5.1). The additional renal and hepatic safety 
assessments may be performed at the investigational site or remotely at a location more 
convenient for the subject or via a home health service. If the use of a home health service is 
permitted, testing may be performed at the central laboratory or at a remote laboratory. The 
results from laboratory testing performed at a local or remote must be provided to the 
investigational site. The use of a local or remote laboratory in this manner, and any differences in 
analyte panels with the central laboratory, based on the availability of testing at the local or 
remote laboratory, will not be considered protocol deviations for the purposes of this protocol. 
Reference ranges for each local or remote laboratory used will be provided to the sponsor and 
included in data listings. 
Results from laboratories should be reviewed as received by the investigator. Evidence of this 
review should be provided in the source records and may include printing of the laboratory 
reports with a signature attesting to a review. For out-of-range laboratory findings, the 
interpretation of clinically significant or not clinically significant should be denoted in the source 
records. Clinically significant laboratory findings, as assessed by the investigator, should be 
recorded as AEs as described in the protocol (Section 12.1). 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
97 
 
CONFIDENTIAL 
Table 6: 
Clinical Laboratory Evaluations 
Serum Chemistry 
Urinalysisa 
Albumin 
Alanine aminotransferase (ALT) (SGPT) 
Alkaline phosphatase (ALP) 
Amylaseb 
Aspartate aminotransferase (AST) (SGOT) 
Bicarbonate or carbon dioxidec 
Bilirubin (total and direct) 
Blood urea nitrogen (BUN) 
Calcium 
Chloride 
Cholesterol (total, high- and low-density 
lipoprotein) 
Creatine (phospho)kinase (C[P]K) 
Creatinine (sCr) 
Glucose 
Haptoglobin 
Lactate dehydrogenase (LDH) 
Magnesium 
Potassium 
Sodium 
Protein (total) 
Triglycerides 
Uric acid 
Albumin 
Bilirubin 
Blood 
Creatinine 
Glucose 
Ketones 
Leukocytes 
Nitrites 
pH 
Protein 
Specific gravity  
Urobilinogen 
Urine Drug Screen 
Amphetamines 
Barbiturates 
Benzodiazepines 
Ecstasy 
Methamphetamine 
Opiates 
Pregnancy/Menopause 
Follicle-stimulating hormone (FSH) 
β-human chorionic gonadotropin (hCG)d 
Urine pregnancy teste 
Hematology 
Hemoglobin (Hb) 
Hematocrit (Hct) 
Mean corpuscular hemoglobin (MCH) 
Mean corpuscular hemoglobin concentration 
(MCHC) 
Mean corpuscular volume (MCV) 
Platelet count (PLT) 
Red blood cell (erythrocyte) count (RBC) 
Reticulocyte count 
White blood cell count (WBC) with differential 
Iron, Folate, and Vitamin B12 
Erythroferrone 
Ferritin 
Folate 
Hepcidin 
Hemosiderin (urine) 
Iron 
Total iron binding capacity) 
Transferrin 
Vitamin B12 
Other Testing 
C-reactive protein 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
98 
 
CONFIDENTIAL 
Coagulation/Fibrinolysis 
Cystatin C (in blood) 
Estimated glomerular filtration rate(eGFR)f 
HBV surface antigen (HBsAg) 
HBV core antibody (HBcAb)g,h 
HCV antibody (HCVAb)i,h 
HIV antibodyj,h 
PNH RBC clone size (total) 
PNH WBC clone size 
VZV immunoglobulin G (IgG) titer 
Activated partial thromboplastin time (aPTT) 
 
Prothrombin time (PT) 
International normalized ratio (INR) 
 
Thrombin time 
Urine Biomarkersk 
β-2-microglobulin 
Cystatin C 
Kidney injury molecule 1 (KIM-1) 
Liver-type fatty acid-binding protein (L-FABP) 
Urine albumin to creatinine ratio (uACR) 
Urine neutrophil gelatinase-associated lipocalin 
(uNGAL) 
Urine aliquots for storagel 
Note: Some analytes may not be analyzed, depending on the availability of validated assays at the designated 
regional central laboratory. 
Abbreviations: DNA = deoxyribonucleic acid; HBV = hepatitis B virus; HCV = hepatitis C virus; HIV = human 
immunodeficiency virus; PNH = paroxysmal nocturnal hemoglobinuria; RNA = ribonucleic acid; SGOT = serum 
glutamic-oxaloacetic transaminase; SGPT = serum glutamic-pyruvic transaminase; VZV = varicella-zoster virus. 
a For local laboratory testing, urinalysis analytes may be different. 
b If amylase is elevated, reflex to lipase. 
c In those regions where bicarbonate or carbon dioxide is analyzed and reported. 
d Serum (screening) or urine (all other scheduled visits) for women of childbearing potential or post-menopausal for 
≤ 2 years (or as required by institutional practice). 
e For women of childbearing potential (or as required by local or institutional practice). 
f To be calculated by the designated central reference laboratory using the Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) equation using the serum creatinine method (Levey and Stevens 2010). 
g Subjects with a positive HBV core antibody (HBcAb) test at screening will be reflexed to confirmatory HBV DNA 
viral load and excluded for a positive viral titer. 
h Confirmatory sample for serology may be collected at screening visit in some regions but analysis will be 
performed only if serology result is positive. Otherwise, confirmatory sample will be discarded. 
i Subjects with a positive HCV antibody test at screening will be reflexed to confirmatory HCV RNA viral load and 
excluded from the study for a positive viral titer. 
j Subjects with a positive HIV antibody test will be reflexed to confirmatory HIV RNA viral load. 
k KIM-1 and L-FABP will not be tested at screening. 
l Urine will be aliquoted, frozen, and sent to the central laboratory for possible future analysis of urine biomarkers. 
Additional biomarkers may be recommended by the Nephrology Risk Mitigation Working Group. 
11.7.5.1. Urine Collections for Urinalysis, Microscopy, and Biomarker Testing 
Investigators should emphasize to staff and the subjects the importance of collecting fresh, 
high-quality urine specimens (clean-catch, mid-void, etc.) and ensuring appropriate handling and 
prompt analysis of the samples for urinalysis. Urine microscopy will be performed on all urine 
samples collected for urinalysis at investigational site visits. Because of the potential for 
extended transit times to the central laboratory, where possible, the urine microscopy should be 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
99 
 
CONFIDENTIAL 
performed using the site’s local laboratory (where appropriate on-site testing capability exists) in 
lieu of the designated central laboratory. Urine microscopy should also be performed at any 
remote laboratory where appropriate on-site testing capability exists. If the local or remote 
laboratory does not have on-site testing capability, the sample may be sent to the designated 
central laboratory. 
Urine will be collected at all investigational site visits for analysis of uACR, β-2-microglobulin, 
cystatin C, urine neutrophil gelatinase-associated lipocalin (uNGAL), kidney injury molecule 1 
(KIM-1), and liver-type fatty acid-binding protein (L-FABP). In addition, aliquots of urine will 
be frozen and shipped to the central laboratory for storage for possible future analysis of urine 
biomarkers. 
11.7.6. 
Menopause and Pregnancy Testing 
FSH will be measured at screening in women declaring themselves postmenopausal ≤ 2 years to 
confirm non-childbearing status if above the reference range. At screening, a serum pregnancy 
test should also be drawn in the event that a female subject who is postmenopausal ≤ 2 years is 
found to be of childbearing potential. 
For all women of childbearing potential, a serum β-human chorionic gonadotropin (β-hCG) test 
will be performed at screening. Urine pregnancy tests will be assessed at baseline (Day 1) and 
every 4 weeks thereafter as specified in the schedule of events presented in Table 3 for Part 1 and 
Table 4 for Part 2, or as required per normal site practice. Urine pregnancy tests will be provided 
by the central laboratory, but will be administered and read at the clinical site. A serum 
pregnancy test should immediately be drawn and sent for analysis for any positive urine 
pregnancy test. Where required, pregnancy testing may be performed using the local laboratory, 
and using serum testing in lieu of the supplied urine pregnancy tests. 
For female participants who meet the criteria for postmenopausal status, an FSH can be 
measured during the study; pregnancy testing will continue until postmenopausal status by the 
above definition is met. 
12. 
ADVERSE EVENTS 
In this section, “study drug/IMP” is intended to refer to BCX9930 and/or placebo, unless 
otherwise noted. 
12.1. 
Definition of Adverse Events 
12.1.1. 
Adverse Event 
An AE is any untoward medical occurrence in a clinical study subject. No causal relationship 
with the study drug/IMP or with the clinical study itself is implied. An AE may be an 
unfavorable and unintended sign, symptom, syndrome, or illness that develops or worsens during 
the clinical study. Clinically relevant abnormal results of diagnostic procedures including 
abnormal laboratory findings (eg, requiring unscheduled diagnostic procedures or treatment 
measures, or resulting in withdrawal from the study) are considered to be AEs. Abnormal results 
of diagnostic procedures that are incidental or not clinically relevant are not reportable as AEs. If 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
100 
 
CONFIDENTIAL 
the diagnostic procedure prompts no additional treatment, visits, or monitoring, it will not meet 
the definition of an AE. 
This includes the following: 
• AEs not previously observed in the subject that emerge during the protocol-specified 
AE reporting period (see Section 12.4.1). 
• Findings from protocol-mandated interventions. This can include laboratory 
assessments performed in the course of the clinical study. AEs should be reported 
only if the abnormalities are changes from baseline and are clinically significant as 
described above. 
• Pre-existing medical conditions (other than the condition being studied) judged by the 
investigator to have worsened in severity or frequency or changed in character during 
the protocol-specified AE reporting period. When recording such events on an 
AE/SAE eCRF page, it is important to convey the concept that the pre-existing 
condition has changed by including applicable descriptors (eg, “more frequent 
headaches”). 
• In addition, for this study, the disease-related events of acute symptomatic hemolysis 
and MAVEs (including thromboembolic events) will be reported as AEs, even if 
deemed related to the disease under investigation. 
An adverse reaction is defined in International Council for Harmonisation (ICH) E6 guideline as 
follows: all untoward and unintended responses to a study drug/IMP related to any dose 
administered. The definition covers also medication errors and uses outside what is foreseen in 
the protocol, including misuse and abuse of the product. The definition implies a reasonable 
possibility of a causal relationship between the event and the study drug/IMP. This means that 
there are facts (evidence) or arguments to suggest a causal relationship. 
Hospitalization scenarios do not require reporting as an SAE where there is no occurrence of an 
AE. These scenarios include a planned hospitalization or prolonged hospitalization to: 
• Perform a routine control screening for a pre-existing illness or to diagnose a 
suspected illness. In the case of the latter, the symptomatology should be reported as 
an AE and amended if a diagnosis is confirmed. 
• Undergo a diagnostic or elective surgical procedure for a pre-existing medical 
condition that has not changed (eg, a joint replacement for which the subject was on a 
waiting list). 
• Undergo medical observation without the occurrence of an AE due to standard of care 
in the region or hospital. 
Surgical procedures should not be reported as AEs. The condition for which the surgery is 
required should be reported as the AE if it occurs or is detected during the study period. Planned 
surgical measures permitted by the clinical study protocol and the conditions(s) leading to these 
measures are not AEs if the condition(s) was (were) known before the start of study treatment. In 
the latter case, the condition should be reported as medical history. 
AEs are designated as “nonserious” or “serious”. 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
101 
 
CONFIDENTIAL 
12.1.2. 
Serious Adverse Event  
An SAE is an adverse event/reaction that results in any of the following outcomes: 
• Death 
• Is life-threatening (subject is at immediate risk of death at the time of the event; it 
does not refer to an event that hypothetically might have caused death if it were more 
severe) 
• Requires subject hospitalization (formal admission to a hospital for medical reasons) 
or prolongation of existing hospitalization 
• Results in persistent or significant disability/incapacity (ie, there is a substantial 
disruption of a person's ability to carry out normal life functions) 
• Is a congenital anomaly/birth defect 
Important medical events that may not result in death, are not life-threatening, or do not require 
hospitalization may be considered SAEs when, based upon appropriate medical judgment, they 
may jeopardize the subject’s health or may require medical or surgical intervention to prevent 
one of the outcomes listed in this definition. Examples of such events may include allergic 
bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias, 
or convulsions that do not result in subject hospitalization.  
In addition, the sponsor considers any abortions (elective or spontaneous), fetal demise, and still 
birth to be SAEs for reporting purposes (see Section 12.4.2). 
Some hospitalization scenarios, as outlined in Section 12.1.1 do not require reporting as SAEs. 
Overdose will be considered an SAE only if any of the seriousness criteria are met. Any clinical 
complication in association with the overdose should be reported as an AE or SAE (as 
applicable) along with the overdose (see Section 12.6). Details of signs or symptoms, clinical 
management, and outcome should be reported, if available. Overdose without associated signs or 
symptoms should not be recorded as AEs but should be recorded as protocol deviations. 
12.1.3. 
Events of Special Monitoring 
Events of special monitoring (EOSM) are AEs or safety topics for which special monitoring, 
additional data collection activities, and/or enhanced signal detection activities within BioCryst 
are considered appropriate for this population and study. Identified EOSMs can be of particular 
concern based on findings from the IMP clinical program to date, potential and/or known risks 
generally associated with the underlying disease, or comorbidities and risk factors prevalent in 
the study population. 
EOSM for this study include acute symptomatic hemolysis, SARS-CoV-2 infections 
(asymptomatic and symptomatic), 
 
 
 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
102 
 
CONFIDENTIAL 
12.2. 
Definition of Severity 
All AEs will be assessed (graded) for severity by the investigator and classified using the US 
NCI CTCAE (version 5.0, published 27 November 2017). The NCI CTCAE is a descriptive 
terminology that can be used for AE reporting. The CTCAE displays Grades 1 through 5 with 
unique clinical descriptions of severity for each AE based on the following general guideline: 
Mild: 
(Grade 1): Mild; asymptomatic or mild symptoms; clinical or diagnostic 
observations only; intervention not indicated. 
Moderate: 
(Grade 2): Moderate; minimal, local or noninvasive intervention indicated; 
limiting age-appropriate instrumental ADLa. 
Severe: 
(Grade 3): Severe or medically significant but not immediately 
life-threatening; hospitalization or prolongation of hospitalization 
indicated; disabling; limiting self-care ADLb. 
Life-threatening: 
(Grade 4): Life-threatening consequences; urgent intervention indicated. 
Death 
(Grade 5): Death related to AEc. 
Abbreviations: ADL = activities of daily living; AE = adverse event. 
a Instrumental ADL refer to preparing meals, shopping for groceries or clothes, using the telephone, managing 
money, etc. 
b Self-care ADL refer to bathing, dressing, and undressing, feeding self, using the toilet, taking medications, and not 
bedridden. 
c Grade 5 (Death) is not appropriate for some AEs and therefore is not an option. 
It is important to distinguish between serious and severe AEs. Severity is a measure of intensity, 
as defined above, whereas seriousness is defined by the criteria under Section 12.1.2. An AE of 
severe intensity may or may not be considered serious. 
12.3. 
Relationship to Study Drug 
An investigator who is qualified in medicine must make the determination of relationship to the 
study drug/IMP for each AE (not related, unlikely related, possibly related, probably related, 
definitely related). The investigator should decide whether, in his or her medical judgment, there 
is a reasonable possibility that the event may have been caused by the investigational product. If 
no valid reason exists for suggesting a relationship, then the AE should be classified as “not 
related”. If there is any valid reason, even if undetermined, for suspecting a possible cause-and-
effect relationship between the study drug/IMP and the occurrence of the AE, then the AE should 
be considered “related”. 
Not Related: 
The event can be readily explained by other factors such as the subject’s 
underlying medical condition, concomitant therapy, or accident, and no 
temporal relationship exists between the study drug/IMP and the event. 
Unlikely 
Related: 
The event does not follow a reasonable temporal sequence from drug 
administration and is readily explained by the subject’s clinical state or by 
other modes of therapy administered to the subject. 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
103 
 
CONFIDENTIAL 
Possibly 
Related: 
There is some temporal relationship between the event and the administration 
of the study drug/IMP and the event is unlikely to be explained by the subject’s 
medical condition, other therapies, or accident. 
Probably 
Related: 
The event follows a reasonable temporal sequence from study drug/IMP 
administration, abates upon discontinuation of the study drug/IMP, and cannot 
be reasonably explained by the known characteristics of the subject’s clinical 
state. 
Definitely 
Related: 
The event follows a reasonable temporal sequence from study drug/IMP 
administration, follows a known or suspected response pattern to the study 
drug/IMP, is confirmed by improvement upon stopping the study drug/IMP 
(dechallenge), and reappears upon repeated exposure (rechallenge, if 
rechallenge is medically appropriate). 
If the relationship between the (S)AE and the investigational product is determined to be 
“possible”, “probable”, or “definite”, the event will be considered to be related to the study 
drug/IMP for the purposes of expedited regulatory reporting (as applicable per country-specific 
regulatory requirements). 
The sponsor may upgrade causality if deemed appropriate. 
12.4. 
Method, Frequency, and Time Period for Detecting Adverse Events 
and Reporting Serious Adverse Events 
Reports of all AEs and SAEs, regardless of investigator attribution, are to be collected from the 
time of signing of the ICF through to the last study visit (ie, through the post-treatment follow-up 
visit). All AEs and SAEs are to be reported on the AE eCRF. 
AEs should be documented on the eCRFs as investigators become aware of them. AEs are to be 
followed until the event resolves. If an event is ongoing at the last follow-up visit, Grade 1 and 
Grade 2 events do not need to be followed if the event is deemed unlikely to be related or not 
related to study drug/IMP (see Section 12.2 for AE grading). For all Grade 3 and Grade 4 events 
or events deemed possibly, probably, or definitely related to use of study drug/IMP, the event 
should be followed until the AE is resolved or the subject is in a clinically stable condition with 
regards to the AE. 
The investigator shall report all SAEs immediately and no later than 24 hours of their knowledge 
of the event to the sponsor by communicating with the medical monitor (phone or email) and by 
entering the event into the AE eCRF and by completion of the SAE eCRF. The SAE eCRF is an 
additional form to the AE eCRF that provides important details on the SAE. The investigator 
should follow all unresolved SAEs observed during the study until they are resolved, or are 
judged medically stable, or are otherwise medically explained. 
The investigator should attempt, if possible, to establish a diagnosis based on the presenting 
signs and symptoms. In such cases, the diagnosis should be documented as the AE and not the 
individual sign/symptom. If a clear diagnosis cannot be established, each sign and symptom must 
be recorded individually. Once a diagnosis is made during evaluation or treatment, the 
investigator will update the AE record with this diagnosis and delete the previously reported 
signs and symptoms. The rapid reporting of SAEs ensures that the sponsor shall have the 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
104 
 
CONFIDENTIAL 
necessary information to continuously assess the benefit-risk profile of the study drug in clinical 
studies. 
12.4.1. 
Serious Adverse Events and Suspected Unexpected Serious Adverse Reactions 
The investigator must report all SAEs immediately and in no case later than within 24 hours of 
their knowledge of the event. Investigators should adhere to their country or region requirements 
for the reporting timeframe, which may not allow any delay. SAEs should be reported to the 
sponsor medical monitor and via the AE and SAE eCRFs. All additional follow-up evaluations 
of the SAE must be reported to BioCryst or its designee as soon as they are available by 
amending these eCRFs. The eCRF system automatically sends SAE notifications to the 
following email address: 
 
 
Email: safety@biocryst.com 
In the event the eCRF system is not functioning, the reporting of an SAE must not be delayed. 
Sites will have SAE report forms (electronic Word document) that can be completed and emailed 
to the above recipient. As soon as the eCRF system is functioning, that particular SAE must be 
entered into the AE eCRF. 
Immediate reporting should allow BioCryst to take the appropriate measures to address potential 
new risks in a clinical study. Therefore, the initial report should be submitted by the investigator 
within a very short period of time and under no circumstances should this period exceed 24 hours 
following awareness of the SAE. 
The follow-up report should allow BioCryst to determine whether the SAE requires a 
reassessment of the benefit-risk profile of the study drug/IMP in clinical study, if the relevant 
information was not already available and provided in the initial report. 
Country-specific rules and requirements for safety management will be described in the Safety 
Management Plan prepared for this study.  
Investigators or designees at each site are responsible for retaining copies of all suspected 
unexpected serious adverse reaction (SUSAR) reports (initial and follow-up) and other safety 
information (eg, revised IB) in the investigator site files. 
BioCryst shall ensure that all relevant information about SUSARs that are fatal or 
life-threatening is recorded and reported as soon as possible to all competent authorities, and to 
the applicable ethics committee in any case no later than 7 calendar days after knowledge by 
BioCryst of such a case, and that relevant follow-up information is subsequently communicated 
within an additional 8 days. All other SUSARs shall be reported to the competent authorities 
concerned and to the ethics committees, as applicable, according to local regulations, as soon as 
possible but in no case later than 15 calendar days of first knowledge by BioCryst. BioCryst or 
designee shall also inform the investigator. Although acute kidney injury is considered an 
expected event (see Section 6.11 of the IB), the event will be reported in an expedited manner. 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
105 
 
CONFIDENTIAL 
12.4.2. 
Pregnancy 
Any female subject who becomes pregnant during the course of the study should have BCX9930 
discontinued immediately and must be followed through the end of the pregnancy. While 
pregnancy is not considered an AE, all cases of fetal drug exposure via the parent as a study 
participant (including partners of study participants) are to be reported immediately to BioCryst 
or its designee. Consent from study partners who become pregnant will be obtained prior to 
reporting any details of the pregnancy. Information related to the pregnancy must be given on a 
“Pregnancy Notification and Outcome” form that will be provided by the sponsor or its designee 
so that the pregnancy may be followed, and an outcome determined. Any AEs or SAEs 
experienced by a pregnant subject are to be reported as directed in Section 12.4.1. Any 
complications reported in a subject’s pregnant partner should be reported on the Pregnancy 
Notification and Outcome form. All pregnancies must be followed to outcome, which occurs 
when an infant is delivered (live or still born), there is fetal demise, or there is an abortion 
(spontaneous or induced). Abortion (spontaneous or induced), fetal demise, and still birth, along 
with congenital abnormalities in the newborn, should be reported as separate SAEs. 
12.4.3. 
Emergency Unblinding Procedures 
Access to study drug/IMP assignment will be available immediately through the IWRS system if 
the investigator deems it necessary to break the study blind in the interest of a subject’s medical 
safety, in case of a medical emergency, to meet regulatory reporting obligations, or if warranted 
during scheduled safety reviews. Where medically appropriate, the investigator will contact the 
sponsor medical monitor to discuss the situation that has arisen and resulted in the need for 
unblinding of the subject. The sponsor medical monitor will not be involved in the decision to 
unblind or the actual unblinding. 
12.5. 
Adverse Event Management 
The investigator (or qualified designee) will grade clinically significant events and laboratory 
abnormalities (if considered AEs) as detailed in Section 12.2. Grade 3 and Grade 4 clinically 
significant laboratory abnormalities should be confirmed by repeat testing and before any 
contemplated study drug/IMP discontinuation, unless such a delay is not consistent with good 
medical practice. 
12.5.1. 
Potential Drug-induced Liver Injury: Monitoring, Evaluation, and 
Discontinuation Criteria 
All treatment-emergent ALT elevations > 3 × ULN should be confirmed, preferably within 
72 hours, with repeat assessment of ALT, AST, total bilirubin, ALP, prothrombin time/INR, and 
complete blood count with differential. These may be repeated at a local laboratory as long as the 
results are reported to the investigator when available and the investigative site contacts the 
subject to ascertain any symptoms. 
Subjects with ALT elevation > 3 × ULN must be assessed to determine whether study drug must 
be withheld or discontinued. In addition, any potentially contributing medications, supplements, 
or over-the-counter medications that are not medically necessary should be discontinued if 
medically feasible. 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
106 
 
CONFIDENTIAL 
Discontinuation of treatment should be considered for any of the following, and should be 
discussed with the sponsor medical monitor prior to BCX9930 discontinuation, considering the 
benefit-risk of discontinuing BCX9930: 
• ALT or AST > 8 × ULN 
• ALT or AST > 5 × ULN for more than 2 weeks 
• ALT or AST > 3 × ULN and (total bilirubin > 2 × ULN [unless there is evidence that 
the increase in bilirubin is due to hemolysis or Gilbert’s syndrome] or 
INR > 1.5 × ULN in the absence of warfarin therapy) 
• ALT or AST > 3 × ULN with the appearance of fatigue (over baseline fatigue), 
nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or 
eosinophilia (> 5%) 
If subjects are asymptomatic with no other pertinent laboratory abnormality, study drug may be 
continued under close observation. Transaminases, total bilirubin, ALP, and INR should be 
repeated at least twice weekly. Frequency of retesting can decrease to once per week or less if 
abnormalities stabilize or the study drug has been discontinued and the subject is asymptomatic. 
Additionally, several other items should be considered, including obtaining a more detailed 
history of symptoms and prior or concurrent diseases; obtaining a history of concomitant use of 
nonprescriptive medications, herbal and dietary supplements, alcohol intake, recreational drug 
use, or special diets; evaluation for acute viral hepatitis A, B, C, D, and E and potentially other 
serologies; evaluation for others as clinically indicated including alcoholic and autoimmune 
hepatitis, non-alcoholic steatohepatitis (NASH), and biliary tract disease. 
The above criteria will be applied to increases in AST unless there is evidence that the increase is 
due to hemolysis. If both ALT and AST are elevated, subjects will be managed based on their 
ALT level, regardless of whether their AST increase is thought to be due to hemolysis. 
If Hy’s Law criterion is met and is assessed as probably or definitely related per treatment 
discontinuation criterion in Section 7.5.1, then study drug must be discontinued. Prior to 
discontinuation from study drug/BCX9930, the investigator should contact the sponsor medical 
monitor for a discussion regarding the event and assessment. If medically indicated, the 
investigator can discontinue the subject immediately and follow up with the sponsor within 
24 hours. 
12.5.2. 
Renal Events 
12.5.2.1. Monitoring, Evaluation, and Subject Discontinuation Criteria 
There are multiple potential reasons that sCr can increase in those with PNH, including 
hemolysis. For subjects who have a confirmed treatment-emergent increase in sCr, evaluations to 
investigate potential etiology should be chosen considering baseline renal function, history of 
prior renal events including those due to PNH, other comorbidities, concomitant medications, 
and other relevant factors. In addition:  
• For all subjects, ensure adequate hydration, stop or substitute potentially nephrotoxic 
medications, and evaluate for tuberculosis if sterile pyuria is present if potential exposure 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
107 
 
CONFIDENTIAL 
• For treatment-emergent increases in sCr > ULN or ≥ 0.3 mg/dL (≥ 26.5 µmol/L) from 
baseline confirmed by repeat testing, notify sponsor medical monitor 
• A renal ultrasound with doppler should be considered to exclude renal vein thrombosis or 
other incidental causes 
• Subject data may be reviewed by a Nephrology Risk Mitigation Working Group 
(NRMWG) for additional recommendations, including dose reduction, interruption of 
dosing, and permanent discontinuation 
• If a biopsy is performed, a redacted copy of the biopsy report and available images 
(whole slide images of light microscopy or electron microscopy specimens, 
immunofluorescence, immunohistochemistry, etc.) should be made available 
The following table gives additional actions based on sCr: 
sCr > ULN but 
≤ 1.5 × ULN 
• 
Assessment frequency as per the schedule specified in Table 3 (Part 1) or 
Table 4 (Part 2) (ie, every 1 to 4 weeks, as applicable) until sCr is ≤ ULN 
• 
Consider evaluation by nephrologist 
sCr > 1.5 × ULN but 
< 3 × ULN 
• 
Assessment frequency weekly until sCr is ≤ ULN 
• 
Evaluation by nephrologist 
sCr ≥ 3 × ULN 
• 
BCX9930 should be discontinued, with taper (see Section 9.4.2), after 
confirmation  
• 
If hemolysis or any other potentially reversible cause is suspected, 
contact sponsor medical monitor 
12.5.2.2. Study Stopping Rule 
The NRMWG will be notified promptly of and review any instances of subjects experiencing 
increased sCr ≥ 3 × ULN, and the DMC will be notified of each confirmed case, regardless of 
causality. 
In the event that 3 subjects are determined by the NRMWG to have confirmed elevations of sCr 
≥ 3 × ULN considered related to BCX9930, the study will be stopped. This will apply only to 
newly enrolled subjects treated at a dose of 400 mg BID. 
12.5.3. 
Risk of Hemolysis After Missed Doses, Treatment Interruption, or Permanent 
Discontinuation of BCX9930 
Subjects must be warned of the potential risk of hemolysis following missed doses (particularly 
multiple consecutive missed doses) and treatment interruption, and the definite risk after 
permanent discontinuation of BCX9930. By inhibiting the AP of complement, BCX9930 may 
improve Hb levels and increase circulating RBC clone size by reducing the hemolysis of PNH 
RBCs. Missed doses and treatment interruption of BCX9930 may lead to hemolysis. Subjects are 
at risk of severe hemolysis when BCX9930 is permanently discontinued. Based on available data 
regarding the PK and PD of BCX9930, severe hemolysis, if it occurs, would be expected to 
present within days after discontinuation of therapy. 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
108 
 
CONFIDENTIAL 
Therefore, when subjects permanently discontinue blinded study drug in Part 1 or BCX9930 in 
Part 2 (either at the end of the study for those who do not continue treatment or those who 
permanently discontinue BCX9930 treatment prematurely at any time during the study), they 
must be monitored for hemolysis. When an investigator is made aware that a subject has 
permanently discontinued study drug or BCX9930, if the subject is asymptomatic, contact with 
the subject should occur at least daily for a minimum of 7 days. Contact may be conducted by 
telephone, email, or other means, including in person, if preferred. When any sign or symptom of 
hemolysis occurs, the subject should be promptly evaluated (refer to Section 10.3.7 for a list of 
minimum laboratory testing). Additional monitoring following the first contact after permanent 
discontinuation should be guided by the medical judgement of the investigator. For subjects who 
are already symptomatic when treatment is discontinued, whether the subject should be assessed 
in person or can be followed with daily contact will be based on the investigator’s medical 
judgement taking into account the severity of the reported signs or symptoms and/or any reported 
worsening of the signs or symptoms. When possible, subjects should return to the investigative 
center; however, when this is not possible, arrangements may be made for the subject to be 
assessed by his or her local hematologist and a local laboratory used for clinical laboratory 
testing. When hemolysis occurs after the permanent discontinuation of BCX9930, supportive 
treatment should be provided according to the judgement of the investigator. 
Treatment with study drug/BCX9930 should not be interrupted or withheld unless there is an 
absolute contraindication for continued dosing. Suggestions for anti-emetic therapy for subject 
with active nausea and vomiting when tablet contents are vomited are given in Section 9.6.2. The 
sponsor medical monitor should be contacted for guidance in both cases as soon as possible after 
the investigator is made aware of the event.  
The sponsor medical monitor should be notified in the event of hemolysis symptoms, any 
planned treatment interruption, and permanent discontinuation of study drug/BCX9930. Any 
missed doses, treatment interruption, or permanent discontinuation must be recorded in the eCRF 
and source documents, including the reason for the interruption, missed doses, or 
discontinuation. 
Study assessments for monitoring of potential hemolysis for missed doses, treatment 
interruption, and permanent discontinuation of blinded study drug or BCX9930 for subjects who 
experience signs or symptoms of hemolysis are in Section 10.3.7. 
12.5.4. 
Acute Symptomatic Hemolysis 
Subjects should contact the investigator if they experience any new or worsening signs or 
symptoms of hemolysis, including increased fatigue over baseline, abdominal pain, dysphagia, 
shortness of breath over baseline, hemoglobinuria, new signs and/or symptoms suggestive of 
thrombosis, or new or worsening erectile dysfunction, upon first awareness. Subjects should be 
evaluated per the investigator’s medical judgement. In person evaluation is preferred, but can 
include phone or telemedicine contact with documentation, if in-person evaluation is not 
possible. 
For subjects receiving blinded study drug in Part 1 or BCX9930 in Part 2, a review of dosing 
compliance to ensure that the subject is taking the drug correctly must be performed, regardless 
of the method used to evaluate the subject (ie, in-person or remote assessment), and any missed 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
109 
 
CONFIDENTIAL 
doses should be recorded. It should also be determined whether the subject has had any recent 
CACs (eg, infection, trauma, or surgery) that may have contributed to the hemolytic event. 
For this study, the term “acute symptomatic hemolysis” is defined by the following: 
• ≥ 1 new or worsening acute sign or symptom of IVH, such as fatigue, 
hemoglobinuria, abdominal pain, dyspnea, MAVE (including thrombosis), dysphagia, 
erectile dysfunction, or acute kidney injury [AKI; defined as eGFR decrease of ≥ 50% 
or doubling of serum creatinine]) 
AND 
• acute reduction in Hb of > 2 g/dL and a 2-fold increase (ie, doubling) in LDH, as 
compared to the most recent Hb and LDH values (ie, while not experiencing 
symptoms of acute symptomatic hemolysis). 
The sponsor medical monitor should be notified when the investigator first becomes aware of a 
potential acute symptomatic hemolysis event. Treatment with blinded study drug in Part 1, and 
BCX9930 for all subjects in Part 2, should continue in addition to any other treatments. 
12.6. 
Overdose 
To date, there is no experience with overdose of BCX9930. Healthy subjects received BCX9930 
at a dose of 2000 mg administered as single doses and as multiple once-daily doses for 3 days in 
Study 101 with no clinically significant safety concerns. In the event that study personnel 
become aware of an overdose of BCX9930 that is associated with an AE, both the overdose and 
the resultant event should be reported as AEs. Overdose without any symptoms (ie, AEs) does 
not need to be reported as an AE. If overdose occurs with or without associated AEs, subjects 
should undergo clinical and laboratory monitoring, as appropriate, for their clinical condition 
and, if indicated, should receive clinically indicated supportive therapy. See also Section 12.1.2. 
12.7. 
Data Monitoring Committees 
A DMC will be established for interim safety monitoring. The specific responsibilities and 
composition of the DMC are outlined in a separate DMC charter. In addition, the details of 
outputs provided for the meetings will be referenced in this charter. 
A NRMWG will review and advise on subjects with treatment-emergent increases in sCr and 
other renal events. The specific responsibilities and composition of the NRMWG are outlined in 
a separate charter. 
13. 
STATISTICS 
13.1. 
Hypotheses 
The primary study hypothesis is the differential effect on the mean CFB in Hb at Week 12 in Hb 
between BCX9930 and placebo. 
The primary null and alternative hypotheses are: 
• CFB in Hb at Week 12. 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
110 
 
CONFIDENTIAL 
− Ho: HbB = HbP; BCX9930 does not have a differential effect on the mean CFB in 
Hb at Week 12 as compared to placebo 
− HA: HbB ≠ HbP; BCX9930 does have a differential effect on the mean CFB in Hb 
at Week 12 as compared to placebo 
where HbB is the mean CFB in Hb at Week 12 for BCX9930 and HbP is the mean 
CFB in Hb at Week 12 for placebo. 
Key secondary hypotheses comparing BCX9930 to placebo are as follows: 
• Proportion of subjects who are transfusion-free from Week 4 to Week 12 
− Ho: TAB = TAP; BCX9930 does not have a differential effect on the proportion of 
subjects who are transfusion-free from Week 4 to Week 12 
− HA: TAB ≠ TAP; BCX9930 does have a differential effect on the proportion of 
subjects who are transfusion-free from Week 4 to Week 12 
where TAB is the proportion of subjects who are transfusion-free from Week 4 to 
Week 12 for BCX9930 and TAP is the proportion of subjects who are transfusion-free 
for placebo. 
• Number of units of pRBCs transfused from Week 4 to Week 12 
− Ho: pRBCB = pRBCP; BCX9930 does not have a differential effect on the number 
of units of pRBCs transfused from Week 4 to Week 12 
− HA: pRBCB ≠ pRBCP; BCX9930 does have a differential effect on the number of 
units of pRBCs transfused from Week 4 to Week 12 
where pRBCB is the number of units of pRBCs administered from Week 4 to 
Week 12 for BCX9930 and pRBCP is the number of units of pRBCs administered for 
placebo. 
• Percent CFB in LDH at Week 12 
− Ho: LDHB = LDHP; BCX9930 does not have a differential effect on the mean 
percent CFB in LDH at Week 12 as compared to placebo 
− HA: LDHB ≠ LDHP; BCX9930 does have a differential effect on the mean percent 
CFB in LDH at Week 12 as compared to placebo 
where LDHB is the mean percent CFB in LDH at Week 12 for BCX9930 and LDHP is 
the mean percent CFB for placebo. 
• Change from baseline in FACIT-Fatigue scale score at Week 12 
− Ho: FACITB = FACITP; BCX9930 does not have a differential effect on the mean 
CFB in FACIT-Fatigue scale score at Week 12 
− HA: FACITB ≠ FACITP; BCX9930 does have a differential effect on the mean 
CFB in FACIT-Fatigue scale score at Week 12 
where FACITB is the mean CFB in FACIT-Fatigue scale score at Week 12 for 
BCX9930 and FACITP is the mean CFB in FACIT-Fatigue scale score for placebo. 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
111 
 
CONFIDENTIAL 
Inferential testing for the primary endpoint of interest (CFB in Hb at Week 12) will be conducted 
at the α = 0.05 level of significance. The alpha level for tests of primary and key secondary 
endpoints will be adjusted for multiplicity using hierarchical testing in the order the endpoints 
are specified as described in Section 13.1.1. All hypothesis tests will be 2-sided. 
13.1.1. 
Controlling for Multiplicity 
Five endpoints are being tested: the primary endpoint and 4 secondary endpoints. The Type I 
error rate will be controlled at the study level using a hierarchical testing procedure. 
Statistical testing for the primary hypothesis will be performed using an alpha of 0.05. All 
hypothesis tests will be two-sided. If the null hypothesis associated with the primary endpoint is 
rejected, the key secondary endpoints for Part 1 will be tested in the following order using an 
alpha of 0.05. Testing will stop when an endpoint has an associated p-value ≥ 0.05 or when all 
endpoints have been tested (ie, all p-values are < 0.05): 
1. Proportion of subjects who are transfusion-free [from Week 4 to Week 12] 
2. Number of units of pRBCs transfused [from Week 4 to Week 12] 
3. Percent CFB in LDH [at Week 12] 
4. CFB in FACIT-Fatigue scale score [at Week 12] 
13.2. 
Sample Size Considerations 
Assuming a common standard deviation (SD) for Hb of 2.3 g/dL from Lee and colleagues (Lee, 
Peffault de Latour, et al. 2019) and a randomization ratio of 2:1, a sample size of 57 subjects 
(approximately 38 subjects in the BCX9930 200/400 mg arm and approximately 19 subjects in 
the placebo arm) will provide 85.3% power to detect a treatment difference of 2.0 g/dL in change 
from baseline Hb for subjects randomized to BCX9930 200/400 mg compared to subjects 
randomized to placebo. Because missing data will be imputed for the primary analysis, 
enrollment has not been increased to account for drop-outs. 
13.3. 
Sample Size Re-estimation 
No sample size re-estimation is planned. 
13.4. 
Stratification 
Randomization will be stratified based on whether a pRBC transfusion was received within the 
6 months prior to baseline (yes vs. no). 
13.5. 
Statistical Methods 
A detailed statistical analysis plan (SAP) will be developed to describe the methods of analyses 
and summaries, including all endpoints, time points, populations, missing data, etc. Deviations 
from the analyses outlined in the SAP will be described in the clinical study report (CSR).  
13.5.1. 
Analysis Populations 
The analysis populations for the study are defined below. 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
112 
 
CONFIDENTIAL 
13.5.1.1. Screen Failures 
Subjects who give informed written consent but are not randomized to study treatment and are 
noted as screen failures in the eCRF are considered screen failures. Reasons for screen failure 
will be summarized using this population. 
13.5.1.2. Intent-to-Treat Population 
The intent-to-treat (ITT) population is defined as all randomized subjects, regardless of whether 
study treatment was administered. This population will be the primary population for efficacy 
analyses. Subjects will be analyzed according to the treatment randomized. 
13.5.1.3. Safety Population 
The safety population is defined as all subjects who receive at least 1 dose of study drug, whether 
BCX9930 or placebo. This population will be used for all analyses of accountability, 
demographics, and safety. Data will be analyzed according to the actual treatment received at 
first dose for all subjects or at first dose of Part 2 for subjects originally randomized to placebo. 
13.5.1.4. Per Protocol Population 
The per-protocol (PP) population is defined as all subjects who did not violate key protocol 
inclusion or exclusion criteria, received only the study drug to which they were randomized, and 
did not have any protocol deviations or violations that would affect analysis, as determined by 
the sponsor. This population will be used for a sensitivity analysis of the primary efficacy 
analysis. Analyses based on the PP population will be produced for Part 1 only. Subjects will be 
analyzed according to the treatment randomized. 
13.5.1.5. Completers Population 
The subset of subjects in the ITT population who complete Part 1 of the study and 12 weeks of 
blinded study drug will compose the completers population. This population will be used for a 
sensitivity analysis of the primary efficacy analysis for Part 1 only. Subjects will be analyzed 
according to the treatment randomized. 
13.5.1.6. Pharmacokinetic Population 
The PK population will comprise the subset of subjects in the safety population for whom 
BCX9930 concentration data are available. The PK substudy population will include all subjects 
who participate in the optional PK/PD substudy and have 1 post-dose concentration collected 
during a substudy visit. 
13.5.1.7. Pharmacodynamic Population 
The PD population will include all safety population subjects for whom at least 1 pre-dose and 
1 post-dose PD or complement biomarker measurement can be obtained. This population will be 
used for all PD and complement biomarker analyses and for correlation with BCX9930 PK 
parameters or BCX9930 concentrations. Subpopulations including subjects for whom at least 
1 pre-dose and 1 post-dose measurement for each PD or complement biomarker may be used for 
analysis. Subjects will be analyzed according to the treatment received. 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
113 
 
CONFIDENTIAL 
13.5.2. 
General Considerations for Data Analysis 
In general, descriptive summaries will include n, mean, standard deviation, median, minimum, 
and maximum for continuous variables and n and percent for categorical variables. Summaries 
will be presented by treatment and study visit. 
All individual subject data will be listed as measured. All statistical summaries and analyses will 
be performed using SAS® software (SAS Institute, Cary, North Carolina, USA). 
13.5.3. 
Subject Demographic and Disposition Data 
Demographic data and baseline characteristics including age, gender, race or ethnicity, height, 
body weight, BMI, and PNH history will be summarized by treatment and overall. 
The following baseline measures will be summarized using descriptive statistics: Hb levels, LDH 
levels, and FACIT-Fatigue scale score. 
Subject disposition will be presented by treatment and overall. The number of subjects who 
completed the study and those that discontinued from the study will be provided. The reasons for 
early discontinuation will be presented. A tabulation of the number of subjects exposed to study 
drug and duration of exposure will also be presented for each treatment and overall. Treatment 
adherence, dose interruptions, and reason for dose interruptions will be provided as summaries or 
listed as appropriate. 
13.5.4. 
Analysis of Efficacy Variables 
The primary efficacy analyses will be based on Part 1 of the study. The efficacy analyses will be 
based on the ITT population. The analyses of the PP population and completers population will 
be used to support the primary efficacy analyses. 
Efficacy data will be summarized by treatment in Part 1. 
13.5.4.1. Primary Efficacy Analysis 
The primary endpoint is the CFB in Hb at Week 12. The analysis of the primary endpoint will be 
conducted using Part 1 data. 
The primary efficacy analysis will be produced using the ITT population. The estimand will be 
based on data from subjects while taking study treatment and prior to any rescue, if applicable, 
with data missing not at random imputed to be similar to what would have been observed on the 
reference treatment (ie, placebo) and data missing at random imputed to be similar to that of the 
randomized treatment of the subject. Statistical testing will be two-sided.  
CFB in Hb will be summarized by treatment and visit. The difference between treatment groups 
in CFB Hb at Week 12 will be analyzed using an analysis of covariance (ANCOVA) model. The 
model will include treatment and randomization stratum as categorical covariates and baseline 
Hb as a continuous covariate. Observed data will be included up to the time of discontinuation of 
study treatment or to start of rescue treatment, if applicable. In addition, CFB Hb values that 
occur within 14 days after the subjects receives a pRBC transfusion (ie, the interval between the 
transfusion day and the current study day is ≤ 13 days) will be replaced with an unscheduled 
CFB Hb if one is available within the 14-day period prior to Week 12 and it was not obtained 
within 14 days after pRBC transfusion or, if an unscheduled value is not available, will be 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
114 
 
CONFIDENTIAL 
censored unless the CFB Hb value is ≤ 0. Central laboratory values will be used. If a central 
laboratory value is missing but a local laboratory value is available, the local laboratory value 
will be used in place of the censored lab value. Missing data will be imputed using the method of 
Jump-to-Reference (J2R) (Carpenter, Roger, et al. 2013). The estimated treatment difference 
comparing BCX9930 to placebo at Week 12 will be displayed together with the 95% CI and the 
associated p-value. Least-squares means (LSM) will also be presented with the standard error 
(SE). 
Sensitivity analyses will be conducted to support the primary analysis. This will include the 
following analyses: 
1) Analyses based on data from subjects who are in the completers population using the 
same analysis methodology as for the primary analysis.  
2) Analyses based on data from subjects in the PP population using the same analysis 
methodology as for the primary analysis.  
3) An ITT analysis will also be conducted using observed data up to the time of 
discontinuation of study treatment or to start of rescue treatment, if applicable, without 
imputation of missing data.  
4) A tipping point analysis will be conducted to further examine the effect of missingness.  
5) A Mixed Models Repeated Measures (MMRM) analysis will be conducted using the ITT 
population and observed data to look at trends over time by treatment. 
Details of sensitivity analyses will be provided in the SAP. 
Subgroup analyses will be conducted by geographical region and by race. Additional subgroup 
analyses will be described in the SAP. 
Plots of mean Hb and mean CFB Hb by visit and treatment will be produced for Part 1, using a 
different color for each treatment. Plots will be updated to include Part 2 data at the final 
analysis. 
13.5.4.2. Analyses of Key Secondary, Other Secondary, and Exploratory Efficacy 
Endpoints 
13.5.4.2.1. Part 1 
Key secondary hypotheses comparing BCX9930 to placebo for Part 1 will be analyzed as 
follows: 
1. Proportion of subjects who are transfusion-free [from Week 4 to Week 12] 
2. Number of units of pRBCs transfused [from Week 4 to Week 12] 
3. Percent CFB in LDH [at Week 12] 
4. CFB in FACIT-Fatigue scale score [at Week 12] 
The proportion of subjects who are transfusion-free from Week 4 to Week 12 will be 
summarized by treatment. Subjects who either (1) discontinue treatment prior to Week 12, or 
(2) do not receive a transfusion during the Week 4 to Week 12 time period despite recording a 
Hb value ≤ 9 g/dL with symptoms warranting transfusion or a Hb value ≤ 7 g/dL regardless of 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
115 
 
CONFIDENTIAL 
symptoms will not be considered transfusion-free. A Cochran-Mantel-Haenszel (CMH) 
chi-squared analysis will be conducted to test the hypothesis of interest and to compute an odds 
ratio and 95% CI comparing the odds of being transfusion-free for BCX9930 treatment as 
opposed to treatment with placebo. As a supportive analysis, a logistic regression analysis will be 
conducted with a fixed effect for treatment and an indicator variable for the randomization 
stratum. A sensitivity analysis using CMH will be conducted in which subjects who discontinue 
treatment prior to Week 12 will not be considered transfusion-free, but subjects who do not 
receive a transfusion despite a Hb value ≤ 9 g/dL with symptoms warranting transfusion or a Hb 
value ≤ 7 g/dL regardless of symptoms will be considered as transfusion-free. 
The number of units of pRBCs transfused from Week 4 to Week 12 will be summarized by 
treatment. The van Elteren test will be used to compare the two treatments with respect to the 
number of pRBCs transfused from Week 4 to Week 12. As a supportive analysis, the rate of 
pRBCs units transfused per 28 days will be derived using a negative binomial model. The 
negative binomial model will include the number of units of pRBCs from Week 4 to Week 12 as 
the dependent variable, the treatment and an indicator variable for the randomization factor as 
independent variables, and the logarithm of duration on treatment included as an offset variable. 
The model-estimated rate of pRBCs per 28 days from Week 4 to Week 12 will be reported for 
each treatment group. A rate ratio (with 95% CI) comparing BCX9930 to placebo will be 
obtained as well as a percent reduction in rate (with 95% CI) for BCX9930 as compared to 
placebo. 
The actual and change from baseline in the endpoints of LDH and FACIT-Fatigue scale score 
will be summarized by treatment group and visit. The difference between treatment groups in 
percent CFB LDH at Week 12 and CFB FACIT-Fatigue score at Week 12 will be separately 
analyzed using an ANCOVA model. The model will include the CFB endpoint at Week 12 as the 
dependent variable with the treatment, an indicator variable for the randomization stratum, and 
baseline endpoint value as independent variables. Values obtained after treatment 
discontinuation or after rescue treatment, if applicable, will not be included. FACIT-Fatigue 
values occurring within a 14-day window after transfusion (ie, the interval between the 
transfusion day and the current study day is ≤ 13 days) will be censored. As such, the J2R 
method for handling of missing data will be used for the CFB FACIT-Fatigue analysis. Percent 
CFB LDH values will not be censored following a transfusion and the analysis for that endpoint 
will use observed data prior to study discontinuation or rescue treatment without imputation of 
missing data. For percent CFB in LDH and CFB in FACIT-Fatigue scale score, a supportive 
analysis using observed data will be conducted using MMRM with fixed effects for 
randomization stratum, treatment, baseline endpoint, visit, a visit-by-treatment interaction, and a 
random effect for subject. An unstructured covariance structure will be used. The 
Kenward-Roger approximation will be used to estimate denominator degrees of freedom. The 
estimated treatment difference comparing BCX9930 to placebo at each post-baseline visit will be 
displayed together with the 95% CI and the associated p-value. LSM for each visit will also be 
presented with the SE. Plots of the mean endpoint and change from baseline by visit and 
treatment group will be produced for Part 1. Cumulative density function (CDF) and probability 
density function (PDF) plots of observed data for CFB FACIT-Fatigue at Week 12 will be 
produced. As an additional sensitivity analysis for CFB in FACIT-Fatigue scale score at 
Week 12, an ANCOVA analysis will be conducted using observed data with censoring due to 
transfusion within a 14-day window but without imputation of missing data. For percent CFB in 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
116 
 
CONFIDENTIAL 
LDH at Week 12, a sensitivity analysis will be conducted using ANCOVA with missing data 
imputed using the J2R method. 
Nominal p-values will be provided for other secondary and exploratory endpoints. 
• Percent reduction in the rate of pRBC units transfused [from Week 4 to Week 12 vs. 
prestudy transfusion rate] 
• Proportion of subjects with Hb ≥ 12 g/dL [at Week 12] 
• Proportion of subjects with Hb stabilization, defined as avoidance of a > 2 g/dL 
decrease in the absence of transfusion [from Week 4 to Week 12] 
• CFB in total PNH RBC clone size [at Week 12] 
• CFB in ratio of total PNH RBC clone size to PNH WBC clone size (ie, percent PNH 
RBCs / percent PNH WBCs) [at Week 12] 
• CFB in ARC [at Week 12] 
• Proportion of subjects with ARC in the normal range [at Week 12] 
• CFB in haptoglobin [at Week 12] 
• Proportion of subjects with haptoglobin ≥ LLN [at Week 12] 
• CFB in total bilirubin [at Week 12] 
• CFB in AST [at Week 12] 
 
 
CFB in the continuous endpoints will be summarized by treatment group and visit. An 
ANCOVA analysis will be conducted with CFB value at Week 12 as the dependent variable, 
treatment, an indicator variable for randomization stratum, and the value of the endpoint at 
baseline included as independent variables. Missing data will not be imputed. CFB in ARC, CFB 
total PNH RBC clone size, CFB ratio of total PNH RBC clone size to PNH WBC clone size, and 
CFB in haptoglobin will be censored if the subject had a transfusion within 14 days prior to 
measurement of the endpoint (ie, the interval between the transfusion day and the current study 
day is ≤ 13 days). 
The rate of pRBC units transfused from Week 4 to Week 12 will be calculated and compared to 
the rate of pRBC units transfused during the 12 months prior to screening. The percent reduction 
in rate of pRBC units transfused is the percent difference in rate relative to the retrospective rate, 
calculated as: (current rate – retrospective rate)/retrospective rate * 100%. Summary statistics 
will be provided for the percent reduction in rate of pRBC units transfused. In addition, the 
proportion of subjects with ≥ 50%/70%/90% reduction in rate will be reported. 
Proportions of subjects with Hb ≥ 12 g/dL, with ARC in the normal range, and with haptoglobin 
≥ LLN will be summarized by treatment and visit. Subjects will not be considered to meet the 
criteria for the endpoint of Hb ≥ 12 g/dL, ARC in the normal range, or haptoglobin ≥ LLN if 
they had a transfusion within 14 days of the endpoint measurement. The proportion of subjects 
with Hb stabilization from Week 4 to Week 12 will also be summarized. The proportion of 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
117 
 
CONFIDENTIAL 
subjects with Hb ≥ 12 g/dL at Week 12, Hb stabilization from Week 4 to Week 12, Week 12 
ARC in the normal range, and Week 12 haptoglobin ≥ LLN will be separately analyzed using the 
CMH chi-squared analysis method. For proportion of subjects with Hb ≥ 12 g/dL, proportion of 
subjects with ARC in the normal range, and proportion of subjects with haptoglobin ≥ LLN, 
subjects will be considered as not meeting these endpoints if they have had a transfusion within 
14 days prior to the Week 12 visit (ie, the interval between the transfusion day and the Week 12 
visit is ≤ 13 days) 
Nominal p-values for other HRQoL endpoints for Part 1 will be provided for: 
• Proportion of subjects achieving a within-subject meaningful change for the 
FACIT-Fatigue scale [at Week 12] 
• CFB in QLQ-AA/PNH Physical Functioning and other domain scores [at Week 12] 
• Proportion of subjects with improvement on individual PNH symptom items 
(ie, frequency, severity, and/or interference) from baseline as assessed using the 
modified PRO-AA/PNH symptom collection tool [at Week 12] 
• CFB in individual PNH symptom items on the modified PRO-AA/PNH scores [at 
Week 12] 
• CFB in EQ-5D-5L utility and VAS scores [at Week 12] 
• TSQM scale score [at Week 12] 
• Patient global impression of change in fatigue, impact of fatigue, and physical 
functioning as assessed using the PGIC-Fatigue, PGIC-Impact of Fatigue, and PGIC-
Physical Functioning scores, respectively [at Week 12] 
• CFB in patient global impression of severity of fatigue, impact of fatigue, and 
physical functioning as assessed using the PGIS-Fatigue, PGIS-Impact of Fatigue, 
and PGIS-Physical Functioning scores, respectively [at Week 12] 
The proportion of subjects achieving a within-subject meaningful change for the FACIT-Fatigue 
scale at Week 12 and the proportion of subjects with improvement on individual PNH symptom 
items as assessed using the modified PRO-AA/PNH at Week 12 will be analyzed using the CMH 
chi-squared analysis method. The level required for meaningful within-person change will be 
determined for the FACIT-Fatigue scale using anchor-based analyses. These analyses will be 
described in the SAP. 
QLQ-AA/PNH Physical Functioning and other domain scores, the PNH symptom items on the 
modified PRO-AA/PNH, EQ-5D-5L utility and VAS scores, and PGIS-Fatigue, PGIS-Impact of 
Fatigue, and PGIS-Physical Functioning scores will be summarized by visit for both actual and 
CFB values and the Week 12 CFB result will be analyzed using ANCOVA with effects for 
treatment, randomization stratum, and baseline value. Note that for TSQM scale scores, a similar 
analysis will be conducted but with the actual Week 12 value rather than the CFB Week 12 value 
as the dependent variable. For the QLQ-AA/PNH Physical Functioning domain score, CDF and 
PDF plots will be provided for the CFB score at Week 12. 
PGIC for fatigue, impact of fatigue, and physical functioning scores will be summarized using 
descriptive statistics by treatment group and study visit. For ease of interpretation and 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
118 
 
CONFIDENTIAL 
comparison, the PGIC items will be mapped to the values -3 to 3, from the worst outcome to the 
best outcome, respectively. PGIC items at Week 12 will be summarized by treatment group and 
study visit and analyzed using an ANCOVA model. The model will include effects for treatment, 
randomization stratum, and baseline score. 
13.5.4.2.2. Part 2 
The baseline for Part 2 for subjects who switch from placebo to BCX9930 at the end of Part 1 
will be the last value prior to the first dose of BCX9930 in Part 2. The baseline value for subjects 
randomized to BCX9930 treatment will be the same as for Part 1. 
Analysis of Part 2 secondary endpoints will generally be descriptive with summaries of actual 
and CFB values provided by visit for Hb, ARC, haptoglobin, total PNH RBC clone size, and 
ratio of total PNH RBC clone size to PNH WBC clone size. The mean (SD) of CFB values at 
Weeks 12 to 52 for subjects randomized to BCX9930 in Part 1 and for Weeks 24 to 52 for 
subjects randomized to placebo will be provided. Similar summaries will be provided for percent 
CFB in LDH. 
The proportion of subjects with Hb ≥ 12 g/dL at Week 52, with haptoglobin ≥ LLN at Week 52, 
with Hb stabilization during the relevant Part 2 period, and who are transfusion-free during the 
relevant Part 2 period will be presented by randomized treatment in Part 1.  
The number of units of pRBCs will be summarized using summary statistics. The rate of pRBC 
units transfused during the relevant period in Part 2 will be calculated along with the percent 
reduction in the rate of pRBCs transfused as compared to the rate of pRBC units transfused 
prestudy during the 12 months prior to screening. Summary statistics will be provided along with 
a summary of the number of subjects with a ≥ 50%/70%/90% reduction in rate of pRBC units 
transfused.  
Summaries of actual and CFB values will be provided by visit for 
 
 
Analysis of Part 2 HRQoL endpoints will generally be descriptive with summaries of actual and 
CFB values provided by visit for FACIT-Fatigue scale, QLQ-AA/PNH domain, modified 
PRO-AA/PNH, EQ-5D-5L utility and VAS, and TSQM scale scores. Summaries of individual 
PNH symptom items at each visit will also be produced. 
Summaries of FACIT-Fatigue scale scores and PNH symptom items by Part 1 treatment group 
and study visit will be provided. The proportion of subjects achieving a within-subject 
meaningful change for FACIT-Fatigue and with improvement in individual PNH symptoms 
items as compared to baseline will be summarized by visit. 
For PGIC and PGIS for fatigue, impact of fatigue, and physical functioning, descriptive 
summaries by treatment group and study visit will show the number and percentage of subjects 
with each choice of response as well as summary statistics for PGIC items, PGIS items, and CFB 
PGIS items. For ease of interpretation, PGIC items will be mapped to the values -3 to 3, from the 
worst outcome to the best outcome, respectively. 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
119 
 
CONFIDENTIAL 
13.5.5. 
Analysis of Safety Variables 
Separate safety analyses will be produced for the analysis at the end of Part 1 and again at the 
end of Part 2, based on actual exposure. Subjects enrolled at a starting dose of 500 mg BID will 
be reported separately. 
Safety endpoints that will be summarized include, at a minimum, the number and proportion of 
subjects 1) with a TEAE; 2) who discontinue BCX9930 due to a TEAE; 3) who experience a 
TESAE; 4) who experience a treatment-emergent CTCAE Grade 3 or Grade 4 AE; and 5) who 
experience a treatment-emergent CTCAE Grade 3 or Grade 4 laboratory abnormality. 
AEs will be assessed and recorded from the time of signing of the ICF through the appropriate 
follow-up period. AEs will be mapped to a Medical Dictionary for Regulatory Activities 
(MedDRA) preferred term and system organ class (SOC). The occurrence of TEAEs will be 
summarized using MedDRA preferred terms, SOCs, and severity. Separate summaries of 
TEAEs, TESAEs and AEs considered to be related to study drug, and AEs leading to study drug 
interruption will be generated. All AEs will be listed for individual subjects showing both 
verbatim and preferred terms. 
Clinical laboratory assessments and corresponding changes from baseline will be summarized 
for each laboratory panel by treatment and study visit. 
Descriptive summaries (actual and CFB) of vital signs, body weight, 12-lead ECG parameters, 
and clinical laboratory results will be presented. Laboratory abnormalities will be graded 
according to the CTCAE scales (Version 5.0, 27 November 2017). 
Any graded abnormality that occurs following the initiation of study drug and represents at least 
a 1-grade increase from the baseline assessment is defined as treatment emergent. The number 
and percentage of subjects experiencing treatment-emergent graded toxicities will be 
summarized. Laboratory toxicity shifts from baseline to worst post-baseline assessments will be 
summarized. 
Vital signs (systolic and diastolic blood pressure, pulse rate, and temperature) and body weight 
and corresponding changes from baseline will be summarized by treatment and study visit using 
descriptive statistics. These data will be listed by subject, treatment, and study visit. 
At each time point ECGs are analyzed, an individual subject’s change from baseline will be 
calculated using the average of the triplicate ECGs performed at baseline (Day 1) and single 
values at each post-dose time point. The number and proportion of subjects with QTcF ≤ 450, 
> 450 to ≤ 480, > 480 to ≤ 500, and > 500 msec; or CFB of ≤ 30, > 30 to ≤ 60, or > 60 msec will 
be summarized. Clinically significant abnormal morphological ECG findings will be 
summarized. 
Physical examination findings will be listed.  
A listing of pregnancy test results will be provided. Other pregnancy data captured in the eCRF 
will also be listed if necessary. 
Concomitant medications will be coded using the WHO drug dictionary and summarized. 
As applicable, safety data will be summarized by treatment and overall. 
No tests of hypothesis are planned for safety data. 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
120 
 
CONFIDENTIAL 
13.5.6. 
Acute Symptomatic Hemolysis 
Acute symptomatic hemolysis is defined as: ≥ 1 new or worsening acute sign or symptom of 
IVH (fatigue, hemoglobinuria, abdominal pain, dyspnea, MAVE [including thrombosis], 
dysphagia, erectile dysfunction, or AKI [defined as an eGFR decrease of ≥ 50% or ≥ doubling of 
serum creatinine]) associated with an acute reduction in Hb of > 2 g/dL and a 2-fold increase 
(ie, doubling) in LDH, as compared to the most recent Hb and LDH values while not 
experiencing symptoms of acute symptomatic hemolysis. The sites will complete the Acute 
Symptomatic Hemolysis eCRF module for each episode of acute symptomatic hemolysis; these 
will be summarized by treatment group. 
13.5.7. 
Breakthrough Hemolysis 
BTH is defined as: ≥ 1 new or worsening sign or symptom of IVH (fatigue, hemoglobinuria, 
abdominal pain, dyspnea, anemia [Hb < 10 g/dL], MAVE [including thrombosis], dysphagia, or 
erectile dysfunction) in the presence of LDH ≥ 2 × ULN after prior LDH reduction to 
≤ 1.5 × ULN on therapy. The number of subjects experiencing BTH with and without AKI and 
the number of BTH episodes will be summarized by treatment group. 
13.5.8. 
Major Adverse Vascular Events 
MAVEs are defined as: deep vein thrombosis; pulmonary embolus; myocardial infarction; 
transient ischemic attack; unstable angina; renal vein thrombosis; acute peripheral vascular 
occlusion; mesenteric/visceral vein thrombosis or infarction; mesenteric/visceral arterial 
thrombosis or infarction; hepatic/portal vein thrombosis (Budd-Chiari syndrome); cerebral 
arterial occlusion/cerebrovascular accident; cerebral venous occlusion; renal arterial thrombosis; 
gangrene (nontraumatic; nondiabetic); amputation (nontraumatic; nondiabetic); and dermal 
thrombosis. 
All MAVEs and will be summarized by treatment group; thrombosis events will also be 
summarized separately. 
13.5.9. 
Pharmacokinetic Analyses 
All subjects who are included in the safety population and have available BCX9930 
concentration data will be included in the PK population. 
Plasma and urine samples for analysis of BCX9930 concentration will be collected according to 
the schedules presented in Table 3 to Table 5. Plasma PK sampling will include both sparse (all 
subjects) and serial (subjects participating in the PK/PD substudy only) collection. Urine 
sampling will include spot collections only. 
Sparse plasma and spot urine concentration data will be listed. 
For subjects enrolled in the PK/PD substudy, the plasma concentration data for BCX9930 will be 
summarized by visit (first dose vs. steady state) and nominal timepoint. 
Metabolites of BCX9930 may also be included in PK analyses if deemed appropriate. 
Plasma PK data collected from this study may be pooled with other clinical studies to develop 
population PK models. These analyses will be reported separately from the CSR. 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
121 
 
CONFIDENTIAL 
Further details of the plasma PK analyses for this study will be included in a specific analysis 
plan. 
13.5.10. 
Pharmacodynamic and Biomarker Analyses 
PD assessments include plasma Factor Bb, C3a, and C5a, and serum AP activity (AP Wieslab 
assay), as well as plasma Factor D as the pharmacologic target of BCX9930. Additionally, total 
PNH RBC clone size, PNH WBC clone size, and the ratio of total PNH RBC clone size to PNH 
WBC clone size will be assessed. Biomarkers that would be indicative of disease state such as 
LDH levels, Hb and RBC counts, ARC, and haptoglobin will be assessed. Additional PD 
markers may also be analyzed. 
Descriptive summaries of the above assessments (actual, CFB, and percent CFB) will be 
presented by parameter, time point, treatment, and study part. 
Exposure-response (E-R) analyses of the relationships between BCX9930 plasma concentrations 
and PD endpoints, such as complement biomarkers, may be explored using quantitative, model-
based techniques. Model-based analyses will possibly incorporate data from other clinical studies 
and will be reported separately from the CSR. 
Further details of the PK/PD and E-R analyses for this study will be included in a specific 
analysis plan. 
14. 
STUDY ADMINISTRATION 
14.1. 
Study Monitoring 
Before an investigational site can enter a patient into the study, a representative(s) of BioCryst or 
its designee will assess the investigational study site to: 
• Determine the adequacy of the facilities 
• Discuss with the investigator(s) and other personnel their responsibilities with regard to 
protocol adherence, and the responsibilities of BioCryst or its designee. This will be 
documented in a Clinical Study Agreement between BioCryst and the investigator. 
During study conduct, BioCryst or its designee will conduct periodic monitoring visits to ensure 
that the protocol and Good Clinical Practice (GCP) are being followed. The monitor(s) will 
review source documents to confirm that the data recorded on eCRFs are accurate. The 
investigator and institution will allow the representative(s) of BioCryst or its designee direct 
access to source documents to perform this verification. 
It is important that the investigator(s) and relevant personnel are available during the monitoring 
visits and that sufficient time is devoted to the process. 
During the study, a representative(s) from BioCryst or its designee will have regular contacts 
with the investigational site personnel for the following: 
• Provide information and support to the investigator(s) 
• Confirm that facilities remain acceptable 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
122 
 
CONFIDENTIAL 
• Confirm that the investigational team is adhering to the protocol, that data are being 
accurately recorded in the eCRFs, and that investigational product accountability checks 
are being performed 
• Perform source data verification. This includes a comparison of the data in the eCRFs 
with the subject’s medical records at the hospital or practice, and other records relevant to 
the study. This will require direct access to all original records for each subject (eg, clinic 
charts). 
• Record and report any protocol deviations not previously sent to BioCryst or its designee 
• Confirm AEs and SAEs have been properly documented on the eCRFs and confirm any 
SAEs have been forwarded to BioCryst or its designee and those SAEs that met criteria 
for reporting have been forwarded to the ethics committee 
The representative(s) of BioCryst or its designee will be available between visits if the 
investigator(s) or other staff needs information or advice. 
14.2. 
Audits and Inspections 
Authorized representatives of BioCryst or its designee, US Food and Drug Administration 
(FDA) and other regulatory authorities, and/or ethics committee may visit the site to perform 
audits or inspections, including source data verification. The purpose of a BioCryst audit or 
inspection is to systematically and independently examine all study-related activities and 
documents to determine whether these activities were conducted, and data were recorded, 
analyzed, and accurately reported according to the protocol, standard operating procedures, ICH 
GCP guidelines, and any applicable regulatory requirements. The investigator should contact 
BioCryst immediately if contacted by a regulatory agency about an inspection. 
It is important that the investigator and relevant personnel are available during the possible audits 
or inspections and that sufficient time is devoted to the process. 
14.3. 
Ethics Committee 
The investigator must obtain ethics approval for the investigation. Initial ethics approval, and all 
materials approved by the ethics committee, including the ICF and any recruitment materials, 
must be maintained by the investigator and made available for inspection. 
14.4. 
Serious Breaches of GCP 
It is the responsibility of the sponsor to notify the competent authority of any serious breach of 
GCP that is likely to affect, to a significant degree, the safety or mental integrity of the subjects 
of the study or the scientific value of the study. All serious breaches will be notified to the 
relevant competent authority in accordance with locally applicable regulations. The reporting to 
the sponsor will be performed by the party who suspects the serious breach. 
15. 
QUALITY CONTROL AND QUALITY ASSURANCE 
During study conduct, BioCryst or its designee will conduct periodic monitoring visits to ensure 
that the protocol and GCP are being followed as described in Section 14.1. 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
123 
 
CONFIDENTIAL 
To ensure compliance with GCP and all applicable regulatory requirements, BioCryst or its 
designee may conduct a quality assurance audit. Please see Section 14.2 for more details 
regarding the audit process. The investigator agrees to allow the auditors to inspect the drug 
storage area, study drug stocks, drug accountability records, subject charts and study source 
documents, and other records relative to study conduct. 
16. 
ETHICS 
16.1. 
Ethics Review 
The final study protocol and the final version of the ICF must be approved or given a favorable 
opinion in writing by an ethics committee, as appropriate. The investigator must submit written 
approval from the ethics committee to BioCryst before he or she can enroll any subject into the 
study. 
The ethics committee will be informed of any amendment to the protocol in accordance with 
local requirements. In addition, the ethics committee must approve any advertising used to 
recruit subjects for the study. The protocol must be re-approved by the ethics committee upon 
receipt of amendments and annually, as local regulations require. 
The ethics committee will be provided with reports of any reportable serious adverse drug 
reactions from any other study conducted with the investigational product, in accordance with 
local regulations. BioCryst will provide this information to the investigator. 
Progress reports and notifications of serious adverse drug reactions will be provided to the ethics 
committee according to local regulations and guidelines. 
16.2. 
Ethical Conduct of the Study 
The study will be performed in accordance with ethical principles that have their origin in the 
Declaration of Helsinki and are consistent with ICH GCP, applicable regulatory requirements, 
and BioCryst’s policies. 
16.3. 
Written Informed Consent 
In accordance with applicable national or local law, and current institutional practice, written 
informed consent to participate in the study will be obtained from each subject prior to 
conducting any study-related assessments/procedures. 
A signed ICF must be obtained from each subject prior to performing any study-related 
procedures. Each subject should be given both oral and written information describing the 
nature, purpose, and duration of the study. Subjects will be informed that they are free not to 
participate in the study and that they may withdraw consent to participate at any time. They will 
be told that refusal to participate in the study will not prejudice future treatment. They will also 
be told that their records may be examined by competent authorities and authorized persons, but 
that personal information will be treated as strictly confidential and will not be publicly 
available. The informed consent process should take place under conditions where the subject 
has adequate time to consider the risks and benefits associated with participation in the study. 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
124 
 
CONFIDENTIAL 
Subjects must be given the opportunity to ask questions. Subjects will not be screened or treated 
until the subject has signed an approved ICF written in a language in which the subject is fluent. 
The ICF that is used must be approved both by BioCryst and by the governing ethics committee. 
The ICF should be in accordance with the current revision of the Declaration of Helsinki, current 
ICH and GCP guidelines, and BioCryst policies. 
The subject should receive a signed and dated copy of the ICF. The original signed ICF should 
be retained in the study files. 
The investigator shall maintain a log of all subjects for whom consent was signed and indicate if 
the subject was enrolled into the study or reason for non-enrollment. 
17. 
DATA HANDLING AND RECORDKEEPING 
17.1. 
Inspection of Records 
BioCryst or designee will be allowed to conduct site visits to the investigation facilities for the 
purpose of monitoring any aspect of the study. The investigator agrees to allow the monitor to 
inspect the drug storage area, study drug stocks, drug accountability records, subject charts, and 
study source documents, and other records relative to study conduct. 
17.2. 
Retention of Records 
To enable evaluations and/or audits from regulatory authorities or BioCryst, the investigator 
agrees to keep records, including the identity of all participating subjects (sufficient information 
to link records, eCRFs, and medical/hospital records), all original signed ICFs, all eCRFs, and 
detailed records of study drug accountability and treatment disposition. The records should be 
retained by the investigator according to local regulations or as specified in the Clinical Study 
Agreement, whichever is longer. 
If the investigator relocates, retires, or for any reason withdraws from the study, the study 
records may be transferred to an acceptable designee, such as another investigator, another 
institution, or to BioCryst. The investigator must obtain BioCryst’s written permission before 
disposing of any records and must notify BioCryst before transferring any records to another 
facility. 
All correspondence related to records retention, destruction, or transfer of study documents, 
should be sent directly to BioCryst study personnel, copying the email archives@biocryst.com. 
17.3. 
Confidentiality of Information and Data  
BioCryst affirms the subject’s right to protection against invasion of privacy and secure 
maintenance of the confidential nature of his/her personal data. Only a subject identification 
number and subject identifiers permitted by local regulation will identify subject data retrieved 
by BioCryst. However, in compliance with federal regulations, BioCryst requires the investigator 
to permit BioCryst’s representatives and, when necessary, representatives of the FDA or other 
regulatory authorities to review and/or copy any medical records relevant to the study, 
maintaining pseudo-anonymity. 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
125 
 
CONFIDENTIAL 
All parties will abide by all applicable laws and regulations regarding subject privacy and 
confidentiality, including the Health Insurance Portability and Accountability Act (HIPAA), 
where this rule is applicable, and the requirements of the General Data Protection Regulation 
(GDPR) in the EU, where applicable. A valid authorization and consent must meet the 
specifications of the applicable laws and regulations relating to such personal data and health 
information. It is the responsibility of the investigator and institution to obtain such 
waiver/authorization in writing from the appropriate individual. HIPAA authorizations are 
required for US sites only. 
18. 
PUBLICATION POLICY 
All data generated from this study are the property of BioCryst and shall be held in strict 
confidence along with all information furnished by BioCryst. Except as provided through written 
agreement between BioCryst, independent analysis and/or publication of these data by the 
investigator or any member of his/her staff is not permitted without prior written consent of 
BioCryst. Such consent will not be withheld unreasonably. BioCryst is in agreement with the 
principle of full disclosure of clinical study results. 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
126 
 
CONFIDENTIAL 
19. 
LIST OF REFERENCES 
Alexion Pharmaceuticals Soliris PI, I. (2020). "Soliris (eculizumab) injection, for intravenous 
use." 
Alexion Pharmaceuticals Ultomiris PI, I. (2020). "Ultomiris (ravulizumab-cwvz) injection, for 
intravenous use." 
Apellis Pharmaceutical Empaveli PI, I. (2021). "Empaveli (pegcetacoplan) injection, for 
subcutaneous use." 
Borowitz, M. J., F. E. Craig, J. A. Digiuseppe, A. J. Illingworth, W. Rosse, D. R. Sutherland, C. 
T. Wittwer, S. J. Richards, and S. Clinical Cytometry (2010). "Guidelines for the diagnosis and 
monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry." 
Cytometry B Clin Cytom 78(4): 211-30. 
Brodsky, R. (2008). "Narrative review: paroxysmal nocturnal hemoglobinuria: the physiology of 
complement-related hemolytic anemia." Ann Intern Med 148(8): 587-95. 
Brodsky, R. A. (2014). "Paroxysmal nocturnal hemoglobinuria." Blood 124(18): 2804-11. 
Cannizzo, E., M. Raia, M. S. De Propris, A. Triolo, B. Scarpati, A. Marfia, A. Stacchini, F. 
Buccisano, F. Lanza, A. Regazzoli, A. Michelutti, S. Cesaro, C. A. Conte, L. Vanelli, E. Tedone, 
P. Omede, M. M. Ciriello, R. Caporale, V. Catinella, G. Pantano, C. De Rosa, C. Lo Pardo, G. 
Poletti, F. Ulbar, M. C. Pavanelli, L. Del Pup, V. Ottaviano, A. M. Santonocito, C. Bartocci, E. 
Boscaro, M. Arras, R. Amodeo, A. Mestice, B. Oliva, L. Ferrari, T. Statuto, F. D'Auria, G. 
Pianezze, D. Tanca, F. Visconte, F. Rubba, P. Musto, M. Geuna, A. Gatti, B. Brando, and L. Del 
Vecchio (2019). "Features, reason for testing, and changes with time of 583 paroxysmal 
nocturnal hemoglobinuria clones from 529 patients: a multicenter Italian study." Ann Hematol 
98(5): 1083-93. 
Carpenter, J. R., J. H. Roger, and M. G. Kenward (2013). "Analysis of longitudinal trials with 
protocol deviation: a framework for relevant, accessible assumptions, and inference via multiple 
imputation." J Biopharm Stat 23(6): 1352-71. 
Cella, D., J. S. Lai, C. H. Chang, A. Peterman, and M. Slavin (2002). "Fatigue in cancer patients 
compared with fatigue in the general United States population." Cancer 94(2): 528-38. 
Cella, D., J. S. Lai, and A. Stone (2011). "Self-reported fatigue: one dimension or more? Lessons 
from the Functional Assessment of Chronic Illness Therapy--Fatigue (FACIT-F) questionnaire." 
Support Care Cancer 19(9): 1441-50. 
Chow, K. M., F. M. Lai, A. Y. Wang, Y. L. Chan, N. L. Tang, and P. K. Li (2001). "Reversible 
renal failure in paroxysmal nocturnal hemoglobinuria." Am J Kidney Dis 37(2): E17. 
CIOMS (2016). International Ethical Guidelines for Health-related Research Involving Humans. 
Curran, K. J., N. A. Kernan, S. E. Prockop, A. Scaradavou, T. N. Small, R. Kobos, H. Castro-
Malaspina, D. Araten, D. DiMichele, R. J. O'Reilly, and F. Boulad (2012). "Paroxysmal 
nocturnal hemoglobinuria in pediatric patients." Pediatr Blood Cancer 59(3): 525-9. 
de Latour, R. P., J. Y. Mary, C. Salanoubat, L. Terriou, G. Etienne, M. Mohty, S. Roth, S. de 
Guibert, S. Maury, J. Y. Cahn, G. Socie, H. French Society of, and H. French Association of 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
127 
 
CONFIDENTIAL 
Young (2008). "Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories." 
Blood 112(8): 3099-106. 
Ekdahl, K. N., C. Mohlin, A. Adler, A. Aman, V. A. Manivel, K. Sandholm, M. Huber-Lang, K. 
Fromell, and B. Nilsson (2019). "Is generation of C3(H2O) necessary for activation of the 
alternative pathway in real life?" Mol Immunol 114: 353-61. 
Escalante, C. P., S. Chisolm, J. Song, M. Richardson, E. Salkeld, E. Aoki, and G. Garcia-Manero 
(2019). "Fatigue, symptom burden, and health-related quality of life in patients with 
myelodysplastic syndrome, aplastic anemia, and paroxysmal nocturnal hemoglobinuria." Cancer 
Med 8(2): 543-53. 
Figueroa, J. E., and P. Densen (1991). "Infectious diseases associated with complement 
deficiencies." Clin Microbiol Rev 4(3): 359-95. 
Ge, M., J. Shi, X. Li, Y. Shao, J. Huang, Z. Huang, J. Zhang, N. Nie, and Y. Zheng (2015). 
"Clinical features and survival of asian pediatric patients with paroxysmal nocturnal 
hemoglobinuria: results from a single center in China." Acta Haematol 134(1): 1-6. 
Gerber, G. F., X. Yuan, J. Yu, B. A. Y. Cher, E. M. Braunstein, S. Chaturvedi, and R. A. 
Brodsky (2021). "COVID-19 Vaccines Induce Severe Hemolysis in Paroxysmal Nocturnal 
Hemoglobinuria." Blood. 
Graham, M. L., W. F. Rosse, E. C. Halperin, C. R. Miller, and R. E. Ware (1996). "Resolution of 
Budd-Chiari syndrome following bone marrow transplantation for paroxysmal nocturnal 
haemoglobinuria." Br J Haematol 92(3): 707-10. 
Griesser, C., M. Myskiw, and W. Streif (2020). "Paroxysmal Nocturnal Hemoglobinuria: An 
Underestimated Cause of Pediatric Thromboembolism." TH Open 4(1): e36-e9. 
Griffin, M., and T. Munir (2017). "Management of thrombosis in paroxysmal nocturnal 
hemoglobinuria: a clinician's guide." Ther Adv Hematol 8(3): 119-26. 
Groth, M., S. Singer, C. Niedeggen, A. Petermann-Meyer, A. Roth, H. Schrezenmeier, B. 
Hochsmann, T. H. Brummendorf, and J. Panse (2017). "Development of a disease-specific 
quality of life questionnaire for patients with aplastic anemia and/or paroxysmal nocturnal 
hemoglobinuria (QLQ-AA/PNH)-report on phases I and II." Ann Hematol 96(2): 171-81. 
Guasch, A. (2010). "Improving renal outcomes in chronic anemia: learning from paroxysmal 
nocturnal hemoglobinuria." Am J Hematol 85(8): 551-2. 
Hall, C., S. Richards, and P. Hillmen (2003). "Primary prophylaxis with warfarin prevents 
thrombosis in paroxysmal nocturnal hemoglobinuria (PNH)." Blood 102(10): 3587-91. 
Harris, J. W., R. Koscick, H. M. Lazarus, J. R. Eshleman, and M. E. Medof (1999). "Leukemia 
arising out of paroxysmal nocturnal hemoglobinuria." Leuk Lymphoma 32(5-6): 401-26. 
Hauser, A. C., A. Brichta, I. Pabinger-Fasching, and U. Jager (2003). "Fibrinolytic therapy with 
rt-PA in a patient with paroxysmal nocturnal hemoglobinuria and Budd-Chiari syndrome." Ann 
Hematol 82(5): 299-302. 
Heller, P. G., A. R. Grinberg, M. Lencioni, M. M. Molina, and A. J. Roncoroni (1992). 
"Pulmonary hypertension in paroxysmal nocturnal hemoglobinuria." Chest 102(2): 642-3. 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
128 
 
CONFIDENTIAL 
Hill, A., A. E. DeZern, T. Kinoshita, and R. A. Brodsky (2017). "Paroxysmal nocturnal 
haemoglobinuria." Nat Rev Dis Primers 3: 17028. 
Hill, A., R. J. Kelly, and P. Hillmen (2013). "Thrombosis in paroxysmal nocturnal 
hemoglobinuria." Blood 121(25): 4985-96; quiz 5105. 
Hillmen, P., M. Elebute, R. Kelly, A. Urbano-Ispizua, A. Hill, R. P. Rother, G. Khursigara, C. L. 
Fu, M. Omine, P. Browne, and W. Rosse (2010). "Long-term effect of the complement inhibitor 
eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria." Am J 
Hematol 85(8): 553-9. 
Hillmen, P., S. M. Lewis, M. Bessler, L. Luzzatto, and J. V. Dacie (1995). "Natural history of 
paroxysmal nocturnal hemoglobinuria." N Engl J Med 333(19): 1253-8. 
Hillmen, P., P. Muus, A. Roth, M. O. Elebute, A. M. Risitano, H. Schrezenmeier, J. Szer, P. 
Browne, J. P. Maciejewski, J. Schubert, A. Urbano-Ispizua, C. de Castro, G. Socie, and R. A. 
Brodsky (2013). "Long-term safety and efficacy of sustained eculizumab treatment in patients 
with paroxysmal nocturnal haemoglobinuria." Br J Haematol 162(1): 62-73. 
Hillmen, P., J. Szer, I. Weitz, A. Roth, B. Hochsmann, J. Panse, K. Usuki, M. Griffin, J. J. 
Kiladjian, C. de Castro, H. Nishimori, L. Tan, M. Hamdani, P. Deschatelets, C. Francois, F. 
Grossi, T. Ajayi, A. Risitano, and R. P. de la Tour (2021). "Pegcetacoplan versus Eculizumab in 
Paroxysmal Nocturnal Hemoglobinuria." N Engl J Med 384(11): 1028-37. 
Hillmen, P., N. S. Young, J. Schubert, R. A. Brodsky, G. Socie, P. Muus, A. Roth, J. Szer, M. O. 
Elebute, R. Nakamura, P. Browne, A. M. Risitano, A. Hill, H. Schrezenmeier, C. L. Fu, J. 
Maciejewski, S. A. Rollins, C. F. Mojcik, R. P. Rother, and L. Luzzatto (2006). "The 
complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria." N Engl J Med 
355(12): 1233-43. 
Holers, V. M. (2008). "The spectrum of complement alternative pathway-mediated diseases." 
Immunol Rev 223: 300-16. 
Jackson, G. H., R. S. Noble, Z. T. Maung, J. Main, S. R. Smith, and M. M. Reid (1992). "Severe 
haemolysis and renal failure in a patient with paroxysmal nocturnal haemoglobinuria." J Clin 
Pathol 45(2): 176-7. 
Jain, P. (2010). "An unusual cause of Budd-Chiari syndrome: paroxysmal nocturnal 
hemoglobinuria." J Gastrointestin Liver Dis 19(1): 107-8. 
Jalbert, J. J., U. Chaudhari, H. Zhang, J. Weyne, and J. M. Shammo (2019). "Epidemiology of 
PNH and Real-World Treatment Patterns Following an Incident PNH Diagnosis in the US." 
Blood 134(Supplement_1): 3407-. 
Kellum, J. A., N. Lamiere, P. Aspelin, R. S. Barsoum, E. A. Burdmann, S. L. Goldstein, C. A. 
Hertzog, M. Joannidis, A. Kribben, A. S. Levey, A. M. MacLeod, R. L. Mehta, P. T. Murray, S. 
Naicker, S. M. Opal, F. Schaefer, M. Schetz, and S. Uchino (2012). "Kidney disease: improving 
global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline 
for acute kidney injury." Kidney Int Suppl (2011) 2(1): 1-138. 
Kroger, A., L. Bahta, and P. Hunter. (2021). "General Best Practice Guidelines for 
Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
129 
 
CONFIDENTIAL 
(ACIP)." Retrieved March 11, 2021, from www.cdc.gov/vaccines/hcp/acip-recs/general-
recs/downloads/general-recs.pdf. 
Kulasekararaj, A., A. M. Risitano, J. P. Maciejewski, R. Notaro, P. Browett, J.-W. Lee, M. 
Huang, M. Geffner, and R. A. Brodsky (2019). "A Phase 2 Open-Label Study of Danicopan 
(ACH-0144471) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have an 
Inadequate Response to Eculizumab Monotherapy." Blood 134(Supplement_1): 3514-. 
Kulasekararaj, A. G., A. Hill, S. T. Rottinghaus, S. Langemeijer, R. Wells, F. A. Gonzalez-
Fernandez, A. Gaya, J. W. Lee, E. O. Gutierrez, C. I. Piatek, J. Szer, A. Risitano, S. Nakao, E. 
Bachman, L. Shafner, A. I. Damokosh, S. Ortiz, A. Roth, and R. Peffault de Latour (2019). 
"Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: 
the 302 study." Blood 133(6): 540-9. 
Lee, J. W., R. Peffault de Latour, R. A. Brodsky, J. H. Jang, A. Hill, A. Roth, H. Schrezenmeier, 
A. Wilson, J. L. Marantz, and J. P. Maciejewski (2019). "Effectiveness of eculizumab in patients 
with paroxysmal nocturnal hemoglobinuria (PNH) with or without aplastic anemia in the 
International PNH Registry." Am J Hematol 94(1): E37-E41. 
Lee, J. W., F. Sicre de Fontbrune, L. Wong Lee Lee, V. Pessoa, S. Gualandro, W. Fureder, V. 
Ptushkin, S. T. Rottinghaus, L. Volles, L. Shafner, R. Aguzzi, R. Pradhan, H. Schrezenmeier, 
and A. Hill (2019). "Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive 
to complement inhibitors: the 301 study." Blood 133(6): 530-9. 
Lesavre, P. H., and H. J. Muller-Eberhard (1978). "Mechanism of action of factor D of the 
alternative complement pathway." J Exp Med 148(6): 1498-509. 
Levey, A. S., and L. A. Stevens (2010). "Estimating GFR using the CKD Epidemiology 
Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD 
prevalence estimates, and better risk predictions." Am J Kidney Dis 55(4): 622-7. 
Loschi, M., R. Porcher, F. Barraco, L. Terriou, M. Mohty, S. de Guibert, B. Mahe, R. Lemal, P. 
Y. Dumas, G. Etienne, F. Jardin, B. Royer, D. Bordessoule, P. S. Rohrlich, L. M. Fornecker, C. 
Salanoubat, S. Maury, J. Y. Cahn, L. Vincent, T. Sene, S. Rigaudeau, S. Nguyen, A. C. Lepretre, 
J. Y. Mary, B. Corront, G. Socie, and R. Peffault de Latour (2016). "Impact of eculizumab 
treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study." Am 
J Hematol 91(4): 366-70. 
Marti-Carvajal, A. J., V. Anand, A. F. Cardona, and I. Sola (2014). "Eculizumab for treating 
patients with paroxysmal nocturnal hemoglobinuria." Cochrane Database Syst Rev(10): 
CD010340. 
Mbaeyi, S. A. B., C.H.; Duffy, J.; Rubin, L.G.; Hariri, S.; Stephens, D.S.; MacNeil, J.R. (2020). 
Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization 
Practices, United States, 2020. CDC Morbidity and Mortality Weekly Report. C. K. Kent. 69: 1-
32. 
Mercuri, A., P. Farruggia, F. Timeus, L. Lombardi, D. Onofrillo, M. C. Putti, M. Pillon, M. E. 
Cantarini, P. Corti, G. Tridello, M. De Bortoli, A. Pegoraro, and S. Cesaro (2017). "A 
retrospective study of paroxysmal nocturnal hemoglobinuria in pediatric and adolescent 
patients." Blood Cells Mol Dis 64: 45-50. 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
130 
 
CONFIDENTIAL 
Nair, R. K., A. Khaira, A. Sharma, S. Mahajan, and A. K. Dinda (2008). "Spectrum of renal 
involvement in paroxysmal nocturnal hemoglobinuria: report of three cases and a brief review of 
the literature." Int Urol Nephrol 40(2): 471-5. 
Narita, A., H. Muramatsu, Y. Okuno, Y. Sekiya, K. Suzuki, M. Hamada, S. Kataoka, D. 
Ichikawa, R. Taniguchi, N. Murakami, D. Kojima, E. Nishikawa, N. Kawashima, N. Nishio, A. 
Hama, Y. Takahashi, and S. Kojima (2017). "Development of clinical paroxysmal nocturnal 
haemoglobinuria in children with aplastic anaemia." Br J Haematol 178(6): 954-8. 
Niedeggen, C., S. Singer, M. Groth, A. Petermann-Meyer, A. Roth, H. Schrezenmeier, B. 
Hochsmann, T. H. Brummendorf, and J. Panse (2019). "Design and development of a disease-
specific quality of life tool for patients with aplastic anaemia and/or paroxysmal nocturnal 
haemoglobinuria (QLQ-AA/PNH)-a report on phase III." Ann Hematol 98(7): 1547-59. 
Parker, C., M. Omine, S. Richards, J. Nishimura, M. Bessler, R. Ware, P. Hillmen, L. Luzzatto, 
N. Young, T. Kinoshita, W. Rosse, G. Socie, and P. N. H. I. G. International (2005). "Diagnosis 
and management of paroxysmal nocturnal hemoglobinuria." Blood 106(12): 3699-709. 
Parker, C. J. (2009). "Bone marrow failure syndromes: paroxysmal nocturnal hemoglobinuria." 
Hematol Oncol Clin North Am 23(2): 333-46. 
Parker, C. J. (2012). "Paroxysmal nocturnal hemoglobinuria." Curr Opin Hematol 19(3): 141-8. 
Pu, J. J., and R. A. Brodsky (2011). "Paroxysmal nocturnal hemoglobinuria from bench to 
bedside." Clin Transl Sci 4(3): 219-24. 
Rachidi, S., K. M. Musallam, and A. T. Taher (2010). "A closer look at paroxysmal nocturnal 
hemoglobinuria." Eur J Intern Med 21(4): 260-7. 
Ram, S., L. A. Lewis, and P. A. Rice (2010). "Infections of people with complement deficiencies 
and patients who have undergone splenectomy." Clin Microbiol Rev 23(4): 740-80. 
Ray, J. G., R. F. Burows, J. S. Ginsberg, and E. A. Burrows (2000). "Paroxysmal nocturnal 
hemoglobinuria and the risk of venous thrombosis: review and recommendations for 
management of the pregnant and nonpregnant patient." Haemostasis 30(3): 103-17. 
Ricklin, D., E. S. Reis, and J. D. Lambris (2016). "Complement in disease: a defence system 
turning offensive." Nat Rev Nephrol 12(7): 383-401. 
Risitano, A. M. (2016). "Paroxysmal nocturnal hemoglobinuria in the era of complement 
inhibition." Am J Hematol 91(4): 359-60. 
Risitano, A. M., S. Marotta, P. Ricci, L. Marano, C. Frieri, F. Cacace, M. Sica, A. Kulasekararaj, 
R. T. Calado, P. Scheinberg, R. Notaro, and R. Peffault de Latour (2019). "Anti-complement 
Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement 
Inhibition? A Position Paper From the SAAWP of the EBMT." Front Immunol 10: 1157. 
Risitano, A. M., R. Notaro, L. Marando, B. Serio, D. Ranaldi, E. Seneca, P. Ricci, F. Alfinito, A. 
Camera, G. Gianfaldoni, A. Amendola, C. Boschetti, E. Di Bona, G. Fratellanza, F. Barbano, F. 
Rodeghiero, A. Zanella, A. P. Iori, C. Selleri, L. Luzzatto, and B. Rotoli (2009). "Complement 
fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal 
hemoglobinuria patients treated by eculizumab." Blood 113(17): 4094-100. 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
131 
 
CONFIDENTIAL 
Risitano, A. M., R. Notaro, C. Pascariello, M. Sica, L. del Vecchio, C. J. Horvath, M. Fridkis-
Hareli, C. Selleri, M. A. Lindorfer, R. P. Taylor, L. Luzzatto, and V. M. Holers (2012). "The 
complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal 
hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment." Blood 
119(26): 6307-16. 
Risitano, A. M., A. Roth, J. Soret, C. Frieri, F. S. de Fontbrune, L. Marano, F. Alashkar, L. 
Benajiba, S. Marotta, I. Rozenberg, J. Milojevic, P. End, P. K. Nidamarthy, G. Junge, and R. 
Peffault de Latour (2021). "Addition of iptacopan, an oral factor B inhibitor, to eculizumab in 
patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, 
single-arm, phase 2, proof-of-concept trial." Lancet Haematol 8(5): e344-e54. 
Roth, A., S. T. Rottinghaus, A. Hill, E. S. Bachman, J. S. Kim, H. Schrezenmeier, L. Terriou, A. 
Urbano-Ispizua, R. A. Wells, J. H. Jang, A. G. Kulasekararaj, J. Szer, R. Aguzzi, A. I. 
Damokosh, L. Shafner, and J. W. Lee (2018). "Ravulizumab (ALXN1210) in patients with 
paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies." Blood Adv 2(17): 2176-
85. 
Rother, R. P., L. Bell, P. Hillmen, and M. T. Gladwin (2005). "The clinical sequelae of 
intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human 
disease." JAMA 293(13): 1653-62. 
Savage, W. J., and R. A. Brodsky (2007). "New insights into paroxysmal nocturnal 
hemoglobinuria." Hematology 12(5): 371-6. 
Schrezenmeier, H., A. Roth, D. J. Araten, Y. Kanakura, L. Larratt, J. M. Shammo, A. Wilson, G. 
Shayan, and J. P. Maciejewski (2020). "Baseline clinical characteristics and disease burden in 
patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the 
International PNH Registry." Ann Hematol 99(7): 1505-14. 
Sechi, L. A., A. Marigliano, and R. Tedde (1988). "Venous thrombosis and acute renal failure in 
paroxysmal nocturnal haemoglobinuria." Nephrol Dial Transplant 3(5): 708-9. 
Socie, G., J. Y. Mary, A. de Gramont, B. Rio, M. Leporrier, C. Rose, P. Heudier, H. Rochant, J. 
Y. Cahn, and E. Gluckman (1996). "Paroxysmal nocturnal haemoglobinuria: long-term follow-
up and prognostic factors. French Society of Haematology." Lancet 348(9027): 573-7. 
Thurman, J. M., and V. M. Holers (2006). "The central role of the alternative complement 
pathway in human disease." J Immunol 176(3): 1305-10. 
Torreira, E., A. Tortajada, T. Montes, S. Rodriguez de Cordoba, and O. Llorca (2009). "3D 
structure of the C3bB complex provides insights into the activation and regulation of the 
complement alternative pathway convertase." Proc Natl Acad Sci U S A 106(3): 882-7. 
Torres, J., B. De Vroey, M. P. Noel, B. Notteghem, and J. F. Colombel (2010). "Recurrent small 
bowel ischemia in a patient with paroxysmal nocturnal hemoglobinuria." Nat Rev Gastroenterol 
Hepatol 7(7): 410-4. 
Volanakis, J. E., and S. V. Narayana (1996). "Complement factor D, a novel serine protease." 
Protein Sci 5(4): 553-64. 
Weisshaar, K., H. Ewald, J. Halter, S. Gerull, S. Schonfeld, Y. Senft, M. Martinez, A. Leuppi-
Taegtmeyer, N. Khanna, B. Maier, A. Risitano, R. Peffault de Latour, A. Tichelli, J. Passweg, 

BioCryst Pharmaceuticals, Inc. 
Protocol BCX9930-203 
 
Version 4.0: 01 August 2022 
 
132 
 
CONFIDENTIAL 
and B. Drexler (2020). "Development of a patient-reported outcome questionnaire for aplastic 
anemia and paroxysmal nocturnal hemoglobinuria (PRO-AA/PNH)." Orphanet J Rare Dis 15(1): 
249. 
Weitz, I., G. Meyers, T. Lamy, J. Y. Cahn, M. T. Uranga, J. A. Garcia Vela, M. A. Sanz, B. 
Severino, R. J. Kelly, P. Hillmen, and A. Hill (2013). "Cross-sectional validation study of 
patient-reported outcomes in patients with paroxysmal nocturnal haemoglobinuria." Intern Med J 
43(3): 298-307. 
White, R. T., D. Damm, N. Hancock, B. S. Rosen, B. B. Lowell, P. Usher, J. S. Flier, and B. M. 
Spiegelman (1992). "Human adipsin is identical to complement factor D and is expressed at high 
levels in adipose tissue." J Biol Chem 267(13): 9210-3. 
Wong, R. S., K. Ignatova, H. Pullon, J. Sathar, P. Niparuck, T. Numbenjapon, E. Tse, S. 
Issaragrisil, E. Roman, I. Amine, L. Tan, C. Casoli, P. Deschatelets, C. Francois, F. Grossi, and 
A. Bogdanovic (2020). C3 Inhibition with Pegcetacoplan in Patients with Paroxysmal Nocturnal 
Hemoglobinuria: Results from the Paddock and Palomino Trials. 62nd ASH Annual Meeting and 
Exposition. 
Xu, Y., S. V. Narayana, and J. E. Volanakis (2001). "Structural biology of the alternative 
pathway convertase." Immunol Rev 180: 123-35. 
Yellen, S. B., D. F. Cella, K. Webster, C. Blendowski, and E. Kaplan (1997). "Measuring fatigue 
and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) 
measurement system." J Pain Symptom Manage 13(2): 63-74. 
Yin, D. L., L. X. Liu, S. G. Zhang, L. T. Tian, Z. Y. Lu, and H. C. Jiang (2009). "Portal 
hypertension resulted from paroxysmal nocturnal hemoglobinuria: a case report and review of 
literature." Int J Hematol 89(3): 302-4. 
Ziakas, P. D., L. S. Poulou, and A. Pomoni (2008). "Thrombosis in paroxysmal nocturnal 
hemoglobinuria at a glance: a clinical review." Curr Vasc Pharmacol 6(4): 347-53. 
Zipfel, P. F., C. Skerka, Q. Chen, T. Wiech, T. Goodship, S. Johnson, V. Fremeaux-Bacchi, C. 
Nester, S. R. de Cordoba, M. Noris, M. Pickering, and R. Smith (2015). "The role of 
complement in C3 glomerulopathy." Mol Immunol 67(1): 21-30.